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Mild cognitive impairment is a heterogeneous condition; while typically viewed as the transition 
stage between healthy cognitive function and dementia, the cognitive and clinical patterns of this 
condition vary, as do its prognosis. The two most common neurodegenerative dementias, 
dementia with Lewy bodies and Alzheimer’s disease, differ in their clinical features, patterns of 
cognitive impairment, and prognosis. It is not known whether the respective mild cognitive 
impairment stages preceding onset of dementia also differ in these characteristics. Two cohorts of 
people with recent mild cognitive impairment diagnosis were assessed, undergoing annual review 
of cognition, diagnosis and presence of clinical features of Lewy body disease by an expert panel 
of old age psychiatrists, and repeated imaging, to reach a consensus diagnosis of either mild 
cognitive impairment due to Alzheimer’s disease, or with Lewy bodies, in line with current 
consensus criteria for these. Making use of annually repeated cognitive assessment and clinical 
diagnostic information, the longitudinal progression of these two conditions was characterised 
with flexible statistical methods, using the first cohort for model development, and the second for 
validation: different trajectories of decline in specific cognitive domains were observed in the 
diagnostic groups, reflecting typical patterns of impairment in their respective dementia 
syndromes. Mild cognitive impairment with Lewy bodies was also observed to have a worse 
prognosis, in keeping with its dementia stage, with a greater risk of progressive cognitive decline, 
and faster onset of dementia. Individuals with neuropsychiatric symptoms (cognitive fluctuations 
and visual hallucinations) were also at more risk of decline than those with slower-developing 
features (REM sleep behaviour disorder or parkinsonism) or those with Alzheimer’s disease. 
Mild cognitive impairment with Lewy bodies may therefore feature early cognitive, clinical, and 
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Chapter 1. Conceptual Background 
1.1 Dementia 
Dementia is a common age-related disorder (Ferri et al., 2006) characterised by the onset of a 
cognitive impairment that is sufficiently severe so as to interfere with capability to function 
independently (McKhann et al., 2011) and consequently an increased reliance on family and 
caregivers to undertake daily activities such as cooking, cleaning, and self-care. The impairments 
characterising this clinical syndrome must represent a decline from the individual’s previous 
level of function and be more severe than the relatively more subtle changes experienced in the 
normal process of ageing. While regional rates vary, dementia is a global issue with prevalence 
rates of approximately five to seven percent in people over the age of 60 (Prince et al., 2013); 
while incidence rates are falling at estimated rates of 7-19% per decade in Europe and the United 
States (Wolters et al., 2020), overall prevalence is rising, and is expected to continue to do so as 
the global population continues to age (Livingston et al., 2020).  
As a leading cause of disability and dependency in old age, dementia is responsible for a high 
level of societal burden, impaired quality of life, and financial cost to healthcare services. 
Worldwide costs have been recently estimated at over one trillion US dollars per year, and are 
projected to continue to rise (Wimo et al., 2017). 
1.1.1 Causes of dementia 
Dementia is a heterogeneous clinical syndrome and may result from any one of many underlying 
pathophysiological processes, or a combination of these; neurodegenerative diseases, 
cerebrovascular disease, or genetic mutations being common examples. Less commonly, 
malnutrition or viral infection may also lead to dementia. Reflecting these varying underlying 
causes, individual cases of dementia may have highly variable clinical presentations. As many as 
40% of cases of dementia have been estimated to be preventable through earlier interventions 
(Livingston et al., 2017; Livingston et al., 2020) to address twelve key risk factors; low 
education, hearing loss, traumatic brain injury, hypertension, alcohol misuse, obesity, smoking, 
depression, social isolation, physical inactivity, diabetes, and air pollution. However, the 
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majority of dementia cases (neurodegenerative causes in particular) are currently not preventable 
and may require appropriately targeted disease-modifying therapies to treat or prevent.  
 
Dementia due to Alzheimer’s disease 
The commonest cause (Barker et al., 2002) of dementia is Alzheimer’s disease (AD), estimated 
to account for between 60 and 80% of cases (Brenowitz et al., 2017a; Kapasi et al., 2017). AD is 
a neurodegenerative disease characterised by the accumulation of abnormal protein inclusions in 
the brain (Hyman et al., 2012); primarily, hyperphosphorylated tau proteins form neurofibrillary 
tangles within neurons, and beta-amyloid proteins aggregate to form extracellular ‘plaques’ 
(Nelson et al., 2011). These protein aggregates are associated with varying patterns of cortical 
atrophy and consequent dysfunction (Murray et al., 2011). White matter damage in the form of 
demyelination and axonal degeneration secondary to cortical pathology (McAleese et al., 
2017b), and transactive response DNA-binding protein 43 (TDP-43) pathology also commonly 
co-occur (McAleese et al., 2017a) and may contribute to clinical outcomes (James et al., 2016). 
 
The medial temporal lobes (MTL), which are important for memory and learning processes 
(Eichenbaum et al., 2007; Bird, 2017), are particularly affected by typical AD-related atrophy 
(Jack et al., 1998). Consequently, a dementia due to AD is often characterised cognitively by 
amnestic memory impairment, the severity of which is associated with the extent of MTL 
atrophy (Scheltens et al., 1992). However, this atrophy is typically not isolated to the MTL alone 
(Rabinovici et al., 2008), and so cognitive impairments may also extend to other functions such 
as attention (Malhotra, 2019), working memory (Baddeley et al., 1991), or visuospatial functions 
(Wilson et al., 2011).  
 
This is further complicated by the considerable heterogeneity possible in patterns of AD-related 
pathology and atrophy, with hippocampal-sparing patterns of neuropathology (Murray et al., 
2011) and atrophy (Ferreira et al., 2017) being atypical, but far from uncommon. Atypical 
subtypes such as this, or other rare patterns of neurodegeneration, may also give rise to a distinct 
clinico-cognitive syndrome, which may feature an earlier onset and different profile of cognitive 
impairment such as the particular speech and language dysfunction of a logopenic primary 
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progressive aphasia (PPA; Gorno-Tempini et al., 2011) or visuospatial dysfunction characteristic 
of posterior cortical atrophy (PCA; Crutch et al., 2012). 
 
The diagnosis of AD may be supported by a number of biomarkers (Jack et al., 2018). As AD is 
defined by the presence of abnormal amyloid and tau protein formations, AD-specific 
biomarkers typically aim to identify markers of abnormal accumulation of these proteins in vivo; 
currently these include elevated levels of phosphorylated tau or decreased amyloid-β42 (Blennow 
and Zetterberg, 2018) in cerebrospinal fluid (CSF), and the binding of particular positron-
emission tomography (PET) ligands to cortical amyloid (Ossenkoppele et al., 2015; Rice and 
Bisdas, 2017) or tau (Saint-Aubert et al., 2017) accumulations. More general markers of 
neurodegeneration include cortical atrophy observed by MRI as introduced above, reduced 
cerebral glucose metabolism identified with fluorodeoxyglucose (FDG) PET, and increased total 
tau in CSF; however, these could reflect neurological damage attributable to other disease 
processes, which may also contribute to cognitive impairment, not just AD (Jack et al., 2018).  
 
Treatment and management 
There are currently no disease-modifying therapies approved for any neurodegenerative 
dementia; recent trials looking to treat Alzheimer’s disease have largely focussed on preventing 
accumulation of the hallmark neuropathological features of this disease (e.g. with anti-amyloid 
therapies), without any clear benefits shown to date (Reiss et al., 2020). Treatment and 
management of dementia is therefore currently focussed on addressing the pathophysiological 
processes mediating relationships between the underlying disease and clinical symptoms, and on 
improving the psychological and social management of symptoms (e.g. in caregiving settings), 
as well as more effective prevention through modifiable health factors. 
 
Cholinesterase inhibitors (donepezil, galantamine, and rivastigmine) are effective at attenuating 
the cognitive symptoms of Alzheimer’s disease, though with only a modest effect (Birks, 2006), 
and considered as the frontline therapy for management of AD dementia, in addition to the less-
favoured NMDA-receptor antagonist memantine (Schneider et al., 2014). These treatments work 
to address the cholinergic deficiency which often results from degeneration of the nucleus basalis 
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of Meynert (NBM) and its cholinergic projections to the cerebral cortex in Alzheimer’s disease 
(Hampel et al., 2018) and related disorders. However, these treatments do not prevent worsening 
of symptoms, only reduce them for a time. 
Efforts to more effectively treat or prevent dementia are complicated by the high degree of 
heterogeneity within this clinical syndrome. The effective management, treatment, or eventual 
prevention of a neurodegenerative dementia relies upon a clear understanding of the disease 
underlying it in each case. 
 
While the commonest cause, AD is not the only cause of dementia. Cerebrovascular factors 
including stroke, infarcts, ischaemia and haemorrhages (O'Brien and Thomas, 2015) are 
common, with vascular pathology featuring in isolation in approximately 10% of dementia cases 
(Jellinger and Attems, 2011), but also often co-occurring alongside other pathologies (Attems 
and Jellinger, 2014; Brenowitz et al., 2017a). These, and other neurodegenerative diseases can 
lead to cognitive impairment and dementia with varying additional symptoms, and may require 
different management and prevention strategies, particularly when considering putative disease-
modifying therapies with specific pathological targets. One of these neurodegenerative 
conditions which has risen to prominence relatively more recently in the dementia literature is 
Lewy body disease; the resulting syndrome of dementia with Lewy bodies, and its cognitive 
prodrome, are the primary interest of this work. 
 
1.2 Dementia with Lewy bodies 
The pathology of Lewy body (LB) disease has long been associated with Parkinson’s disease 
(PD), the clinical entity characterised by progressive motor impairment in later life (Hughes et 
al., 1992). The hallmark pathological findings of PD are the formation of Lewy bodies and Lewy 
neurites in the substantia nigra in particular, as well as other areas of the basal forebrain and 
brain stem (Forno, 1996).  
 
There has since been a growing recognition that more widespread sub-cortical and cortical Lewy 
body pathology is also a common cause of dementia, and is currently understood to be the 
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second most common cause of neurodegenerative dementia (Heidebrink, 2002; Jellinger and 
Attems, 2011; Vann Jones and O'Brien, 2014), after AD. Lewy body pathology is present in 
relative isolation in at least 8.5% of cases of dementia, and in up to 17.4% of cases in 
combination with other pathological findings (Jellinger and Attems, 2011). The associated 
clinico-cognitive syndrome has been described under various names historically, including 
‘Lewy body variant Alzheimer’s disease’ (Hansen et al., 1990; Galasko et al., 1994) and ‘senile 
dementia of Lewy body type’ (McKeith et al., 1994), reflecting a previous lack of consensus in 
its conceptualisation, but since the formulation of consensus diagnostic criteria (McKeith et al., 
1996) this has been consistently identified as dementia with Lewy bodies (DLB) in the revised 
criteria (McKeith et al., 2005; McKeith et al., 2017).  
 
Previous descriptions of DLB as a variant of AD (Olichney et al., 1998) reflect the ostensible 
similarities between these syndromes in their clinical presentation, and common overlap in 
underlying neuropathological presentation, which remain as obstacles in distinguishing these in 
clinical research and practice. While both AD and DLB may feature insidious onset of single- or 
multi-domain cognitive decline, and consequently loss of independent function, DLB is a distinct 
form of dementia with its own particular challenges in diagnosis, treatment, and care reflecting 
the different underlying patterns of neuronal dysfunction (Taylor et al., 2020). Despite this, 
relative to the prevalence expected from neuropathological studies (Jellinger and Attems, 2011; 
Brenowitz et al., 2017a) DLB is apparently still under-diagnosed in clinical practice (Kane et al., 
2018) suggesting that more work is required to disentangle this syndrome from competing 
clinical diagnoses. 
 
Current consensus criteria (McKeith et al., 2017) for DLB require that ante-mortem diagnosis be 
made on the basis of the presence of specific core clinical features and indicative biomarkers, in 
addition to an all-cause dementia diagnosis as introduced in Section 1.1 (McKhann et al., 2011). 
These clinical features and biomarkers may specifically distinguish DLB from competing 
diagnoses such as AD, a vascular cognitive impairment, or a frontotemporal dementia. The 
current criteria include four equally weighted core clinical features, and three indicative 
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biomarkers, which in combination may distinguish DLB in clinical settings (see Figure 1.1 
reproduced from McKeith et al., 2017). 
 
Figure 1.1. Current consensus criteria for clinical diagnosis of DLB, adapted from McKeith et al. (2017), 




1.2.1 Core clinical features 
Visual hallucinations 
Hallucinations, erroneous sensory perceptions in the absence of any real stimulus, are a feature 
of a wide range of medical conditions, though they may also be a normal experience in certain 
situations e.g. hypnagogic hallucinations. Hallucinations may be simple or complex, may present 
in any of the sensory domains (e.g. as tactile, auditory, or visual hallucinations), and may 
sometimes develop when normal sensory input is disrupted or removed entirely; for example 
hallucinatory pain experienced in an amputated limb (Collins et al., 2018), or auditory 
hallucinations after hearing loss (Waters et al., 2018).  
 
Visual hallucinations are a common feature in psychiatric, neurological, and ophthalmological 
disease (O'Brien et al., 2020), occurring in 11-17% of AD cases, 5-14% of people with vascular 
cognitive impairments, and in 15-60% of people with primary visual impairment depending on 
the severity of sight loss (ffytche, 2009). Visual hallucinations may present as simple visual 
experiences without form (e.g. colours or simple shapes), misidentifications, or distortions of real 
stimuli, but may also present as more complex hallucinations with a clear form (e.g. as humans, 
objects or animals, in the absence of any real stimuli to misidentify or distort). Complex, well-
formed visual hallucinations are a hallmark feature of DLB and are present in as many as 80% of 
developed cases (McKeith et al., 2017) and may appear, though less commonly, at the very early 
stages (31.6% of cases; Lin et al., 2018). Autopsy-confirmed cases of DLB are considerably 
more likely to have presented with visual hallucinations during life than AD cases (Luis et al., 
1999) and the development of visual hallucinations in an AD syndrome is highly indicative of 
the additional presence of LB pathology, and therefore a mixed AD-DLB dementia (Thomas et 
al., 2018).  
 
Because of the common and variable nature of visual hallucinations in other conditions, the 
nature of hallucinatory experiences must be carefully assessed by an experienced clinician. 
Simple visual hallucinations are a common feature in eye disease-related sight loss (ffytche, 
2009), for which ageing is a considerable risk factor; age-related macular degeneration, the most 
common cause of visual impairment, has an estimated global prevalence of 11.2-15.1% (early) 
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and 2.2-3.9% (late) in those aged over 70 years. Amongst other psychiatric disorders, complex 
visual hallucinations often also occur in delirium, which is similarly associated with ageing and 
dementia (Inouye et al., 2014), and in schizophrenia (Waters et al., 2014). Consequently, 
consideration of the diagnostic relevance of visual hallucinations to suspected DLB must 
consider the complexity of the visual experience alongside any competing explanation for the 
hallucinations (Manford and Andermann, 1998; Terao and Collinson, 2000) on a case-by-case 
basis. In DLB, complex visual hallucinations may often take on forms of humans, animals, or 
objects, and may be sufficiently credible to compel the hallucinator to attempt to act on their 
presence (e.g. by attempting to interact with the person, or to tidy away the clutter caused by 
perceived objects) which may lead to a realisation that they are not real (Yumoto and Suwa, 
2019). Descriptions of phenomena such as these, along with an absence for any alternative 
explanation for the visual experiences, may be highly supportive of a diagnosis of DLB. 
 
While the exact aetiology responsible for visual hallucinations in DLB is uncertain, DLB is 
associated with focal functional disturbance in the cortical (Minoshima et al., 2001; Fujishiro et 
al., 2013) and sub-cortical (Delli Pizzi et al., 2014) visual systems, without extensive structural 
atrophy. This particular pattern of pathological changes has been theorised (Erskine et al., 2019) 
to be responsible for the form of visual hallucinations typical of DLB; functionally degraded 
visual input is misinterpreted downstream by preserved cortical structures, manifesting in well-
formed hallucinations. The perception of visual hallucinations in general may be supported by an 
increased reliance, in some individuals, on top-down prior expectations rather than bottom-up 
sensory input due to attentional dysfunction (Collerton et al., 2005; Zarkali et al., 2019), a failure 
in source monitoring leading to internally-originating visual imagery to be misattributed to 
external stimuli (Allen et al., 2008; Aynsworth et al., 2017), or hyperexcitability in the 
structurally-preserved visual cortex (Burke, 2002). These different hypothesised causes may 
likely account for the varying presentations of visual hallucinations in disorders with widely 
differing pathophysiology. 
 
In AD, PD and DLB, visual hallucinations have been consistently associated with particular 
patterns of pathophysiology, including cholinergic denervation (Court et al., 2001), though 
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patterns may vary between diseases (Hepp et al., 2013). Consequently cholinergic treatment may 
reduce the severity of visual hallucinations in DLB (Satoh et al., 2010). 
 
Cognitive fluctuations 
Cognitive fluctuations, intra-individual variations in level of alertness, attention and arousal, and 
cognitive functioning, are commonly reported in most common types of dementia (Lee et al., 
2012), though they are considerably more likely to be observed in DLB. Fluctuating cognition 
and attention is present in as many as 90% of DLB cases (O'Dowd et al., 2019), compared with 
10% of AD cases (though these may be qualitatively different as noted below), and may be 
observed prior to onset of dementia in DLB (Donaghy et al., 2017).  
 
Apparent fluctuations may be reported in AD and vascular cognitive impairments, but are 
recognised as being qualitatively different in presentation (Bradshaw et al., 2004). DLB-type 
fluctuations are described as periods of blank unresponsiveness while the patient is seemingly 
awake, lasting from seconds to minutes or even considerably longer, followed by a return to 
apparently normal alertness and lucidity; fluctuations are therefore worse in severity in DLB 
(Walker et al., 2000a). This pattern of fluctuation has been theorised to reflect dysfunction of 
widespread networks responsible for regulating attention, arousal, and sleep (Matar et al., 2019b; 
O'Dowd et al., 2019) and may be traced back to a central cholinergic deficiency (Ballard et al., 
2002; O'Brien et al., 2005; Schumacher et al., 2020b). In comparison, fluctuations as described 
in AD have been reported by caregivers as periods of severe forgetfulness and repeated 
questioning often in response to environmental stressors, while retaining active alertness 
(Bradshaw et al., 2004). Appearing to be episodes of particularly severe AD-typical amnestic 
memory impairments, fluctuations as described in this way would not be considered as 
symptomatic of DLB, and likely reflect a different pathophysiological process relating to the 
primary memory dysfunction, possibly interacting with other causes of periodic worsening of 
dementia symptoms such as ‘sundowning’, which may be reported in up to 82% of people with 




REM sleep behaviour disorder 
In healthy individuals, the rapid eye movement (REM) stage of sleep normally features a loss of 
muscle tone, paralysing the body and preventing movement during dreaming. REM sleep 
behaviour disorder (RBD) is a sleep disorder characterised by an aberrant lack of typical atonia 
in this sleep stage; this leads to the enactment of motor actions from vivid dreams, such as the 
thrashing of limbs, vocalisations, and grasping behaviours, which may lead to physical harm to 
self or others, as well as distress to bed-sharers (Boeve, 2010). RBD has been recognised as a 
common early presentation of synucleinopathic neurodegenerative diseases (Boeve et al., 2001), 
and while it may remain as an isolated RBD syndrome for some time, this may develop into one 
of the multi-faceted synucleinopathies (i.e. PD or DLB). 
 
A history of RBD is highly indicative of DLB (Ferman et al., 2011), being present in 76% cases 
of autopsy-confirmed DLB, in comparison to only 4% of non-DLB, and is therefore considered 
to be a core feature of the syndrome. While a history of RBD is also a risk factor for 
development of other Lewy body diseases such as PD (Hickey et al., 2007), people with either 
PD or DLB are considerably more likely to have experienced RBD than those with AD (Boeve et 
al., 2001). A clear history of RBD is therefore highly predictive of underlying LB disease, even 
prior to onset of motor or cognitive symptoms; RBD may present in cases of eventual DLB or 
PD years and occasionally decades before the onset of cognitive or motor symptoms (Claassen et 
al., 2010) and so may be one of the earliest observable symptoms of an underlying 
neurodegenerative process in some cases. Postuma et al. (2019) identified that, in isolated RBD 
without cognitive impairment or parkinsonism, 73.5% had developed PD or DLB after twelve 
years of follow-up, with an annual conversion rate of 6.3%. In this sample, a parkinsonism-first 
onset (i.e. PD) was slightly more common than a dementia-first onset (DLB), with PD occurring 
first in 56% of cases, versus DLB in 44%.  
 
Definitive presence of REM sleep without atonia (RSWA) is confirmed with polysomnography 
(PSG) by the observed preservation of muscle tone during REM sleep. This allows for 
differential diagnosis of RBD from a potential non-REM stage parasomnia, which may mimic 
RBD based on informant or patient description alone (Boeve, 2010). RBD may also be quickly 
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screened with a questionnaire administered to an informant (Boeve et al., 2011b), which is more 
feasible in studies of dementia where PSG confirmation of RSWA would be impracticable, 
though at a cost of specificity (74%), as non-REM stage parasomnias (e.g. obstructive sleep 
apnoea) may mimic RBD in this manner. While sensitivity was high in this sample (98%), all 
patients had a bed partner available as an informant as required by the questionnaire, which may 
not translate as well into community settings; this is a particular limitation given that among over 
65s, the population of primary interest for dementia research and in clinical practice, living alone 
is both common, and increasing. In the developed world between 20-40% of individuals aged 
over 65 are estimated to live alone, largely reflecting increased separation, divorce, and 
widowhood in older age (Reher and Requena, 2018); while rates of living alone are lower in the 
developing world, those who live with extended family may not have a bed partner as an 
informant. In these cases, this questionnaire would not be appropriate to complete, and so the 
presence of RBD may be missed. 
 
Parkinsonism 
PD is clinically characterised by a distinct pattern of motor impairment (Postuma et al., 2015) 
including resting tremor, rigidity, and bradykinesia. This broad group of symptoms is described 
as parkinsonism, which may be observed in conditions other than in PD itself; diagnosis of PD 
requires not only the presence of clinically-diagnosed parkinsonism, but also supportive 
information that these symptoms are due to PD and not any other condition. Conditions in which 
parkinsonism may arise include multiple system atrophy, progressive supranuclear palsy, normal 
pressure hydrocephalus, as a result of one or more strokes, or cerebellar abnormalities.  
 
Due to the shared aetiology underlying both PD and DLB, parkinsonism is often also observed in 
DLB, occurring in up to 85% of cases at an advanced stage (Fujishiro et al., 2008); current 
criteria dictate that symptoms of parkinsonism in DLB are in either insufficient number or 
severity to qualify an independent diagnosis of PD, or that their onset coincides with- or follows 
the emergence of cognitive impairment (preceding cognitive symptoms by fewer than 12 
months; McKeith et al., 2017). The presence of only one feature of parkinsonism is sufficient for 
this to be considered as a core feature of suspected DLB. As in PD, the presence of parkinsonian 
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signs in DLB is indicative of a dopaminergic deficiency (Miller and O'Callaghan, 2015), with 
neuronal loss in the substantia nigra leading to dysfunction of the nigrostriatal pathway and a 
consequent failure to initiate and sustain voluntary movements. In individuals an absence of 
parkinsonism, as seen in at least 15% of DLB cases (Fujishiro et al., 2008), may therefore 
suggest a relative absence of dopaminergic dysfunction. 
 
In DLB, the severity of parkinsonism and any changes over time may be quantified with part 
three of the Unified Parkinson’s Disease Rating Scale (UPDRS; Goetz et al., 2008). With these 
scales any impairments are ‘rated as seen’. Non-parkinsonian causes of motor impairment, e.g. 
arthritis, may therefore contribute to high scores in these. Clinical judgement of parkinsonism for 
diagnostic purposes must therefore be primarily guided by a holistic consideration of all 
information available and follow the Movement Disorder Society (MDS) criteria for these, rather 
than being based on scores on this rating scale alone. 
1.2.2 Supportive clinical features 
In addition to the core clinical features of DLB, a number of supportive features may also be 
observed; these are insufficiently sensitive and/or specific for use in diagnosis, but may support a 
diagnosis in the presence of one or more core clinical features (McKeith et al., 2017). These 
features include: autonomic dysfunction (Horimoto et al., 2003; Thaisetthawatkul et al., 2004), 
neuroleptic sensitivity (McKeith et al., 1992), olfactory dysfunction (Williams et al., 2009), 
unexplained falls (Ballard et al., 1999c) or postural instability, non-visual hallucinations or 
delusions (Ballard et al., 1999a), mood disorders including apathy, anxiety, or depression 
(Rockwell et al., 2000), excessive daytime sleepiness, unresponsiveness or syncope (Boddy et 
al., 2007). While these features may not contribute directly to a diagnosis, they may assist 
clinicians in identifying potential candidates for detailed exploration of DLB and are important 
to recognise as likely impactors on quality of life for people with dementia and their caregivers. 
 
Neuroleptic sensitivity 
Long recognised as a suggestive clinical feature of DLB (McKeith et al., 1996; McKeith et al., 
2005), Lewy body diseases are associated with a severe and life-threatening sensitivity to 
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neuroleptic treatment (McKeith et al., 1992; McKeith et al., 1995). Up to 50% of people with 
DLB exposed to these medications may demonstrate this neuroleptic sensitivity resulting in 
severe sedation or even death, in addition to common ‘normal’ side effects such as 
extrapyramidal symptoms. This may complicate efforts to treat neuropsychiatric symptoms of 
LB disease (Baskys, 2004). With an increase in clinical awareness of this risk, and risks 
associated with antipsychotics in other dementias (Ballard and Howard, 2006), neuroleptics are 
now much less likely to be prescribed to people with dementia. As a result, this symptom is less 
likely to occur and consequently the value of neuroleptic sensitivity as a feature for the diagnosis 
of DLB has diminished. Sensitivity to antipsychotic medication is therefore considered to be a 
supportive feature only in DLB diagnosis (McKeith et al., 2017), but remains an important 
symptom to consider in clinical settings due to the potential for harm if overlooked (Taylor et al., 
2020). 
 
1.2.3 Indicative biomarkers 
The presence of indicative biomarkers of LB disease may aid in differential diagnosis of DLB 
from AD or other causes of dementia. A diagnosis of probable DLB may not be made on the 
basis of multiple biomarker presence alone without core clinical features: in this case a diagnosis 
of possible DLB would be made. 
 
Abnormal uptake of dopamine transporter to the basal ganglia 
Using N-ω-fluoropropyl- 2β-carbomethoxy- 3β-(4-iodophenyl) nortropane (FP-CIT) single-
photon emission computed tomography (SPECT) or PET imaging, presynaptic dopamine 
transporters in the basal ganglia may be visualised and interpreted by an experienced analyst to 
assess dopaminergic deficiencies. Visual ratings of images may be dichotomised as showing 
either normal or abnormal uptake, an ordinal visual rating scale may be used (Benamer et al., 
2000), or semi-quantitative automated analyses may be performed (Colloby et al., 2004) for 
increased granularity; the latter option appears to offer slightly more accuracy than visual ratings 
(McCleery et al., 2015), and in modern clinical practice and research settings, both methods are 




DLB and PD patients are likely to display abnormalities of dopamine transporter FP-CIT binding 
in the corpus striatum in comparison with healthy controls, while AD patients as a group do not 
(Hu et al., 2000; O'Brien et al., 2004), except in advanced cases where tauopathy may affect the 
brainstem and substantia nigra. Abnormal dopaminergic imaging is present in 77.7% of clinically 
probable DLB cases versus 6.9% of clinically probable AD (McKeith et al., 2007a). Patterns of 
abnormality vary, and these may present as unilateral or bilateral reductions or absences of 
uptake in the putamen alone or may also extend symmetrically or asymmetrically to the caudate, 
reflecting progressive degeneration of pre-synaptic dopaminergic neurons. Use of FP-CIT 
imaging has high diagnostic accuracy in DLB, with good sensitivity and specificity (McKeith et 
al., 2007b; Papathanasiou et al., 2012), and its utility in diagnosis has been supported by autopsy 
validation (Thomas et al., 2017). 
 
Comparison of repeated FP-CIT scans after 1-year of follow up has indicated that uptake 
abnormalities in DLB may progressively worsen over time (Colloby et al., 2005). Some DLB 
cases may present with initially normal transporter uptake on FP-CIT, with abnormalities 
emerging further into the disease course (van der Zande et al., 2016), while others may present 
with abnormal uptake at the prodromal stages prior to onset of dementia (Thomas et al., 2019). 
However, not all cases of DLB have any notable dopaminergic dysfunction even by death; 10% 
of cases of DLB have normal projections from the substantia nigra to the striatum at autopsy 
(Thomas et al., 2017). Abnormal dopamine transporter uptake may therefore be characterised as 
a progressive degenerative process with different staging between individuals, and even absence 
of degeneration in some cases, which may partially account for the observed variability in 
patterns of abnormality found in cross-sectional studies. The presence of a normal FP-CIT 
uptake on initial imaging does not necessarily preclude the eventual emergence of abnormal 
dopaminergic imaging further into the disease course, but in some cases may suggest a relative 




Abnormal myocardial uptake of 123I-MIBG 
Reduced uptake of 123I-meta-iodobenzylguanidine (MIBG; a noradrenaline analogue that binds 
to presynaptic noradrenaline receptors) to the heart, relative to the mediastinum, may be 
observed by means of myocardial scintigraphy in DLB (Watanabe et al., 2001). Low cardiac 
uptake of MIBG may reflect early cardiac denervation (Orimo et al., 2005) related to the 
pathological effects of alpha-synuclein present in the sympathetic nervous system (Beach et al., 
2010). This biomarker may be useful to discriminate DLB from AD (Yoshita et al., 2006), 
particularly in the early stages of dementia (Yoshita et al., 2015); both sensitivity and specificity 
for separating DLB from AD appear better in mild dementia (77.4% and 93.8%, respectively) 
than in moderate or severe dementia (59.6% and 83.3%). As pathologically-identified cardiac 
denervation has been found to separate a mixed AD-DLB pathology from pure AD (Serrano et 
al., 2020), cardiac MIBG may also show promise in identifying a mixed AD-DLB clinical 
syndrome ante mortem.  
 
MIBG scintigraphy therefore may have diagnostic utility as an alternative to, or when used in 
conjunction with (Shimizu et al., 2016), dopaminergic imaging to aid in the differential diagnosis 
of DLB or a mixed syndrome from AD. Aside from AD, MIBG imaging may also help 
discriminate DLB and PD from other syndromes with overlapping clinical presentations such as 
progressive supranuclear palsy, multiple system atrophy, and frontotemporal dementias 
(Kashihara et al., 2006; Estorch et al., 2008), which FP-CIT imaging may be unable to 
distinguish between (Morgan et al., 2012). However, several factors may complicate the 
application of MIBG to everyday clinical practice including availability of radioligands, 
experience in undertaking imaging, and rates of cardiovascular comorbidity or of prescription of 
contraindicative medications. Therefore within clinical settings in the United Kingdom, cardiac 
MIBG does not currently appear to be favourable to the more widely used FP-CIT SPECT in 
detecting cases of DLB (Kane et al., 2019), though this could change if clinical experience in 
utilising this develops further. 
 
While a valuable comparison in clinical diagnostic settings, comparing the information garnered 
from MIBG and FP-CIT imaging may be a false dichotomy in research settings; these two 
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imaging methods assess differing pathophysiological processes (cardiac sympathetic denervation 
in the former, nigrostriatal dopaminergic denervation in the latter) which likely differ between 
individuals, given the considerable variation in patterns of LB neuropathology and 
pathophysiology: some individuals may have abnormalities in one system or the other, some in 
both, and some in neither. These differing biomarkers may reflect different clinical phenotypes, 
albeit with some natural degree of overlap. 
 
Polysomnography (PSG)-confirmed REM sleep without atonia 
The presence of PSG-confirmed REM sleep without atonia is highly indicative of DLB; in 
patients with reported RBD as a clinical symptom this biomarker is particularly specific for LB 
diseases (Boeve et al., 2013). Confirmation of REM sleep without atonia may assist in the 
differential diagnosis of RBD from non-REM sleep parasomnias which may mimic RBD based 
on patient or informant report but may not be indicative of the presence of Lewy body disease. 
However, this procedure is laborious, expensive, and may not be practical or ethical to undertake 
in people with moderate-to-severe dementia. 
 
1.2.4 Supportive biomarkers 
A wider range of biomarkers are associated with a respective differential diagnosis of either AD 
or DLB. These markers lack the sensitivity or specificity required to assist in diagnosis but may 
provide a further depth of understanding of underlying disease processes, or heterogeneity of 
dementia features, particularly in research settings.  
 
While AD is typified by extensive atrophy of the MTL, and in particular the hippocampi, such 
atrophy is typically less severe in DLB (Burton et al., 2008). MTL volume is not completely 
preserved in DLB however, and when compared to healthy controls a significant degree of 
atrophy may still be observed (Barber et al., 1999). Hippocampal atrophy in DLB may reflect the 
additional contributions of co-occurring AD pathology (Nedelska et al., 2015; van der Zande et 
al., 2018b). A relative preservation of the hippocampi specifically, and MTL in general (e.g. on 
structural MRI) may therefore be supportive of a diagnosis of DLB, but is most likely not 
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sufficiently specific to DLB (as atypical hippocampal-sparing patterns may occur in AD), nor 
sensitive to it (as hippocampal atrophy may co-occur in DLB) to be considered as an indicative 
biomarker. 
 
While the occipital lobes are largely spared from structural atrophy in both DLB and typical AD 
(Middelkoop et al., 2001), functional disruption of the visual pathways is typical of DLB. In 
comparison with AD, DLB features occipital hypoperfusion (Lobotesis et al., 2001) and 
hypometabolism (Ishii et al., 1999). This may help partially explain some of the cognitive and 
clinical symptoms experienced in DLB, as discussed later. The cingulate island sign is a 
particularly specific pattern of posterior hypometabolism which may be found in DLB, with 
reduced occipital metabolism but a relative sparing of the posterior cingulate cortex. This pattern 
of hypometabolism is not typically found in AD (Imabayashi et al., 2016), but may become less 
useful as LB disease develops and the sign becomes less clear, which may reflect an increase in 
AD co-pathology in more advanced DLB (Iizuka et al., 2017). Generalised reductions in 
metabolism or perfusion, reduced occipital activity specifically, or the cingulate island sign in 
particular may therefore also be supportive of a DLB diagnosis. 
 
Resting state electroencephalography (EEG) has suggested that DLB is associated with dominant 
frequency slowing over the posterior derivation in comparison with AD (Bonanni et al., 2008). 
More specifically, this pattern of slowing appears to be associated with cognitive fluctuations in 
DLB (Stylianou et al., 2018). Focal posterior slow-wave activity may therefore be a suggestive 
biomarker for DLB. EEG may also offer further context in research settings as to the network 
dysfunctions underlying particular clinical symptoms, e.g. as a marker for the cholinergic 
deficiency which may contribute to cognitive fluctuations or visual hallucinations (van der Zande 
et al., 2018a; Schumacher et al., 2020b). 
1.2.5 Neuropathology 
While possible or probable diagnoses may be made of suspected AD and DLB in life, the cause 
of the dementia may only be confirmed with certainty upon death and autopsy. DLB is 
characterised by a pathology distinct from the amyloid- and tauopathy which defines AD 
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(Hyman et al., 2012). DLB is a synucleinopathy, characterised by the presence and progressive 
aggregation of Lewy bodies and Lewy neurites in neurons of the cortex or brainstem; both Lewy 
bodies and neurites contain aggregates of alpha-synuclein protein (Spillantini et al., 1998). In 
addition to its presence in the central nervous system, alpha-synuclein may also present within 
the peripheral nervous system in LB disease (Beach et al., 2010), which may result in autonomic 
dysfunctions and MIBG imaging abnormalities. This underlying pathology is shared by DLB, 
PD in which it was first described, and Parkinson’s disease-dementia (PDD); these distinct 
clinical syndromes are currently conceptualised as different outcomes sharing the underlying 
pathology of Lewy body disease (McKeith et al., 2017). 
 
The staging and spread of Lewy body pathology in the brain, and presence of AD co-pathology, 
is variable, with significant differences between individuals (Brunnström et al., 2012) which may 
contribute to the heterogeneous presentation of symptoms within DLB (Morenas-Rodríguez et 
al., 2018; Coughlin et al., 2020), and the variable timings of parkinsonism and dementia that 
contribute to diagnosis of DLB, PD, or PDD. 
 
It is rare for a clinical diagnosis of DLB to manifest from a ‘pure’ Lewy body disease; Lewy 
bodies can often be accompanied by AD pathology, with significant levels of amyloid deposition 
in some cases (Gomperts et al., 2008). Neurofibrillary tangles may also be present in DLB, but 
are less typical or prolific than in clearly defined AD (Fujishiro et al., 2008). Recent 
neuropathological data has suggested that mixed pathologies may be underestimated in ante-
mortem clinical diagnoses (Selvackadunco et al., 2019) with additional features of DLB often 
being missed in clinical AD. The positive identification of concurrent DLB and AD during life is 
of particular importance given the poorer clinical prospects associated with a mixed AD-LB 
aetiology underlying dementia (Brenowitz et al., 2017a). 
 
Caution must be exercised in interpreting the apparent abundance of mixed pathologies in post-
mortem studies however, as these may not entirely reflect the neurodegenerative processes 
driving early clinical change; increasing age is associated with the presence of AD pathology at 
autopsy, ranging from 15% at age 70, 65% at age 85, to 75% at age 95 (Farfel et al., 2019). This 
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is the case even in unimpaired groups, with up to 40% of apparently cognitively healthy subjects 
having AD-associated pathological findings by the ages of 80-85 (Selvackadunco et al., 2019). 
Cases of DLB may therefore develop more AD-type pathology towards the later stages of 
dementia and prior to death but may be inaccurate to describe as a clinically mixed syndrome at 
the early stages. Post-mortem samples are a snapshot of the end-stage of a long period of 
degeneration, and in some cases an eventual mixed neuropathological profile may not be an 
accurate reflection of the biological processes responsible for their preceding clinical syndrome, 
especially when clinical and cognitive data are derived from the mild or prodromal stages. 
 
While additional pathological processes may not always reach a sufficient threshold in the early 
or intermediate stages of decline to have a clear clinical contribution, in some cases the presence 
of sufficiently evident mixed pathologies may manifest in a mixed clinical profile (Thomas et al., 
2018); this might complicate prospective diagnosis, and may also contribute to variance in 
cognitive decline. In cases of mixed AD-DLB with a high neuropathological Braak staging 
however, the presence of clinical features of DLB within the mixed dementia syndrome may be 
obscured, contributing to misdiagnosis (Merdes et al., 2003). Furthermore, cases of mixed AD-
DLB with missed diagnosis of DLB features feature a poorer prognosis with faster cognitive 
decline than either pure-, or clinically-diagnosed mixed pathologies (Malek-Ahmadi et al., 
2019). 
 
AD and LB pathologies therefore have significant degrees of overlap and are not mutually 
exclusive. This may account in part for the difficulties in distinguishing these diseases prior to 
autopsy, and the lack of symptomatic homogeneity within each disease. 
 
1.2.6 Prognosis, treatment, and management 
As a result of the distinct pathophysiology and clinical presentation, DLB has a different 





A diagnosis of DLB is associated with much greater burden to caregivers and lower ability to 
live well (Wu et al., 2018a). Increased carer stress in DLB is associated with symptoms of 
psychosis, mood disturbance, daytime sleepiness, and the experience of cognitive fluctuations 
(Lee et al., 2013). Delays in diagnosis and lack of guidance or support may also play a role in 
caregiver distress in DLB (Killen et al., 2016). As a result, those with a diagnosis of DLB have a 
greater reliance on residential care (Mueller et al., 2017), and an increased risk of hospitalisation, 
with greater lengths of stay, which is similarly associated with the presence of psychotic 
symptoms (Mueller et al., 2018). 
 
Consequently, a recent meta-analysis has demonstrated that DLB has a shorter average survival 
time after diagnosis (4.11 years) than AD (5.66 years), independent of age, gender, and level of 
cognitive functioning (Mueller et al., 2019). DLB also results in increased economic healthcare 
costs, with those costs increasing with each core clinical feature observed, and being particularly 
high in those experiencing fluctuating attention and cognition (Espinosa et al., 2020). 
 
Treatment and management 
The multi-faceted nature of underlying pathophysiology and resultant symptoms in DLB may 
complicate treatment and require a holistic management strategy, as reviewed by Taylor et al. 
(2020), particularly as therapeutics which typically target one type of symptom may have an 
adverse effect on entirely different symptoms; for example, treatment of hallucinations and 
delusions with typical anti-psychotics may lead to a severe sensitivity reaction (as noted 
previously) while treatment of motor symptoms with dopaminergic medications may worsen 
psychotic symptoms (Goldman et al., 2008). 
 
In general, cholinesterase inhibitors are well tolerated in DLB and have shown utility in treating 
both cognitive symptoms and neuropsychiatric symptoms (Taylor et al., 2020); donepezil and 
rivastigmine being the best supported examples of these, and therefore common in clinical use. 
The efficacy of such treatments supports the key role of cholinergic deficiencies in the clinical 
presentation of DLB. Levodopa, the front-line pharmacological treatment for PD, may have 
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utility in reducing parkinsonism in DLB, however as noted above, dopamine therapy may 
worsen psychotic symptoms in up to one in three patients, requiring careful balance of risk. Deep 
brain stimulation, while effective at alleviating motor symptoms of PD, is contraindicated for 
DLB as this may worsen cognitive impairments when they are already present (Mehanna et al., 
2017). RBD may be managed with a range of treatments, including clonazepam, melatonin, or 
memantine, as well as non-pharmacological interventions to change sleep hygiene and 
environment.  
1.2.7 Section summary 
DLB is a common neurodegenerative syndrome recognised as possessing distinctive clinical and 
pathological features, and consequently has particular management needs in healthcare settings. 
Prospective diagnosis may be complicated by common clinical and pathological overlap with 
AD, but a number of clinical features and biomarkers have been described which may 
appropriately distinguish these syndromes ante-mortem. A diagnosis of DLB has implications for 
both the prognosis of a dementia syndrome, as well as for the treatment and management of this. 
 
1.3 Prodromal dementia 
The symptoms of neurodegenerative diseases typically emerge gradually as the underlying 
pathophysiology develops from the asymptomatic pre-clinical stage, to the prodromal stage when 
mild symptoms begin to emerge, before reaching the fully manifest clinical stage (Jack et al., 
2010). In AD, this prodromal stage will typically present as worsening cognitive functioning 
developing from mild cognitive impairment (discussed in detail in the following section) towards 
eventual dementia (Verlinden et al., 2016; Han et al., 2017).  
 
LB disease has a heterogeneous presentation with a wide range of potential clinical features. 
Accordingly, the prodromal stages of DLB may also have different characteristics in different 
individuals (McKeith et al., 2016), including not only cognitive-onset, but also delirium-, or 
psychiatric-onset presentations prior to dementia (McKeith et al., 2020). RBD (Claassen et al., 
2010), psychiatric symptoms (Jicha et al., 2010), or parkinsonism (Aarsland et al., 2010), may be 
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present for some time before onset of cognitive symptoms, and these may similarly be 
conceptualised as different early symptoms of an underlying synucleinopathy which may be 
prodromal manifestations of eventual DLB, PD, or multiple system atrophy (another less-
common synucleinopathy, which does not fall under the spectrum of LB disease). 
 
While wider definitions vary in the literature, within this work the ‘prodromal stage of DLB’ is 
considered as an umbrella term, including the early symptomatic stages of the many different 
recognised diagnostic routes into DLB including, for example, psychiatric-onset cases or isolated 
RBD which may not yet display (overt) cognitive symptoms. Clinically-diagnosed mild 
cognitive impairment is therefore considered as the cognitive prodrome of DLB, being only one 
of these many possible prodromal DLB conditions, and the best characterised and most common. 
1.3.1 Mild cognitive impairment with Lewy bodies 
Currently conceptualised as a transitional stage between normal cognitive ageing and dementia, 
individuals experiencing a greater-than-normal decline in cognitive functioning but with 
preserved independent daily functioning may be diagnosed with mild cognitive impairment 
(MCI; Albert et al., 2011). As increasing attention is being paid to the prodromal stages of 
dementia syndromes such as DLB and AD in an effort to improve diagnostics and develop 
treatments, MCI has therefore developed into a central concept in current research representing 
the cognitive prodrome to dementia. Recent prevalence estimates for MCI in those aged 60 or 
older range from 5.13% to 29.9%, increasing with age (Overton et al., 2019). While some MCI 
patients will return to normal functioning, and others will remain stable within the MCI category, 
due to the progressive nature of neurodegenerative disease there is a high likelihood of eventual 
conversion to dementia after a diagnosis of MCI (Gauthier et al., 2006), with typical estimates 
ranging from 5-20% per year, though this may vary greatly by the definition of MCI used and the 
assessment setting, to as high as 39% per year, as reviewed by Belleville et al. (2017); when 
drawing from community settings, conversion from MCI to dementia is relatively low, while in 
neurodegenerative-oriented settings, these may be higher, reflecting different conceptualisations 




Two principal methods of diagnosing and classifying MCI sub-types exist; individuals with MCI 
may be assessed with a neuropsychological assessment battery, and assigned a sub-type 
dependent on the domains of observed impairment (amnestic or non-amnestic, single- or multi-
domain; Winblad et al., 2004) in which they score below a given threshold. For example, 
individuals may be defined as amnestic MCI when scoring greater than 1.5 standard deviations 
below education and age-adjusted mean scores on a specific episodic memory test (Craft et al., 
2012) or non-amnestic if the primary cognitive dysfunction exists in a non-memory domain. 
While this method helps classify objective domains of cognitive impairment, these thresholds are 
arbitrary and may be insensitive to meaningful decline in individuals with a high functioning at 
baseline. Furthermore, this method makes it difficult to explore disease-specific 
neuropsychological outcomes, as the outcome measures are not independent of the diagnostic 
criteria. 
 
An alternative method is to classify MCI according to disease-specific clinical features; as the 
clinical symptoms, and many biomarkers, of DLB and AD-type dementia may manifest in 
individuals long before loss of capacity for independent living, it may be possible to identify 
individuals likely to be in the prodromal stages of DLB or AD, and consequently assign a 
specific diagnosis of MCI with Lewy bodies (MCI-LB; Belden et al., 2015; Donaghy et al., 
2017) or AD (MCI-AD; Jicha et al., 2010) should they otherwise meet disease-specific clinical 
criteria despite not yet meeting the threshold of functional impairment required for a dementia 
diagnosis. This method may be preferable when research is interested in the differences in 
neuropsychological patterns associated with different diseases, as the diagnostics remain 
independent of the outcome measures. 
 
As a developing field of study, with a significant degree of heterogeneity between and within 
subtypes (amnestic or non-amnestic, single or multi-domain), MCI is still being firmly 
conceptualised; particularly in the case of MCI-LB. The use of clinically-guided differential MCI 
diagnoses may be gaining traction, with the recent publication of consensus criteria for diagnosis 
of prodromal DLB, including MCI-LB, in research settings (McKeith et al., 2020). In the long 
term these criteria will require validation demonstrating that MCI-LB reliably converts to DLB, 
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and MCI-AD to AD-type dementia, as well as eventual autopsy validation of clinical diagnoses, 
to ensure that that these translate adequately to use in clinical practice. 
 
Non-degenerative MCI 
Understanding the MCI syndrome is complicated by the emergence of non-degenerative cases. 
While rates vary depending on diagnostic method and sampling setting, it is not uncommon for 
MCI cases to remain apparently stable for long periods of time, with past research into MCI in 
AD samples identifying stability in as few as one in three cases (Pagani et al., 2010) or even in a 
majority (55%) of cases (Huang et al., 2000). As noted previously, this heterogeneity likely 
reflects intangible differences in recruitment and clinical assessment (e.g. when considering 
moderate depression as an exclusion for MCI diagnosis) leading to differing rates of inclusion of 
non-degenerative cases.  
 
After further information comes to light (e.g. after follow-up assessment without any clear 
decline), what was previously considered to be a neurodegenerative MCI may be alternatively 
characterised as a non-degenerative vascular cognitive impairment (O'Brien and Thomas, 2015), 
a stable MCI with objective dysfunction but no clear decline (Villemagne et al., 2008), a 
subjective cognitive impairment with self-reported dysfunction but no objective evidence of 
dysfunction (SCI; Prichep et al., 2006; Slot et al., 2018) or fall under the umbrella of the newly-
emerging concept of a functional cognitive disorder (Pennington et al., 2015; McWhirter et al., 
2019). The latter concept describes cognitive dysfunctions which arise and become reinforced in 
a cyclical manner through psychological factors primarily (e.g. a patient with health anxiety who 
erroneously comes to believe that they have a cognitive impairment may become sensitive to 
normal everyday cognitive mistakes, leading to a loss of cognitive automaticity and therefore 
objective dysfunction, reinforcing the root anxiety); this represents an attempt at formalising 
some of the common psychological causes of cognitive dysfunction in the absence of 
neurodegenerative disease. Cognitive symptoms are known to arise secondary to a mood 
disorder, being common during and after major depression (Hammar and Årdal, 2009; Baune et 
al., 2010), as an outcome of sleep disturbance (Lal et al., 2012), health anxiety (Hodgson et al., 
1999; Boone, 2009), or a myriad of other possible causes (Stone et al., 2015). Non-degenerative 
25 
 
cases of MCI such as these may partly account for the low transition rates from MCI to dementia 
in some settings, where neurodegenerative-specific cases of MCI are included alongside 
degenerative cases (Mitchell and Shiri-Feshki, 2009), reflecting differences in conceptualisation 
of MCI between research centres. 
 
Early identification of non-declining-, and by extension, declining-MCI cases has important 
applications in clinical and research settings. Neurodegenerative and non-degenerative MCI 
cases are likely to have different therapeutic and management needs within memory and 
psychiatric services; effective treatments may target particular symptoms underlying a non-
degenerative cognitive disorder, such as metacognitive processes (Bhome et al., 2019) or 
depression (McIntyre et al., 2013). Given the different underlying aetiology of their MCI, non-
degenerative cases may also be inappropriate to include in clinical trials targeting 
neurodegenerative processes. Additionally, the misdiagnosis of a neurodegenerative disorder in a 
subjective or functional syndrome may cause undue distress, reinforce apparent impairments, 
and contribute to a loss of quality of life (e.g. due to stigma associated with the diagnosis). 
 
Even excluding non-degenerative cases, there remains uncertainty as to how quickly a 
degenerative MCI may develop into dementia, the extent to which particular neurodegenerative 
factors might influence this transition, and how specific patterns of cognitive impairment might 
be related to decline. 
 
Section summary 
Mild cognitive impairment is a heterogeneous neurocognitive disorder with numerous potential 
causes; where this cause is a neurodegenerative disease such as AD or LB disease, MCI may 
represent the cognitive prodrome of an eventual dementia syndrome. Differential 
characterisation of the MCI stages of AD and DLB is a focus of current research, given the 
potential benefits of earlier intervention. Research and treatment of neurodegenerative MCI is 
complicated by the presence of non-degenerative cases mimicking neurodegenerative types. 
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1.4 Patterns of cognitive impairment in Lewy body and Alzheimer’s diseases 
A greater understanding has developed of the particular patterns of neurocognitive impairment 
that develop in DLB in comparison with AD. While these may lack the predictive power 
required to contribute to differential diagnosis in isolation, they provide further clues as to the 
underlying development of dementia in different diseases and are commonly included in disease-
specific criteria. Clinicians may benefit from an improved understanding of the expected 
trajectory of cognitive decline, and which domains may be more or less affected in patients. 
1.4.1 Global cognition  
Global cognitive functions are taken to represent the sum of all domain-general and –specific 
functions, and therefore are conceptually a general measure of cognitive ability. A wide range of 
neuropsychological tests are available to assess global cognitive functioning in clinical and 
research settings, with suitability being largely dictated by the length of time available for 
testing, the level of detail or sensitivity desired by the practitioner, or the particular focus of a 
given study. The mini-mental state exam (MMSE; Folstein et al., 1975) is widely used in clinical 
settings and offers a quick view of global cognitive functioning. While offering reasonably good 
sensitivity for dementia, the MMSE lacks sensitivity in the early stages of dementia and MCI 
(Arevalo-Rodriguez et al., 2015) or in the cases where deficits present in non-memory domains 
of cognition (Votruba et al., 2016), such as visuospatial functions, to which only one of 30 
possible marks is allocated. Despite such limitations, the previous ubiquity of the MMSE in 
research and clinical practice means it is familiar to a global audience, and may help 
contextualise the levels of cognitive impairment in any given sample in a more accessible way 
than less-familiar alternatives. The MMSE may also be useful in settings where time is 
particularly limited. A similar test, the Montreal Cognitive Assessment (MoCA; Nasreddine et 
al., 2005) also sees widespread use as an alternative brief screening test to the MMSE, but with 
better sensitivity to mild dementia (Smith et al., 2007) and more equal assessment of non-





Various more detailed alternatives to the MMSE or MoCA also exist, with varying utility in 
research and clinical settings; the Addenbrooke’s Cognitive Examination (ACE) and its revised 
versions (ACE-R and ACE-III; Mioshi et al., 2006) offer a reasonable balance of sensitivity and 
time-cost, and so are commonly administered in memory services in the United Kingdom. The 
ACE and ACE-R both allow for derivation of an MMSE score, and all three variants provide a 
total global cognitive functioning score, and relatively more balanced assessment of different 
cognitive domains in which the MMSE is insensitive, such as visuospatial skills and verbal 
fluency (Bak and Mioshi, 2007). Meta-analysis has indicated that the ACE-R has superior 
sensitivity to both the ACE and MMSE in detecting impairment within a dementia population 
(Larner and Mitchell, 2014). However, all versions of the ACE are more time-intensive than the 
MMSE, and so may not be agreeable in all settings. A myriad of additional assessments see 
varying degrees of use in clinics and research; the Dementia Rating Scale (Mattis, 1988), 
Cambridge Cognitive Examination (CAMCOG; Huppert et al., 1995), and Alzheimer’s Disease 
Assessment Scale – Cognitive Subscale (ADAS-Cog; Wesnes, 2008) also see extensive use in 
assessing global function in clinical or research settings. As in the ACE, these assessments 
provide domain-specific sub-scores to contextualise any observed impairments, with greatly 
expanded scoring ranges for more granularity of assessment. 
 
Automated computerised batteries such as the Cambridge Neuropsychological Test Automated 
Battery (CANTAB; Sahakian and Owen, 1992) or detailed neuropsychological testing 
procedures such as the Wechsler Adult Intelligence Scale (WAIS) provide more in-depth 
information and may be capable of detecting even mild impairments, but are financially- and 
time-costly, limiting their utility in routine clinical assessments.  
 
Likely reflecting the predominance of AD in clinical settings, many common global cognitive 
screening tests disproportionately measure episodic memory functions, and so these may provide 
unequal descriptions of level of function in atypical non-amnestic neurodegenerative syndromes. 
For example, a total ACE-R score of 75 in an amnestic syndrome may not be comparable to a 
total ACE-R score of 75 in a non-amnestic dysexecutive syndrome. There is little in the way of 
an evidence-based consensus as to how each domain should be relatively weighted in its 
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contribution towards a global cognitive measure; indeed, the very notion of a general cognitive 
or intelligence measure is controversial in itself.  
 
As discussed below, premorbid intelligence may be estimated in dementia through the 
administration of a ‘hold test’ (a test in which performance does not deteriorate in a given 
condition); these may allow for estimation and adjustment of an individual’s level of function 
prior to onset of disease to account for the relative deterioration and cognitive reserve. In AD and 
DLB, and in normal ageing, these often take the form of vocabulary tests, and so are discussed in 
depth in the language section which follows. Later life intelligence and cognitive reserve may 
bolstered by a number of protective factors, including educational attainment (Chapko et al., 
2018) and socioeconomic status over the life-course (Staff et al., 2018). A person with a 
neurodegenerative disease but with high educational attainment and from a low-deprivation 
background may still perform relatively well on global tests, obscuring any true cognitive 
impairment. Conversely, an individual from a highly deprived background with low educational 
attainment may score relatively poorly on global cognitive assessments, but this might not 
represent a decline from their normal level. Therefore there may be value in accounting for the 
influence of these variables when considering an individual’s level of functioning in clinical 
settings (in a holistic manner, or with adjusted cut-off scores), or accounting for these in analyses 
in research settings (as confounding variables). 
1.4.2 Domain-specific cognitive dysfunctions in dementia 
Providing further context as to the specific impairments underlying global decline, notable 
differences have been found between AD and DLB groups in the specific domains of cognition 
which are found to be impaired (Walker et al., 1997). These domains may be best assessed by 
dedicated neuropsychological testing, but some clinical-oriented cognitive assessments such as 
the ACE-R, CAMCOG, or ADAS-Cog may also provide domain-specific sub-scores with 




Episodic memory and learning 
A wide range of tests are available to assess episodic memory performance and long-term 
learning capacity; the Wechsler Memory Scale (Wechsler, 1945) and its revised versions 
(Wechsler, 1997) may be sensitive to early memory changes, but has a high time and financial 
cost. However, subscales of this test are commonly administered in dementia research, such as 
the logical memory subtest, which has identified better memory performance in DLB than in AD 
(Ferman et al., 2006; Oda et al., 2009).  
 
Verbal learning tests, either cued or un-cued, are also commonly used either as stand-alone tests 
of episodic memory, or as a subtest within tests of global function; common examples in 
dementia research being the California (Delis et al., 1988), Hopkins (Benedict et al., 1998), or 
Rey (RAVLT; Vakil and Blachstein, 1997) verbal learning tests, or the free and cued selective 
reminding test. These are broadly comparable in their approach, requiring the progressive 
learning of lists of words which must be recalled or recognised over several trials. Tests such as 
these have shown utility in assessing amnestic memory dysfunction in DLB, PD and AD 
(Ferman et al., 2006; Filoteo et al., 2009), and in the MCI stage of AD (Estevez-Gonzalez et al., 
2003). 
 
While AD is characterised by progressive impairment of episodic memory, dysfunctions in this 
domain are typically less severe in DLB; a finding observed with verbal learning tests (Ferman et 
al., 2006), the Wechsler logical memory sub-test (Oda et al., 2009), and CAMCOG memory sub-
scores (Ballard et al., 1999b). More in-depth exploration of this phenomenon indicates that while 
both groups may be equally impaired in ability to freely recall learned information, DLB is 
associated with a non-amnestic pattern, being capable of cued recognition of learned information 
despite failure of overt recall (Hamilton et al., 2004). This suggests that the greater memory 
impairment found in AD may in part be due to failures to efficiently encode and store 
information to memory, with this function being comparatively preserved in DLB.  
 
These distinct patterns of memory impairment may reflect the different pathological patterns 
found in AD and DLB; different regions of the MTL are known to support different aspects of 
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the episodic memory system, with the hippocampus in particular being crucial for recollection of 
learned information (Eichenbaum et al., 2007). Regardless of whether a dementia appears 
clinically as AD or DLB, greater MTL atrophy specifically is associated with a greater level of 
episodic memory impairment (Barber et al., 1999). Clinically-diagnosed DLB typically features 
less MTL and hippocampal atrophy than AD (Barber et al., 2000), and within clinical cases of 
DLB, the presence in cerebrospinal fluid of AD-positive biomarkers has been associated with 
greater levels of MTL atrophy (van der Zande et al., 2018b) than in apparently pure DLB.  
 
Episodic memory impairment in dementia may therefore be an outcome of hippocampal atrophy 
related to AD pathology, and possibly therefore a mixed dementia when observed in an 
otherwise clinically evident case of DLB. However, while relying to a clear extent on 
hippocampal preservation to function adequately, long-term memory functions do not occur in 
isolation from either cognitive or neuroanatomical perspectives; localised damage to other brain 
regions, such as the frontal lobes (Jetter et al., 1986), has been demonstrated to impact on 
memory function. Effortful encoding and retrieval of memory relies upon adequate attention 
being paid to the information at hand and may be further aided through the use of mnemonic 
strategies. Furthermore, adequate encoding and retrieval of the visual, verbal and semantic 
features of memories must also be presumed to rely upon relative preservation of their respective 
cognitive functions, such as verbal and visuospatial perception and working memory functions, 
and associated neural substrates of these. Impairments of memory must therefore be dissociated 
from impairments of other domain-specific functions (e.g. considering the limits imposed by 
verbal attention and working memory capacity when assessing recalled information, as in 
Ferman et al. (2013)) to fully understand the root cause behind observed dysfunctions; while 
episodic memory dysfunctions are certainly correlated with hippocampal atrophy, they could 
also arise in some cases from pathophysiology affecting other domains, or domain-general 
cognitive networks. This warrants further exploration with carefully selected neuropsychological 
tests, and controlling for other domains of impairment; a primary impairment in information 
processing, attention, or working memory may manifest in failed recall later but would not be 




Despite the focus afforded to episodic memory impairments, dysfunction of other memory 
systems is common in many dementia syndromes, including semantic memory (discussed in this 
text within the context of language functions) and working memory (Baddeley et al., 1991). 
Reduced working memory capacity may contribute to impaired function in other domains, such 
as episodic memory failure, producing an early bottleneck in performance. Working memory is 
currently theorised to be domain-specific (Cocchini et al., 2002), and reliant upon the 
recruitment of preserved lower-level sensory networks (Gayet et al., 2018) and so auditory and 




The broad category of visuospatial functions encompasses a variety of cognitive processes, 
ranging from simple perception of visual features such as colour and shape, to higher-order 
cognitive functions such as spatial mental re-orientation and visual construction. Disruption of 
lower-level functions may reflect specific dysfunction of the visual system and visual cortex, 
whereas higher-level tasks may be vulnerable not only to dysfunction of visual perception and 
imagery, but also secondary dysfunction arising from other cognitive domains due to the greater 
task complexity. 
 
After discounting non-cognitive causes of impaired visual acuity, such as eye disease or 
inadequate use of corrective lenses, simple visual perception may be assessed with tests of 
sensitivity to differences in colour (Farnsworth, 1943), orientation (Benton et al., 1978), form 
(De Renzi et al., 1969) or motion (Vaina, 1989). These represent the simple, specific features of 
visual stimuli which form the building blocks of more complex visual functions, such as 
perception of a scene or object, or imagery. 
 
Visual working memory functions appear to be highly related to visual perception (Kang et al., 
2011) and may represent the link between lower-level perceptual functions and higher-level 
complex processing in the visual domain, operating as an emergent function of the same cortical 
regions and cognitive networks responsible for more passive processing of visual sensory 
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information (Harrison and Tong, 2009), allowing for the maintenance of a number of visual 
features in a single mental image for a brief period. Visuospatial dysfunctions could therefore 
manifest in reduced visuospatial working memory capacity in MCI and dementia with fewer 
contributions from domain-general cognitive resources than higher-order functions (e.g. visual 
construction tasks), while incorporating more visual features in a single assessment than simple 
perceptual tasks, though this remains under-explored in DLB currently. Though not commonly 
used in this setting, Corsi block-tapping or similar short-term visual retention tasks (Della Sala et 
al., 1999) may therefore be appropriate to assess visuospatial dysfunctions in MCI. Given the 
increased complexity of working memory tasks, other domain-general cognitive resources may 
represent an additional barrier to completion however, with processing speed limitations or 
executive dysfunctions being potential causes of failure despite maintenance of primary visual 
functions.  
 
Progressively more complex tasks include free drawing, or guided copying of a visual figure, 
which are common components in both dedicated visuospatial tests, and tests of global 
cognition. Short examples being the overlapping pentagons copying (Folstein et al., 1975) or 
clock drawing (Shulman et al., 1986) tests; longer and more complex figure copy tests, such as 
the Rey-Osterreith (ROCF; Rey, 1941) or Taylor (Taylor, 1969) tasks have greater scoring 
resolution and a higher ceiling on performance, but there may be a floor effect for highly 
impaired individuals. While these tests may assess higher-level visuospatial functions which may 
more directly reflect cognitive dysfunctions with real-world implications, complex tasks may be 
vulnerable to either compensation from other cognitive domains preserving performance (e.g. 
use of strategies or heuristics) or conversely, may show apparent visuospatial dysfunction which 
is actually secondary to a different impairment (e.g. motor dysfunction limiting drawing ability 
despite preserved visuospatial skills). 
 
The application of a range of such assessments has provided evidence that in comparison to 
typical AD-related dementia syndromes, DLB is known to result in a greater level of impairment 
of a range of visuospatial functions (Mosimann et al., 2004). This includes lower-level 
impairment in perception of size, shape, orientation and colour (Mori et al., 2000; Simard et al., 
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2003; Matar et al., 2019a), and higher-level dysfunction in guided copying (Ala et al., 2001) and 
free drawing of complex figures (Gnanalingham et al., 1997). PD also demonstrates similar 
patterns of visuospatial dysfunction (Weil et al., 2016), although this is more severe in DLB 
(Mosimann et al., 2004). Furthermore, these visuospatial dysfunctions worsen at a faster rate in 
DLB than in AD (Smirnov et al., 2020). 
 
Visuospatial dysfunctions may arise in DLB as a result of the functional disruptions observed in 
this condition, including reduced metabolic activity and perfusion in the occipital lobes (Ishii et 
al., 1999; Lobotesis et al., 2001). Whilst AD has typically less visuospatial impairment than 
DLB, the uncommon syndrome of posterior cortical atrophy (PCA), which may arise from a 
number of neurodegenerative aetiologies – most commonly AD, is also characterised by 
pronounced cortical-visual dysfunction (McMonagle et al., 2006). Direct comparison with DLB 
has suggested that the respective visual dysfunctions are qualitatively different (Metzler-
Baddeley et al., 2010) with primarily higher-level visual functions being disrupted in DLB, but 
both low- and high-level functions being impaired in PCA, reflecting the extensive degeneration 
of occipital and parietal lobes in this syndrome (Crutch et al., 2012). However, this comparison 
is somewhat limited as, unlike DLB, PCA cohorts are a specific sub-group defined by their 
occipital atrophy and consequent visuospatial deficits; as discussed in greater depth later (see 
1.4.4) cognitive sub-groups may also exist within DLB, and the inclusion of cases of DLB 
without visuospatial impairments could dilute this comparison with PCA. 
 
As discussed previously, visuospatial cognitive impairments and misperceptions have been 
theorised (Uchiyama et al., 2012) to contribute in part to the visual hallucinations experienced in 
DLB; degraded visual input may be reconstructed downstream into well-formed hallucinations. 
Further exploration is warranted to ascertain whether individuals experiencing visual 
hallucinations show a greater level of visuospatial impairment, or if the presence of either one of 
visual hallucinations or visuospatial impairment might anticipate the eventual onset of the other. 
 
While the sporadic nature of visual hallucinations can make them difficult to assess in clinical or 
research settings, DLB patients have been found to show a greater responsiveness to visual 
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illusions and misperceptions than those with AD, as assessed with a pareidolia task (Uchiyama et 
al., 2012). Regardless of whether or not they report experiencing visual hallucinations, 
individuals with DLB are more likely than AD patients or controls to misperceive the forms of 
objects or people in ambiguous or visually-noisy stimuli. 
 
It may be necessary to dissociate other contributions to the visuospatial dysfunctions observed in 
DLB; ophthalmic dysfunction may contribute to degraded input, motor dysfunction may affect 
the ability to reproduce figures accurately in constructional tasks, and slowed processing speed 
may impair overall task performance in tasks with a high cognitive load, or in timed tasks.  
 
Attention and executive functions 
A number of cognitive functions fall under the broad category of attention and executive 
functions, including the ability to appropriately direct and sustain attention, inhibit inappropriate 
responses or actions, form plans, make decisions, think abstractly, and to follow complex 
instructions. Normal performance in tests of attention and executive functioning is generally 
understood to rely upon frontal lobe integrity (Stuss and Benson, 1984), and frontal lobe lesions 
typically lead to impairment in these domains (Baldo et al., 2001; Demakis, 2004). 
Consequently, a prominent attention and executive dysfunction is particularly characteristic of a 
frontotemporal dementia (Rascovsky et al., 2002; Stopford et al., 2012). However, while 
attention and executive functions are sensitive to frontal lobe integrity, evidence for their 
specificity to this anatomical region is more limited (Alvarez and Emory, 2006), and so 
impairments of attentional control and other executive functions are also common in AD and 
other dementias without prominent frontal degeneration (Perry et al., 2000). 
 
Differences have been identified between AD and DLB in performance in a range of attentional 
and executive tasks. Stroop tasks, requiring response inhibition and goal maintenance under time 
pressure, are relatively more impaired in DLB than AD (Calderon et al., 2001), as is 
performance on part B (TMT-B) of the Trail Making Test (Ferman et al., 2006) which requires 
repeated switching between two parallel tasks; these are suggestive of an impairment in 
cognitive flexibility, which could reflect pathological changes to a task-switching network 
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comprising the basal ganglia, anterior cingulate, prefrontal and posterior parietal cortices (Leber 
et al., 2008).  
 
Verbal fluency tasks are a common hybrid test of both executive and verbal functions, with 
impairments in letter fluency tests being particularly associated with frontal lobe dysfunction, for 
example as observed in motor neurone disease (Quinn et al., 2012), and therefore theorised to 
reflect executive dysfunction to a greater extent than category fluency tasks which appear to rely 
more on verbal skills (Shao et al., 2014). Both letter and category fluency tasks are commonly 
included in neuropsychological testing batteries to assess executive and verbal functions, with 
DLB typically featuring greater impairments of letter fluency than AD (Calderon et al., 2001; 
Ferman et al., 2006). Verbal fluency tests have a high ceiling on performance and so may be 
appropriate for assessing mild cognitive impairment as in dementia, but may be particularly 
sensitive to age, education, and gender effects (Bolla et al., 1990). 
 
Various measures of processing speed may fall under the umbrella of executive and attentional 
processes, encompassing a wide range of cortical processes from simple reaction time tests of 
pure psychomotor speed, to more complex tasks reflecting a combination of various attention 
and executive functions. Both AD and DLB have slowed reactions relative to healthy controls 
(Bradshaw et al., 2006), with response times in DLB also being slower and more variable than in 
AD; a pattern which remains after controlling for levels of parkinsonism, suggesting that this is 
not just an outcome of slowed motor responses. 
 
Attentional and executive dysfunctions are therefore seen as particularly characteristic of DLB, 
and have been theorised to underlie cognitive fluctuation symptoms (Walker et al., 2000a). 
Meanwhile, executive dysfunction in DLB may reflect direct or indirect disruption of normal 
frontal lobe functions due to degeneration of cortical or subcortical regions (e.g. the striatum). 
 
Speech, language, and semantic memory 
A number of common cognitive functions may be considered as language-related skills, 
including speech production, reading, and semantic memory. Early declines in speech and 
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language are characteristic of particular patterns of neurodegeneration resulting in syndromes 
such as a PPA (Gorno-Tempini et al., 2011), but semantic memory impairments may also be 
seen in typical AD (Hodges and Patterson, 1995). Semantic memory dysfunctions are typically 
assessed with object-naming tasks such as the Graded Naming Test (GNT; McKenna and 
Warrington, 1980) which is particularly sensitive to left temporal lesions. AD and DLB perform 
comparably in object naming tests (Noe et al., 2004), and do not reliably differ in their semantic 
memory impairments. 
 
In mild dementia, tests of reading are reasonably resilient to declining cognition (Schmand et al., 
1998), though in moderate or severe dementia these may also begin to decline. As reading tests 
are typically insensitive to mild cognitive dysfunction, they are often useful as hold-test 
estimators of premorbid functioning in clinical and research settings where premorbid cognitive 
measures are rarely available, as discussed previously. Common examples of tests which assess 
reading skills as a proxy of premorbid function include the Wechsler Test of Adult Reading 
(Wechsler, 2001) and the National Adult Reading Test (NART; Nelson and Willison, 1991), 
which both require pronunciation of atypically or ambiguously spelled words. These tests may 
therefore be used to adjust for individual differences in premorbid intelligence across both AD 
and DLB, using vocabulary as a proxy. 
 
As noted previously DLB and AD groups do show differences in verbal fluency tasks, which rely 
upon language skills to an extent. However, if these groups do not display differences in 
semantic memory impairments, these differences may be presumed to reflect differing levels of 
executive dysfunction instead. Impairments of goal maintenance, failure to use effective search 
strategies, and lack of inhibition of previous responses may explain poorer verbal fluency 
performance despite otherwise preserved language skills. 
 
Auditory digit-span tasks may assess verbal working memory (e.g. Grégoire and Van Der 
Linden, 1997), reliant upon integrity of the theorised ‘phonological loop’ which is responsible 
for short-term rehearsal and processing of speech, and hence may show impairment in aphasic 
syndromes (Wright and Fergadiotis, 2012). Both DLB and AD show impairment on digit span 
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tasks, but do not appear to differ in this (Calderon et al., 2001). Forward digit span tasks may be 
a relatively pure measure of auditory working memory capacity, reflecting the number of items 
that can be held sequentially in the phonological loop, but due to their simplicity may be less 
sensitive to early dysfunction in dementia than the more complex, but less pure, backwards digit 
span, which shows sensitivity to dysfunction earlier (Lambon Ralph et al., 2003). 
 
1.4.3 Domain-specific dysfunction in mild cognitive impairment 
In comparison to healthy controls (Kemp et al., 2017), clinically-diagnosed “probable prodromal 
DLB” (NIA-AA criteria MCI with two or more core clinical features of DLB, analogous to 
“probable MCI-LB” as described in this work) has been shown to feature impairments in a wide 
range of cognitive functions: visuospatial functions, particularly visuoconstructive functions (as 
assessed by copy of the ROCF), and executive functions (Trail Making Test parts A and B, and 
the frontal assessment battery) being impaired relative to normative data (> 1.5 SDs worse than 
normal mean performance). Additionally, MCI-LB featured poorer recall and recognition 
memory, impaired social cognition, and dyspraxia (though not to the point of objective 
‘impairment’ based on normative scores available).  
 
Therefore, cognitive impairments associated with the presence of Lewy body disease features 
may already be multidimensional at the MCI stage. Episodic memory impairments were 
observed with a multi-domain amnestic cognitive profile in approximately half of cases, which 
may be attributed to primary attentional and executive dysfunctions limiting memory 
performance (Bryan et al., 1999), or the effects of additional AD pathology. However, clinically-
suspected mixed AD-DLB cases were excluded, and hippocampal atrophy ratings did not 
significantly differ between prodromal DLB and healthy comparators. Alongside clinical 
diagnosis of MCI, parkinsonian rigidity and fluctuating cognition were the most common clinical 
feature of DLB in this sample (76% of cases for both), followed by visual hallucinations (65%), 
bradykinesia (59%) and resting tremor (27%). RBD was either not assessed, or not reported. 
These cases likely represent a particular subset of probable MCI-LB cases, recruited from 
memory services with clinical MCI, but with clear mixed AD cases excluded and RBD not 
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apparently assessed, and so may naturally differ from other samples with a differing 
pathophysiology. 
 
As reviewed by Ciafone et al. (2019), there has been limited data comparing the cognitive 
profiles of MCI-LB with MCI-AD, and existent examples have typically been underpowered 
with small sample sizes (e.g. Jicha et al., 2010). However, recent data have suggested that AD 
and LB disease may manifest in different patterns of cognitive dysfunction in the MCI stages, 
reflecting their eventual dementia profiles; amnestic MCI is more likely to convert to AD-type 
dementia, while a non-amnestic is more likely to convert to DLB (Ferman et al., 2013), 
consistent with the greater association between AD neuropathology and amnestic memory 
dysfunction. More directly related, when diagnosed according to clinical DLB features present in 
MCI, probable MCI-LB is associated with poorer attentional functions, verbal fluency, and 
visuospatial performance than is MCI-AD (Donaghy et al., 2018); this cross-sectional study was 
directly built upon in this work. 
 
However, recent retrospective study of MCI-LB cases has identified different baseline cognitive 
profiles between MCI-AD and MCI–LB, consistent with those found in their respective dementia 
syndromes; MCI-AD featuring poorer memory performance, and MCI-LB poorer non-memory 
domain performance (van de Beek et al., 2020). Different domain-specific longitudinal 
trajectories were also identified, as discussed later in this chapter. 
 
Cognitive dysfunctions in other LB and prodromal DLB syndromes 
To supplement these findings, comparisons may be drawn from the related study of mild 
cognitive impairments which emerge within established PD (PD-MCI), given the shared 
underlying pathology of this syndrome with MCI-LB; however, it should be noted that 
diagnostic criteria for MCI in PD differ to NIA-AA criteria for this (Albert et al., 2011), which 
may have consequences for direct comparison of these results. NIA-AA criteria for MCI are 
based on clinical reasoning, including scores derived from global or domain-specific cognitive 
tests, but are ultimately independent from any cut-off score for neuropsychological tests in 
particular cognitive domains. In comparison, PD-MCI is specifically defined by the presence of 
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scores below pre-determined thresholds on domain-specific tests, e.g. memory scores between 1-
2 SDs below healthy norms (Litvan et al., 2012; Goldman et al., 2015) in addition to clinical PD. 
This may present issues of circularity in cases where groups are assessed on cognitive outcome 
measures which are not independent of, or possibly even identical to, the neuropsychological 
assessments which helped define those same groups. Accordingly, while PD-MCI may be readily 
contrasted with healthy controls, it may be less easy to compare the cognitive outcomes to those 
found in MCI-AD, due to the differently characterised MCI underlying these. 
 
In contrast with healthy controls, PD-MCI has been associated with impairments in a broad 
range of cognitive domains as reviewed by Ciafone et al. (2019), showing executive and 
processing speed dysfunction including greater Stroop task interference, poorer word production 
in verbal fluency tests, and impairments in Trail Making Test parts A (TMT-A) and -B (TMT-
B). Visuospatial performance is typically poorer in PD-MCI, including visual perception (line 
orientation perception), visuoconstruction and visual memory (copy and recall, respectively, of 
complex figure tasks) dysfunction. Verbal working, episodic and semantic memory may also 
show dysfunction, with poorer digit span performance, word list retention, and object naming, 
which is consistent with findings of memory impairment in MCI-LB and DLB (though these 
being less severe than in AD).  
 
Comparisons may also be drawn from prodromal presentations of DLB characterised by early 
isolated RBD; as these are characterised at the early stage prior to apparent cognitive symptoms, 
they may provide important perspectives on the earliest cognitive changes which may precede 
eventual MCI-LB or DLB. In individuals recruited from a sleep centre with PSG-confirmed 
RBD, but no parkinsonism or dementia, executive (TMT-B), verbal fluency, and verbal learning 
(RAVLT) dysfunctions were typical of those who converted to dementia, and visuospatial 
performance (block design and complex figure copy) often declined in the lead-up to dementia, 
but at sub-clinical thresholds (Génier Marchand et al., 2018). Therefore, while executive 
dysfunctions may be apparent at the early stages of prodromal DLB, visuospatial dysfunctions 
may progressively emerge over the course of MCI or even the early stages of dementia. While 
providing important context, the cognitive profiles of RBD-prodromal DLB may not directly 
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translate to the more generally-defined MCI-LB which may or may not include RBD as a 
feature; by definition, cases with initially isolated RBD represent a more specific sub-group of 
prodromal DLB which could have differing underlying neuropathological changes, and 
consequently differing cognitive patterns. It remains to be seen whether different patterns of LB 
symptomatology are associated with different patterns of cognitive impairments. 
1.4.4 Heterogeneity in cognitive profile within disease groups 
As identified in the respective sections above, it is known that neurodegenerative diseases such 
as AD may manifest in any one of a number of heterogeneous clinical syndromes including PCA 
and PPA, reflecting the varying patterns of underlying neuropathology (Galton et al., 2000), and 
each characterised by distinct cognitive, clinical, and behavioural profiles unlike that of the 
‘typical’ amnestic syndrome. While less explored in DLB it remains possible that, underlying the 
broad group differences observed from typical AD, patterns of domain-specific cognitive 
impairment may also differ between individuals with DLB. 
 
Numerous case reports have described PPA (Caselli et al., 2002; Teichmann et al., 2013; 
Watanabe et al., 2020) and PCA (Yoo et al., 2020) syndromes developing into or alongside 
apparent DLB. As highlighted previously, Ferman et al. (2013) described the cognitive profiles 
of MCI as predictors of transition to clinical AD or DLB; in addition the expected association 
between single-domain amnestic MCI and eventual AD, eventual DLB was slightly more 
typically preceded by a single-domain non-amnestic profile than multi-domain (either amnestic 
or non-amnestic). While the exact breakdown is not clearly reported (those with single-domain 
impairments in attention are not differentiated from those with multi-domain attention and 
visuospatial), it appears that the MCI prodrome of DLB may present most often with either 
visuospatial or attentional impairments. These prodromal cognitive profiles may converge by the 
time that DLB becomes fully clinically manifest, though this again remains under-explored. 
 
As also highlighted by Ferman et al. (2013), amnestic memory dysfunctions preceding DLB are 





When performing at comparable levels of global cognitive function, AD and DLB show different 
patterns of domain-specific dysfunction reflecting their varying neurodegenerative processes. 
AD has a typically amnestic profile in dementia, while DLB has relatively worse impairment in 
attention, executive, and visuospatial functions. In both syndromes, speech and language skills 
are generally comparable, and relatively spared. While the evidence base is not extensive, the 
MCI stages of DLB and AD appear to feature cognitive profiles similar to those found in the 
dementia syndromes. In both disease groups, early cognitive sub-types may exist, though further 
exploration is required in DLB to establish if these are found in clinically-defined MCI-LB, and 
whether these converge over time. The presence of amnestic memory impairment in DLB or 
MCI-LB may reflect a mixed AD-LB syndrome, though this is currently speculative. 
 
1.5 Longitudinal decline 
While comparisons of cross-sectional performance on neuropsychological tests can be useful to 
help conceptualise the typical cognitive differences between DLB and AD, neurodegenerative 
dementias are syndromes primarily characterised by progressive deterioration. The very nature of 
cross-sectional studies means they can provide only a snapshot of a declining process; with 
uncertainty over the start point, groups may not be observed at comparable times, and it may be 
unclear if any group differences are diverging, converging, or consistent over time. Therefore, 
further exploration must be undertaken into how global and domain-specific cognitive functions 
deteriorate over time in these diseases. A fuller understanding of the progressive deterioration of 
different cognitive domains from the prodromal to final stages of severe dementia or death may 
improve the clinical and research utility of neuropsychological testing, and provide information 




1.5.1 Longitudinal progression of dementia 
Global decline in dementia with Lewy bodies versus Alzheimer’s disease 
There have been efforts to explore the long-term decline of cognitive function in DLB; 
principally in regards to deterioration of global cognitive functioning in comparison with AD. 
DLB and AD are both associated with progressive decline in global cognitive function over time 
(Boyle et al., 2017), and DLB appears to have a shorter time to death after onset of symptoms 
(Williams et al., 2006), but results vary as to whether global cognitive function in DLB declines 
at a faster or comparable rate to AD.  
 
Some research has reported no difference in rates of cognitive decline in AD and DLB (Ballard 
et al., 2001a; Walker et al., 2012) over one-year periods using the CAMCOG and MMSE, 
respectively; Breitve et al. (2018) also did not identify any difference in rate of cognitive decline 
over a four-year period using the MMSE and a battery of domain-specific tasks. However in the 
longest-running comparable study to date, Rongve et al. (2016) identified a faster decline in 
MMSE performance in DLB than AD over five years of follow-up. Meanwhile, in the largest 
comparable study exploring differences in global cognitive decline to date (Kramberger et al., 
2017), DLB was associated with a faster decline in MMSE scores than AD after controlling for 
baseline performance. 
 
Difficulty arises in comparing rates of decline in tests of global cognitive functioning, however; 
with AD being the most common cause of dementia (Harvey et al., 2003), many common 
clinical screening tests are sensitive by design towards an AD-type dementia profile 
characterised predominantly by memory impairment (Cullen et al., 2007) and so may be less 
sensitive to patterns of decline in DLB. As noted earlier, in the MMSE only one out of thirty 
possible points available are concerned with visuospatial skills with no direct test of executive 
dysfunction, and in the MoCA both visuospatial and executive functions combine to provide five 
out of thirty points; this limits the sensitivity to decline in patients with primarily visuospatial or 
executive impairments (i.e. the cognitive profile associated with DLB). While this is a reflection 
of the specialised screening purposes of these assessments given the predominance of AD in 
clinical dementia settings, the use of more balanced composite scoring systems, or accounting 
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for declines in individual cognitive domains, may be preferable to explore how cognition 
declines over time in DLB as compared with AD in research settings. 
 
Despite the lack of consensus from cognitive outcomes, there is reasonably strong evidence that 
DLB features a faster clinical decline to death (Mueller et al., 2019) and hospitalisation (Mueller 
et al., 2018) than AD, with a median survival time of 3.3 years (male) and 4.0 years (female) 
after diagnosis with DLB, versus 6.7 and 7.0 years respectively in AD (Price et al., 2017), after 
controlling for age and comorbidity. DLB is also associated with greater reliance on caregiving, 
and poorer quality of life for patients and caregivers (Wu et al., 2018a). Therefore, while 
cognitive measures may be insensitive to differences in decline, more clinically specific 
measures such as increased dependency, transition to full-time care, or death, may be more 
sensitive to differences in decline. The mechanisms for this poorer prognosis are unclear, but 
have been theorised to include the effects of cognitive decline, parkinsonism, autonomic 
dysfunction, falls, and psychosis (Mueller et al., 2019), highlighted by aggravating factors such 
as a reduced cough reflex contributing to aspiration pneumonia (Ebihara et al., 2020) as a single 
example. 
 
Domain-specific cognitive decline 
When accounting for specific domains of impairment, different rates of change have been found 
between AD and DLB (Stavitsky et al., 2006), with AD showing a faster decline in recognition 
memory despite parity between the groups at baseline. With this difference in decline excepted, 
differences in cognitive profile between DLB and AD were observed to be clearest at the earliest 
stages, with the decline of non-memory domains eventually leading to a convergence of profiles 
of cognitive impairment between the groups at the advanced stages of dementia.  
 
More recently, Smirnov et al. (2020) described domain-specific differences in progression 
between neuropathologically-confirmed AD, DLB, and PDD. Compared to AD, DLB had 
greater impairment and faster decline in visuospatial and executive functions. AD had greater 
memory impairments, but did not decline faster, and AD and DLB did not differ in language 
impairments or rate of decline. Compared to DLB, PDD had worse executive dysfunction and 
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faster decline in this, less memory dysfunction, and slower decline in language functions. This 
may suggest that not only does LB pathology manifest in different cognitive profiles and 
longitudinal patterns of decline from AD, but that the differing patterns of pathology in LB 
disease (e.g. those manifesting in PDD rather than DLB) may also lead to subtle differences in 
cognitive presentation, providing evidence for heterogeneity in cognitive progressions, as well as 
in clinical patterns in LB disease. In this study however, 71% of pathologically-confirmed DLB 
cases had received a living clinical diagnosis of AD, possibly due to the absence of FP-CIT 
imaging or RBD assessment, with recruitment predating more recent diagnostic criteria. While 
DLB is underdiagnosed in clinical settings, other studies have found lower rates of non-matching 
diagnoses (Selvackadunco et al., 2019) and so this DLB sample may represent a more 
qualitatively AD-like sample than the broader DLB population, accounting for the only subtle 
differences in memory performance between AD and DLB. 
 
Overall results are mixed however, with a study over a four-year period, but lacking 
neuropathological confirmation, finding limited evidence of any differences in rates of decline 
on specific neuropsychological tests (e.g. Breitve et al., 2018). There is currently little consensus 
on the most appropriate neuropsychological tests for assessing dysfunction in different domains 
in DLB, and it is possible that some of this inconsistency between research findings may be 
resolved as further agreement is reached on the best assessment methods; both cross-sectionally, 
and longitudinally. 
1.5.2 Longitudinal progression of mild cognitive impairment 
Relative even to the volume of longitudinal research into cognitive impairment in DLB, there is a 
notable paucity of information on how the cognitive profiles differ between AD and DLB at the 
MCI stage (MCI-AD and MCI-LB, respectively), and especially in how these develop over time 
in prospectively-recruited and clinically-diagnosed groups. 
 
Previous longitudinal research has indicated that baseline neuropsychological profiles in an MCI 
cohort can be predictive of eventual conversion to either AD or DLB (Williams et al., 2006; 
Belden et al., 2015); independent of the presence or absence of memory impairment in MCI, 
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predominantly visuospatial and executive dysfunctions are observed to be indicative of an MCI 
that will convert to DLB, consistent with the executive and visuospatial dysfunctions typical of 
DLB. These studies do not, however, follow up on cognitive measures beyond the baseline.  
 
Retrospective longitudinal comparison of MCI-LB and MCI-AD 
The closest comparable research available has explored longitudinal decline in a cohort 
retrospectively diagnosed as MCI-LB from the Amsterdam Dementia Cohort (van de Beek et al., 
2020); participants met criteria for probable MCI-LB (possible MCI-LB were excluded) based 
either on either eventual diagnosis of probable DLB according to clinical criteria, or a 
retrospective diagnosis of MCI concomitant with either two or more core clinical DLB features, 
or one core clinical feature with abnormal FP-CIT imaging. FP-CIT imaging abnormalities were 
highly over-represented in this group (abnormal in 98%), though not all were offered this, and 
parkinsonism was the most common clinical DLB feature, in 70% of cases; visual hallucinations 
and fluctuations (51%) and RBD (47%) were far less common, which may suggest that the 
recruitment methods for this sample were more biased towards a dopaminergic dysfunction-
prominent MCI-LB group. The MCI-AD group were defined as MCI (NIA-AA criteria) with 
CSF markers positive for AD (reduced Aβ42, and elevated total- and phosphorylated-tau).  
 
In addition to the previously identified baseline differences (worse attention and executive 
function, and better memory function in probable MCI-LB), both groups appeared to deteriorate 
in parallel in executive and visuospatial functions, but MCI-LB featured a faster deterioration in 
attentional functions, assessed with a compound score of the TMT-A, forward digit span, and a 
Stroop task, and less rapid decline in memory (visual association test and recall of the Dutch 
verbal learning test). This study provides the first longitudinal data on the development of MCI 
into an eventual DLB syndrome, suggesting that there may be different longitudinal patterns in 
MCI-LB to MCI-AD, though with retrospective diagnoses this may not translate as readily into 
clinical settings where diagnoses are, by their very nature, prospective. 
 
It therefore remains unclear as to how individual prospects for progression differ after 
prospective MCI diagnosis, given a diagnosis of either AD or a LB syndrome. This represents a 
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notable gap in the literature and affords an opportunity to explore how different patterns of 
neuropsychological impairment might present at the clinically-defined MCI stages of AD and 
DLB, how these prospectively progress over time within individuals and diagnostic groups, and 
how these may be linked with other clinical symptoms and biomarkers associated with either 
DLB or AD. 
1.5.3 Heterogeneity of progression in Lewy bodies and Alzheimer’s disease 
As noted previously, within any particular neurodegenerative disease, there is wide variation in 
individual course of decline, with some individuals progressing rapidly from MCI to dementia, 
or from mild to severe dementia, while others may decline slowly, remain stable, or even regress 
(from apparent MCI to a normal level of functioning). There have been some efforts to 
understand mechanisms and predictors of a rapid course of decline, as this may have 
implications for clinical practice and research.  
 
In AD, different patterns of brain atrophy have been associated with a varying prognosis, with a 
less aggressive course of decline in those with hippocampal-sparing or no measurable atrophy 
relative to the more typical pattern of hippocampal atrophy (Ferreira et al., 2017), which may 
account for some of the clinical heterogeneity within this disease; such cases may be more likely 
to be classified as a stable MCI, subjective cognitive impairment, or a functional cognitive 
disorder during life.  
 
While slower progressing cases have not been clearly explored in DLB, there have been 
numerous reports on individual cases progressing with particularly rapid deterioration (Gaig et 
al., 2011), to the extent that they may mimic Creutzfeldt-Jakob disease in clinical presentation 
(Ukai et al., 2010; Saint-Aubert et al., 2016), a disease for which a precipitous decline in 
cognitive function is more typically characteristic (Tschampa et al., 2001). This could suggest 
that heterogeneity in decline may also exist within DLB as in AD, which would not be accounted 
for in analyses which average across individuals. Such inter-individual variability is evident in 
visualisations of individual-level cognitive trajectories provided by Rongve et al. (2016), with 
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many deteriorating rapidly while others remain relatively stable in both AD and DLB, but 
unaccounted-for in their analysis which treats diagnostic groups as homogeneous.  
 
In addition to relatively slow decline, previous studies have identified atypically rapid decline in 
10-30% of AD cases (Dumont et al., 2005; Cortes et al., 2008; Aubert et al., 2015; Nance et al., 
2019), though methods and definitions vary. Whether a rapid decline occurs at a comparable rate 
in AD and DLB, or is more common in one than the other, is as yet unclear -in part due to this 
lack of consistency in defining rapid decline in AD, but also due to a lack of exploration of 
distinct cognitive trajectories in DLB cohorts.  
 
Cases of rapid decline may be due to the effects of multiple pathologies; neuropathological 
studies have identified co-morbid Lewy body pathology in approximately 16% of clinical AD 
diagnoses (Selvackadunco et al., 2019), and this has been separately associated with a faster 
cognitive decline (Blanc et al., 2017; Brenowitz et al., 2017b; Malek-Ahmadi et al., 2019) and 
progression of clinical severity (Brenowitz et al., 2017a) than in AD or DLB alone. In 
pathologically-confirmed DLB, but not AD, early visuospatial dysfunctions have been associated 
with a subsequent rapid global decline (Hamilton et al., 2012) and higher likelihood of 
experiencing visual hallucinations over the course of disease progression. This association 
remained after controlling for baseline function, suggesting that the aetiology underlying 
visuospatial symptoms may be related to a more severe progressive DLB profile. 
 
In addition to disease-specific explanations, there are several other potential causes of apparent 
rapid decline. Cognitive reserve, reflecting educational attainment and numerous other lifelong 
factors, may protect against apparent cognitive decline at early stages of MCI (Ye et al., 2013), 
however as this progresses and this reserve is ‘depleted’ at the more advanced stages, cognitive 
decline may be faster than anticipated based on their baseline function, leading those with higher 
reserve to ‘catch up’ with those with less reserve. Despite this, low education (and presumably 
therefore low cognitive reserve) is a risk factor for clinical progression of dementia (Xue et al., 
2017). Another possibility is that in regions with greater health inequality, delayed access to 
memory services may lead to an apparent rapid drop in function, when individuals are simply 
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entering services at a later stage. Of course, any or all of these factors may be at play, and may 
vary between individual cases, therefore being important to consider in analysis. 
 
Section summary 
DLB has a worse prognosis than AD and may also feature a faster cognitive decline. The 
cognitive progression of MCI, differentially diagnosed according to clinical symptoms, remains 
to be explored; MCI-LB may decline faster to than MCI-AD if the patterns from the respective 
dementia syndromes are already evident at this earlier stage. Rapid declining cases of MCI may 
reflect a mixed AD-LB syndrome or a more aggressive pattern of underlying pathology, while 
stable cases of MCI may reflect a non-degenerative cause, though both require further 
exploration. 
1.6 Chapter summary 
Lewy body disease is a common neurodegenerative cause of MCI and dementia; the clinical 
syndromes of MCI-LB and DLB may be respectively distinguished from MCI-AD or dementia 
due to AD by the presence of core clinical features and/or indicative biomarkers. DLB and AD 
are known to differ in their prognosis with DLB often having a poorer outlook, as well as 
differing in their cognitive profiles. There is emerging evidence that the domain-specific 
cognitive impairments seen in MCI-LB and MCI-AD may reflect their eventual dementia 
syndromes, but it is unclear how these progress over time, and whether these decline at 
comparable or different rates. This represents a clear gap in the research that needs addressing 
with a comprehensively assessed, prospective cohort of MCI patients, with differential diagnosis 
of either MCI-AD or MCI-LB. 
 
In response to this research question, it was hypothesised that those with MCI-LB would develop 
with a pattern of domain-specific cognitive impairments reflecting those found in DLB, that 
MCI-LB would have a worse prognosis than MCI-AD with greater risk of cognitive decline and 
shorter time to onset of dementia, and that there would be heterogeneity within MCI-LB, with 
specific clinical characteristics being associated with differing rates of decline.  
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Chapter 2. Background to Statistical Methods 
2.1 Longitudinal methods 
There are a variety of statistical approaches which may be undertaken to model longitudinal 
progression, as intended in this work. Selection of an appropriate method must be guided by the 
desired conceptualisation of the data (e.g. reducing multiple observations to a single continuous 
trajectory, or accounting for factors influencing changes in discrete states over time) and 
constraints imposed by the data itself (number of observations, balance of observation timings, 
and clustering within samples). In this chapter, common approaches to these challenges from the 
DLB and related literature are reviewed, and alternative methods are discussed where 
appropriate.  
2.1.1 Characterising longitudinal change in outcomes of neurodegenerative disease 
Jack et al. (2010) conceptualised the cognitive and clinical decline in neurodegenerative diseases 
(typified by AD) as a hypothetical sigmoidal curve of biomarker progression associated with a 
varying rate of cognitive decline; with individuals appearing at the pre-clinical stages to be 
cognitively normal with immeasurably slow or stable progression despite insidious 
neurodegeneration, eventually leading to periods of more rapid cognitive decline leading to the 
early clinical presentations of MCI and dementia (though not necessarily a sigmoidal curve of 
cognitive decline). While this hypothetical conceptualisation is not typically reflected in research 
due to the limitations imposed on the data in shorter-scale studies, it provided a reasonable 
starting point to build from when considering the progression of continuous outcomes in this 
work (i.e. longitudinal change in cognitive function). 
 
This work sought to characterise the changes in cognitive functions over time in individuals 
presenting at the early clinically-manifest stages of AD and LB disease, as their MCI progressed 
towards dementia. Building on previous research into the dementia stages of these diseases, it 
was hypothesised that MCI-LB would feature a faster decline and different pattern of domain-
specific cognitive trajectories in comparison to MCI-AD, comparable to the differences observed 
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between DLB and AD. The availability of repeated cognitive and clinical measures in these 
prospective cohorts allowed for a variety of approaches to analysing cognitive trajectories. 
2.1.2 Traditional approaches and growth curve modelling 
There are several analytical approaches which may describe the progression of cognitive and 
clinical symptoms of neurodegenerative diseases. Traditional methods include repeated measures 
t-tests and ANOVA for change scores at discrete time-points, these being simple but somewhat 
inflexible to violations of their assumptions, such as imbalance in the times or number of 
observations between subjects. Such methods are therefore most appropriate when a balanced 
follow-up schedule is observed, e.g. when assessing cognitive decline between two observations: 
baseline and twelve-month follow-up (Walker et al., 2012). They are also largely limited in their 
potential to describe an overall time trend across observations, being restricted to comparisons 
between discrete time-points and therefore failing to account for all available information in a 
parsimonious manner. 
 
In comparison, growth curve models are a more flexible approach that allow for the description 
of continuous within-person change in longitudinal data. Growth curve analysis (also known by 
various other terms e.g. trajectory modelling) may be undertaken within mixed-effects or 
structural equation modelling (SEM) frameworks (Curran et al., 2010), both approaches having 
respective strengths and limitations. Despite their differences as discussed below, both methods 
arguably have as much in common as their differences, and may typically provide comparable 
results when appropriately specified (Chou et al., 1998). 
2.1.3 Structural equation modelling of longitudinal trajectories 
The SEM approach to growth curve modelling provides a flexible framework for characterising 
longitudinal changes in a given latent process (in this instance, cognitive function) as observed 
by multiple measurements (e.g. repeated instances of one or more cognitive tests), while 
effectively accounting for measurement error in these. Models may be readily extended to 
incorporate complex structures of latent and manifest variables as in any SEM analysis, which is 
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a particular strength of this method given sufficient observations to support the conceptual 
structure.  
 
However, SEM approaches are typically reliant upon the times of observations being roughly 
comparable between participants such as in longitudinal studies with follow-up conducted in 
waves, with data therefore suitable for a ‘wide-format’ layout (with one row per participant, and 
multiple observations separated across separate variables) as required by most common 
statistical packages for SEM, such as lavaan for R (Rosseel, 2012), Mplus, or Amos, amongst 
others. Consequently, SEM approaches to latent growth curve modelling of cognitive change in 
MCI and dementia may be more suitable for studies with complex outcome variable structures, 
sufficient observations to support the necessary model structure, but with reasonable uniformity 
of follow-up timings (with some degree of flexibility allowed) between participants, such as the 
baseline, 6-, 12-, 24-, 36-month follow-up schedule of the Alzheimer’s Disease Neuroimaging 
Initiative (e.g. Johnson et al., 2012). There are therefore few examples of latent growth curve 
models such as these in the DLB literature, though there are relatively more examples in the 
broader field of cognitive ageing (e.g. Muniz-Terrera et al., 2009; Zaninotto et al., 2018), or in 
the larger field of literature in AD. 
2.1.4 Mixed-effects modelling 
While a mixed-effects modelling approach does not offer quite the same strengths in complexity 
as SEM in accounting for measurement error and wider variable structures and relationships, the 
modelling methods are more resilient to variance in observation times between individuals as 
they typically require data in a ‘long-format’ with time treated as a continuous variable, and are 
also reasonably robust when dealing with missing data (Pinheiro and Bates, 2006). Due primarily 
to the unbalanced nature of observations in the LewyPro and SUPErB studies, a mixed-effects 
framework was adopted for growth curve analysis of continuous outcome measures in this work, 
as described further in Section 2.3. 
Section summary 
Growth curve modelling is a flexible approach to longitudinal analysis of repeated measures 
data. The two common frameworks for undertaking this, structural equation- and mixed-effects 
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modelling, each have their respective strengths, but can be largely comparable in many cases. A 
mixed-effects framework was considered as suitable for this work due to its flexibility with 
highly variable observation times. 
2.2 Growth curve shapes 
Both SEM and mixed-effects approaches may be used to describe a variety of growth curve 
shapes; the most common being relatively simple linear and curvilinear trajectories (e.g. 
quadratic slopes), though with sufficient observations and an appropriate relationship between 
the outcome measure and time, more complex non-linear trajectories such as that posited by Jack 
et al. (2010) could be appropriately described (Capuano et al., 2018). 
 
Comparable research into cognitive decline in dementia varies in approach; simple linear models 
are common in prospective clinical cohorts (Rongve et al., 2016; McDade et al., 2018; Malek-
Ahmadi et al., 2019), which typically have more detailed assessment, but consequently smaller 
sample numbers and fewer observations; naturally at least three observations must be available 
per subject for any trajectory other than a linear one to be described. Aside from their statistical 
simplicity, linear models may also be relatively simple to conceptualise for a broad audience but 
will fail to accurately describe any real non-linear trajectory. 
 
With sufficient observations, larger longitudinal studies often identify quadratic or similar 
accelerating trajectories of cognitive decline in normal ageing (Muniz Terrera et al., 2008), and 
in the lead up to, and after, dementia diagnosis (Wilkosz et al., 2010; Verlinden et al., 2016; 
Baker et al., 2017; Rajan et al., 2017; Wang et al., 2019). These trajectories may be expected due 
to the non-linear nature of biological processes presumed to underlie normal and pathological 
cognitive decline, as exemplified by the curvilinear decline in hippocampal volume associated 
with normal ageing (Yang et al., 2013). Decline in MCI towards dementia may also be 
characterised by a comparable cognitive trajectory, though this has not yet been assessed in 




Appropriate model development is to investigate both a linear and curvilinear trajectory to 
identify patterns of cognitive change. Model selection is undertaken using an appropriate 
measure of relative model fit (e.g. Akaike or Bayesian Information Criteria) to assess the value 
of including non-linear terms in addition to the simpler linear term. For the purpose of this work, 
curvilinear trajectories of cognitive progression were therefore considered in all analyses of 
continuous cognitive outcomes, and assessed for suitability by visual inspection and when any 
improvement in model fit was observed in comparison to the simple linear model. However due 
to the limited sample size and number of observations, a linear trajectory was anticipated to be 
the best-fitting in most cases, as in the most comparable previous literature (Rongve et al., 2016; 
van de Beek et al., 2020); this is an acknowledged limitation of the current data being unable to 
reflect the assumed complexity of the underlying neurocognitive declines. 
2.3 (Linear) mixed-effects modelling 
Mixed-effects models are an extension of general(ised) linear models which allow analysts to 
account for non-independence of data, such as when multiple observations are taken from one 
individual as in a typical longitudinal study. Consequently, mixed-effects models may be used to 
estimate growth curve models, as identified in Section 2.1.2. Their utility is not restricted to 
longitudinal analyses however, as they may be reasonably applied to other types of studies with 
simple or complex random effects structures to account for. 
2.3.1 Strengths of mixed-effects models 
The key strengths of mixed models are their reasonable robustness when observations are taken 
at unbalanced time-points (Pinheiro and Bates, 2006; Locascio and Atri, 2011), or when there is 
data missing, as is the case in the LewyPro (Chapter 3) and SUPErB (Chapter 7) studies due to 
censoring, death, drop-out, and adaptive scheduling.  
 
Both general and generalised linear mixed models (LMM) have been used in a number of 
longitudinal studies to compare rates of cognitive decline in DLB and AD (Smits et al., 2015; 
Rongve et al., 2016; Kramberger et al., 2017; Breitve et al., 2018; Malek-Ahmadi et al., 2019; 
Yu et al., 2019; Giil and Aarsland, 2020), and retrospectively in prodromal DLB (van de Beek et 
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al., 2020). Simple LMMs may therefore be the most typical approach taken within this field 
when characterising the longitudinal progression of continuous cognitive and non-cognitive 
outcomes of neurodegenerative diseases, being relatively flexible and familiar to the desired 
audience. For this reason, LMM was the first approach taken in characterising the longitudinal 
decline in global and domain-specific cognitive function in Chapters 4, 8 and 9. 
2.3.2 Practical considerations for mixed-effects models 
Within R software, a number of packages provide functions for mixed-effects modelling, with  
lme4 (Bates et al., 2015) currently being the most popular and well-supported. While lme4 does 
not provide p-values in the model output, due to statistical concerns with their approximation and 
uses, the extension package lmerTest (Kuznetsova et al., 2017) may provide these, by default 
using Satterthwaite approximation, and so these are often used in conjunction. While there are 
valid concerns over the current use and interpretation of p-values in research publishing 
(Wasserstein and Lazar, 2016), it remains an expectation that these are reported transparently 
alongside other information, and so this method was considered as suitable for analysis of the 
LewyPro and SUPErB longitudinal data. 
 
The key research question, whether different neurodegenerative diseases are associated with 
different trajectories of cognitive decline, has typically been answered within comparable LMM 
and similar methods by testing the inclusion of a time x diagnostic group interaction in other 
studies (Stavitsky et al., 2006; Smits et al., 2015; Rongve et al., 2016; van de Beek et al., 2020), 
and so this method was also adopted in these analyses. 
2.3.3 Limitations 
While their simplicity and consequent flexibility may be a strength of these methods, LMMs can 
also be limited by their simplicity. As observed in data visualisations provided by Rongve et al. 
(2016), Baker et al. (2017), and McDade et al. (2018), global cognitive trajectories can be highly 
variable between individuals within a given neurodegenerative syndrome. Typical statistical 
approaches which average across these differences may provide adequate estimates of the 
predicted level and progression of cognitive function in a group, and any broad differences from 
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other groups, but may fail to appropriately describe the cognitive trends experienced by any 
individual within this group, or any subgroups which may have different patterns and trajectories 
from the overall group.  
 
In real-world research settings this heterogeneity, if identified and accounted for, could have 
meaningful contributions in research and clinical practice; for instance, aiding in the 
identification of people with declining rather than stable MCI, and consequently in identifying 
those who may benefit more from potential future treatments. We therefore want to consider that 
the whole population does not have one homogenous pattern of change, and that the scenarios 
given above (some people decline, others improve) are considered in analyses. 
Section summary 
LMM is a common method of analysing longitudinal data in retrospective and prospective 
observational studies into the progression of outcomes in neurodegenerative diseases such as AD 
and DLB. While reasonably flexible, simple LMMs are limited by their inability to describe 
latent trends in the data which may have more clinical and research utility than the average group 
trajectory. 
2.4 Latent class mixed modelling 
Latent class mixed modelling (LCMM) allows mixed-effects models to be extended to identify 
latent classes (prior-unknown subgroups) with distinct trajectories, clustering by statistical 
similarity of growth curve. Within a longitudinal model, this could take the form of subgroups 
differentiated by starting point, rate of progression, shape of slope, or a combination of these. 
Latent class approaches to longitudinal data are less common than traditional LMM in the 
immediate MCI and DLB literature, and so may be less familiar to the intended audience, but 
have shown promise in identifying heterogeneity of cognitive trajectories in AD (Wilkosz et al., 
2010; Leoutsakos et al., 2015), all-cause dementia (Baker et al., 2017), and retrospectively in 
pre-clinical dementia (Verlinden et al., 2016), prior to differential diagnosis.  
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2.4.1 Strengths of latent class mixed models 
The key strength of LCMM over more typical LMM methods is its utility in accounting for 
heterogeneity within samples, such as by identifying non-responders in a clinical trial, or non-
decliners and super-decliners in a purported neurodegenerative sample. In this regard it addresses 
the main limitation of LMM identified above (see Section 2.3.3). Due to the heterogeneous 
nature of decline in MCI and dementia, LCMM methods may be valuable in appropriately 
characterising the varying experiences of people receiving a prospective MCI diagnosis, and may 
be able to characterise non-decline in an objective, data-driven manner, in the absence of any 
normative data for age-related longitudinal decline. 
2.4.2 Undertaking latent class mixed modelling 
Packages such as lcmm (Proust-Lima et al., 2017) and flexmix for R software allow for data-
driven identification of latent classes in longitudinal data, accounting for any effect on model fit 
in a data-driven manner, rather than the (relatively more) arbitrary cut-offs which have been used 
to identify distinct groups in similar cohorts such as quantile splits or rule-of-thumb . 
 
Identified latent classes may be used in a simple descriptive manner as by Wilkosz et al. (2010) 
but may also be treated as outcomes of a predictive model such as a logistic regression or in 
support-vector machine learning (Leoutsakos et al., 2015; Baker et al., 2017). The suitability of 
these predictive models must be considered on an individual basis, as with insufficient 
observations, or the inclusion of too many parameters, the validity of any predictive estimates 
may be questionable.  
 
Building upon the experience of applying LMM to describe cognitive decline over the course of 
MCI in Chapters 4, 8 and 9, LCMM methods were subsequently used to identify groups with 
distinct cognitive trajectories within the heterogeneous MCI cohorts in Chapters 5, 8 and 9, 
with the intention of identifying relatively fast and slow sub-groups, and early predictors of these 
trajectories. As an unsupervised method, it remained possible that other unexpected latent 
trajectories may have been identified, rather than those conceptually anticipated, and so this 
analysis was exploratory in nature. 
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2.5 Multi-state modelling 
Where longitudinal outcome data are discrete, such as when exploring transitions from MCI to 
dementia, these previously-noted methods would not be appropriate. Typical approaches taken in 
exploring prognosis within neurodegenerative diseases utilise survival curve models to assess 
change in discrete states over time; for example, the differing survival times of DLB and AD 
demonstrated by Price et al. (2017). These models can similarly be applied to the analysis of 
‘survival’ from MCI to dementia to establish risks of clinical transition between these syndromes 
(e.g. Aerts et al., 2017). Survival models such as these may be conceptualised as simple two-
state examples of the more flexible wider family of multi-state models (MSM).  
2.5.1 Strengths of multi-state models 
In the event that more discrete states may be observed between the first and last state (as in the 
cohorts available in this work), MSM may provide more flexibility than a typical survival model; 
for example, accounting for competing risks in a single model, or including transitionary stages 
of disease severity with different survival rates, e.g. mild, moderate, or severe heart disease 
(Cannon et al., 2017). These methods are not new, but are less typically utilised in the research 
fields of dementia and cognitive impairment. For the cohorts included in this work, a strength of 
MSM methods was the ability to account for the dynamic nature of the MCI syndrome, with core 
clinical LB symptoms emerging over time which were not present initially, which may have 
been associated with increased risk of transition to dementia.  
2.5.2 Practical considerations in multi-state models 
The msm package (Jackson, 2011) for R software allows for the construction of multi-state and 
competing risk models. Time varying or invariant covariates may then be included into the 
models to explore their associations with rates of transition between states. 
 
As repeated observations were available for each participant in addition to their survival time, 
data on symptom emergence could be utilised in addition to their initial clinical profile; MSM 
was therefore considered to be a promising approach for exploring the risks of transition from 
MCI to dementia or death, and any association between these and Lewy body symptomatology, 
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or other demographic variables. In contrast to other methods of incorporating time-varying 
covariates into survival analysis, this method does not require the manual specification of 
separate start and end times for each observation period. This analysis, and its results, are 
presented in Chapters 6, 8 and 9 for the development, validation, and combined cohorts, 
respectively. 
2.5.3 Limitations 
One major limitation of this method is its applicability to smaller sample sizes, as in the cohorts 
available for this work. The flexibility of MSM (i.e. the number of states that may be 
conceptualised, and the dynamic transitions possible between these) may only be adequately 
realised given a sufficiently large number of observations overall, and a sufficient number of 
transitions observed between these states; with a lack of precedent, this analysis was anticipated 
to be exploratory in nature. 
2.6 Chapter summary 
To address the overall research question – whether the different neurodegenerative diseases, 
Lewy body disease or Alzheimer’s disease, are associated with different patterns and 
progressions of mild cognitive impairment – three main analytical approaches were considered 
as appropriate. Each of these explored the fundamental research question from a different angle; 
these are summarised in Table 2.1.  
 
Mixed-effects models explored the differences between diagnostic groups in their average rates 
of decline in global and domain-specific cognitive function. Latent class mixed models identified 
sub-groups of decline and non-decline within the overall MCI cohort, and explored the 
associations between Lewy body disease symptoms and subsequent trajectories of decline. 
Finally, multi-state models assessed the annual risks of clinical conversion from MCI to 
dementia with death as a competing risk, comparing the rates of conversion between cases of 
MCI with and without specific DLB symptoms. 
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These analyses were explored with a development cohort, and models were assessed with an 






Table 2.1. Summary of methods. 
 Summary 
Mixed-effects modelling  
    Chapters 4, 8 & 9 
    Outcome measures Average global and domain-specific cognitive trajectories 
    Diagnostic measure Differential diagnosis 
    Strengths Simplicity and familiarity 
    Limitations Little account for heterogeneity within groups 
Latent class mixed modelling  
    Chapters 5, 8 & 9 
    Outcome measure Latent global cognitive trajectories 
    Diagnostic measures Differential diagnosis and specific diagnostic characteristics 
    Strengths Ability to identify heterogeneous sub-groups 
    Limitations Limited sample size for predicting smaller latent classes 
Multi-state modelling  
    Chapters 6, 8 & 9 
    Outcome measure Transitions between clinical states (MCI/dementia/death) 
    Diagnostic measures 
DLB diagnostic characteristics accumulation and specific 
individual characteristics 
    Strengths Definitive and clinically relevant outcome measure 




Chapter 3. LewyPro Study Background 
Building on previous research into the clinical and imaging profiles of DLB, the LewyPro study 
aimed to characterise MCI as a prodrome of DLB; a relatively novel approach at the time 
(McKeith et al., 2016) prior to recent codification of MCI-LB research diagnostic criteria 
(McKeith et al., 2020). This study undertook annual follow-ups with an MCI cohort to track 
rates of decline and eventual conversion to dementia in groups differentially diagnosed as either 
MCI-LB or MCI-AD based on contemporary clinical criteria for DLB. 
 
Using data from this study, the aim of this work was to explore how MCI-LB and MCI-AD 
progressed clinically and cognitively towards the comparatively well-researched concepts of 
DLB and AD-type dementia, assessing if the differing underlying pathologies had different 
patterns and trajectories of cognitive decline, how Lewy body symptomatology developed over 
time, and whether different aetiologies were associated with different speeds of transition to 
dementia. 
 
It was hoped that this study would provide further clarity as to the profiles and timelines of 
cognitive impairment in different neurodegenerative diseases, and might assist researchers and 
clinicians in considering appropriate tests and outcome measures for MCI-LB. 
3.1 Participants 
3.1.1 Screening 
Beginning in February 2013, and ending in February 2016, patients were screened from local 
healthcare trusts in North-East England; those considered were aged 60 years or older, had a 
health service clinical diagnosis of MCI, and the reported possible presence of any symptom 
non-specifically associated with DLB, but also found in AD (e.g. unspecified sleep disturbance 




3.1.2 Consent and assessment 
Of those screened, 90 were eligible for inclusion initially and provided written, informed consent 
to undergo baseline assessment within the research study to further assess suitability. Ethical 
approval for this study was given by the National Research Ethics Service Committee North East 
– Newcastle and North Tyneside 2 (Research Ethics Committee No. 12/NE/0290). 
 
For inclusion, all participants had to be medically stable, with no change in prescribed 
medication within the last month prior to baseline assessment. Exclusion criteria were the 
presence of dementia or lack of objective cognitive impairment at baseline, possible 
frontotemporal or vascular aetiology based on clinical features or previous imaging findings, or 
an established history of PD for more than one-year preceding onset of cognitive impairment.  
 
After baseline assessment, four participants were excluded due to the presence of dementia, three 
were excluded due to the presence of only subjective cognitive impairment or an atypical static 
MCI, six withdrew prior to completing baseline assessment, and one was excluded after 
diagnosis of a frontotemporal dementia at follow-up. Seventy-six participants were therefore 
eligible and included. 
 
Participants were followed-up annually unless they withdrew, converted to dementia or other 
serious illness, or died. Once all available participants had completed at least a 2nd year follow-
up, to ensure the availability of a sufficient number of observations for this work, the dataset was 
locked for initial analysis. The available data at each observation point, and any loss to follow-up 




Figure 3.1. Data availability (bold) and loss at each observation year in the LewyPro study cohort. 
 
Where possible, an informant was also sought from family or close friends for each participant, 
with permission, to provide further information on clinical features, functional independence, 
and neuropsychiatric symptoms. Eight participants (10%) did not have any informant available. 
3.2 Diagnosis 
A semi-structured interview was undertaken by a medical doctor with the participant and their 
informant, where available. Clinical notes from this interview were used to rate the presence of 
neurocognitive impairment, either MCI or dementia, independently by a three-person panel of 
experienced old age psychiatrists. MCI diagnoses were made in accordance with NIA-AA 
criteria (Albert et al., 2011) given evidence and concern of relative cognitive decline without loss 
of independent functioning. 
 
Differential diagnosis of MCI was undertaken in the same manner as the later formalised 
consensus criteria for diagnosis of MCI-LB in research settings (McKeith et al., 2020): The 
presence or absence of four core clinical features of DLB (RBD, parkinsonism, complex visual 
hallucinations, and cognitive fluctuations) was rated in each case by the same panel producing a 
consensus for each feature’s presence or absence. Results from dopaminergic imaging, as noted 
below, were also included as an additional diagnostic characteristic, to which the rating panel 
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were blind when assessing clinical features. Diagnostic criteria for DLB (McKeith et al., 2005) 
were adapted for MCI, so that participants with MCI and none of four core DLB diagnostic 
features plus normal FP-CIT imaging were classified as MCI-AD. Those with MCI plus one of 
four core DLB features, or no core DLB features but abnormal FP-CIT imaging, were classified 
as possible MCI-LB. Participants with two or more core DLB features, or one core DLB feature 
and abnormal FP-CIT, were classified as probable MCI-LB.  
 
Severity of neurocognitive impairment (MCI or dementia) and presence of core Lewy body 
symptoms was re-evaluated at each annual follow-up visit according to the same criteria. Those 
who had converted to dementia were diagnosed according to the relevant criteria for AD 
(McKhann et al., 2011), DLB (McKeith et al., 2005), vascular cognitive impairment (Román et 
al., 1993), or a frontotemporal dementia (Rascovsky et al., 2011), with the latter two being cause 
for exclusion as noted previously; cases with either vascular or frontotemporal aetiology at 
follow-up within MCI or upon development of dementia were retrospectively excluded. 
3.2.1 Clinical features 
Data on the presence and accumulation over time of specific clinical features was available for 
each participant, assisting in conceptualising specific patterns of disease and their development 
over time. Quantitative and semi-quantitative scales were available to measure severity of some 
symptoms, such as the UPDRS-III for assessing parkinsonism (Ballard et al., 1997), the North 
East Visual Hallucinations Inventory (NEVHI) for visual hallucinations (Mosimann et al., 2008), 
the Clinician Assessment of Fluctuation (CAF; Walker et al., 2000b) and Dementia Cognitive 
Fluctuation Scale (DCFS; Lee et al., 2014) for cognitive fluctuations, and the Mayo Sleep 
Questionnaire (MSQ; Boeve et al., 2011a) for RBD. 
 
Functional independence was assessed with the Instrumental Activities of Daily Living (IADL) 
scale (Lawton and Brody, 1969). In addition to standard (0-8) scoring range, this was also 
quantified with an extended scoring system treating each item as a scale rather than a binary 
score, so total scores may range from eight to 31 (Cromwell et al., 2003), with total IADL scores 
reflecting greater functional impairment. The Epworth Sleepiness Scale (ESS; Johns, 1991) 
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assessed participants’ levels of daytime sleepiness in various situations, providing a total daytime 
sleepiness score. The Geriatric Depression Scale (GDS; Yesavage et al., 1983) was used to 
assess participants’ present state of depressiveness at each visit. The Neuropsychiatric Inventory 
(NPI; Cummings et al., 1994) assessed overall neuropsychiatric symptomatology. 
3.2.2 Biomarkers 
Dopaminergic function was assessed with FP-CIT SPECT imaging (O'Brien et al., 2004), 
offered to all included participants at baseline regardless of suspected diagnosis. Images were 
visually rated as either normal or abnormal by an experienced consensus panel blind to clinical 
information and diagnosis (Thomas et al., 2019). Imaging results were incorporated into 
differential diagnoses to provide an additional diagnostic characteristic. Seventy-four of 76 
participants consented to FP-CIT imaging, while two did not consent. In both who did not 
consent, there were sufficient clinical diagnostic features of DLB to receive a diagnosis of 
probable MCI-LB without dopaminergic imaging results: both featured cognitive fluctuations, 
complex visual hallucinations, and parkinsonism, while one of the two also had RBD, which the 
other did not. 
3.3 Neuropsychological assessment 
Several neuropsychological measures were available at baseline and follow-up to provide as 
complete of a neurocognitive profile as possible, with consideration for overall time cost.  
3.3.1 Global cognition 
Total score on the ACE-R (Mioshi et al., 2006) was used to measure global cognitive 
functioning. MMSE scores were also derived from this test, allowing comparison of group levels 
of global cognitive impairment with a wider range of published research. The ACE (Ahmed et 
al., 2008) and ACE-R (Yoshida et al., 2012) have displayed good sensitivity to cognitive decline 




3.3.2 Attention and executive functions 
To account for the diverse types of attention and executive functions, a range of tests was used to 
explore these thoroughly at every year of assessment. 
 
Verbal fluency was assessed with the FAS letter-fluency test, which has shown greater 
sensitivity to frontal lesions than temporal in comparison with similar category-fluency tests 
(Baldo et al., 2006). Additionally, ACE-R fluency sub-scores were available. In participants with 
comparable language skills, any differences in verbal fluency should be due to executive 
impairments. 
 
Raw and cognitive processing speeds were measured with computerised simple (SRT) and 
binary-choice (CRT) reaction time tasks using handheld response buttons; the former measures 
how quickly a subject may react to the appearance of a (visual) stimulus, while the latter 
measures how quickly they may distinguish between the stimulus and a competing target. These 
tasks have been indicated to be relatively pure measures of processing speed (the speed at which 
the subject may parse information as it arises), with minimal demand on executive functions 
(Albinet et al., 2012), and therefore favourable to alternatives such as trail making tests for this 
purpose. 
 
Sustained and selective attention were also assessed with a computerised continuous 
performance digit-vigilance task, which had previously been successfully used to measure 
attentional impairment in DLB (Watson et al., 2017). 
 
Completion times for the Trail Making Test parts A (TMT-A) and B (TMT-B) respectively 
assessed visual attention and processing speed, and executive functioning. While less pure as 
measures of processing speed than reaction time tasks, these assessments are low in time and 
material costs, and have high utility in clinical settings. 
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3.3.3 Memory and learning 
The RAVLT was administered at baseline to assess memory encoding, recall, and recognition 
processes (Schmidt, 1996); this test is sensitive to differences in amnestic memory dysfunction 
between DLB and AD (Ferman et al., 2006), but also detects cognitive differences between 
MCI-AD and healthy controls (Estevez-Gonzalez et al., 2003), and may help characterise 
amnestic versus non-amnestic MCI syndromes (Ferman et al., 2013). Verbal learning tests such 
as this allow for the assessment of multiple memory processes at once, and even within a single 
model given enough observations (e.g. Gross et al., 2013), but come with a higher time cost and 
participant burden than many other clinically-oriented assessments, and so these were not 
routinely used as a repeated measure after baseline. Memory sub-scores were available from the 
ACE-R at every year of assessment to provide measures of longitudinal progression of memory. 
3.3.4 Visuospatial functions 
A computerised line-orientation judgement task (LAT), run in MATLAB software, was used to 
assess visuo-perceptual skills in participants, having shown previous suitability in assessing 
visuo-perceptual dysfunction in DLB (Wood et al., 2013a). Similar line-orientation tests have 
shown particular sensitivity to lesions of the posterior parietal cortex (Tranel et al., 2009), and so 
might represent a relatively pure measure of spatial perception in particular, with little-to-no 
motor component.  
 
The ACE-R visuospatial sub-score was also available from each year; this uses a diverse array of 
brief tasks including visuo-construction drawing tasks to assess a wide range of visual skills, 
albeit in less depth. 
3.3.5 Speech, language, and intelligence 
Language skills were expected to remain relatively stable in both control and MCI groups; the 
GNT (McKenna and Warrington, 1980) was used to assess language skills at baseline. 
Participants self-reported their number of years spent in formal education. The NART (Nelson 
and Willison, 1991) was completed by a subset of the sample at a later time, but not available for 
68 
 
all LewyPro participants. Language sub-scores of the ACE-R assessed any other changes at 
follow-up. 
 
It was considered necessary to control for the confounding effects of premorbid functioning and 
health inequalities on intelligence and clinical progression in the absence of the NART. 
Participants reported their number of years spent in formal education to assess the former, and 
local deprivation was estimated from publicly available national deprivation statistics provided 
for each participant’s local neighbourhood (Department for Communities and Local 
Government, 2011). While education was prospectively assessed at baseline, deprivation 
statistics were calculated retrospectively, and so not available in initial analyses. 
3.4 Procedure 
A longitudinal repeated-measures design was utilised. Measures were taken at baseline, and 
again at annual follow-ups, to track differences in within-subject progression between diagnostic 
groups in a mixed design. 
3.4.1 Baseline testing 
At baseline participants were consented, screened, and undertook all pen-and-paper 
neuropsychological assessments in a single visit. Medical review and imaging were undertaken 
at separate visits within the baseline year for a total of three visits; median time between first and 
final baseline visit was 21 days. 
3.4.2 Follow-up testing 
Pen-and-paper and computerised neuropsychological testing, as well as medical review, was 
undertaken within a single session at each annual follow-up. Tests which are insensitive to 
change or vulnerable to practice effects were not repeated and so available only at baseline. This 
general streamlining of data collection was also necessitated by the increasing number of 
participants requiring testing as the cohort developed over time, and to reduce participant burden. 




Data for participants who had converted to dementia after passing baseline screening was 
censored, and they did not undertake any further assessment. Where participants were lost to 
follow-up due to a clinically relevant reason, such as conversion to dementia or death, this was 
recorded where appropriate. After all available participants had completed two or more follow-
up visits in the summer of 2018, the dataset was locked for analysis as presented here. 
3.5 Analysis 
Data from each year were extracted from wide-format databases in SPSS (one row per 
participant, repeat observations across separate databases for each timepoint), cleaned and 
combined into long-format data frames suitable for longitudinal analysis with R software (one 
row per observation with subject as a grouping variable and timepoint as a continuous variable). 
All data were routinely checked for anomalies or inconsistencies, and any suspected input errors 




Chapter 4. LewyPro: Longitudinal Decline in MCI-AD and MCI-LB 
Past research into the cognitive outcomes of Lewy body and Alzheimer’s diseases had 
previously focussed on the dementia stages. While the cognitive prodromes of these diseases had 
been explored, this was predominantly in cross-sectional or retrospective studies, or without 
differential clinical diagnosis. This chapter is adapted from a manuscript accepted for publication 
(Hamilton et al., 2020a). 
 
DLB and AD present with different patterns of impairments in particular cognitive domains 
(Gurnani and Gavett, 2017), and have been observed to decline at different rates; various studies 
report a more aggressive course in DLB than AD in rate of cognitive decline (Rongve et al., 
2016), though this is mixed, with some studies finding no difference in speed of decline over 
shorter periods (Walker et al., 2012). 
 
Cross-sectional data have provided preliminary information on the cognitive profiles of MCI 
with Lewy bodies (MCI-LB) in comparison with MCI-AD and healthy controls (Ferman et al., 
2013; Kemp et al., 2017; Donaghy et al., 2018), suggesting that the DLB-like cognitive profile 
of greater visuospatial and executive impairment, and less amnestic memory dysfunction, may 
already be evident at the MCI stage. There is emerging evidence that the prodromal stages of 
DLB may differ in their cognitive trajectories from an idiopathic REM sleep behaviour disorder 
syndrome (Génier Marchand et al., 2018), but the clinical MCI stages of AD and DLB have not 
been compared longitudinally in a prospective setting. 
4.1 Aims and hypotheses 
We aimed to utilise the longitudinal data now available to better characterise the cognitive 
profiles and trajectories in the LewyPro cohort. We hypothesised that MCI-LB and MCI-AD 
would display differing trajectories of cognitive decline, specifically: greater episodic memory 
decline with MCI-AD, and greater impairments in visuospatial, attention, and executive 
functions in MCI-LB. We also hypothesised that MCI-LB would show a more rapid global 
cognitive decline than MCI-AD, consistent with findings from comparable longitudinal studies 




4.2.1 Participants and diagnosis 
Seventy-six eligible participants were included from the LewyPro study, with recruitment and 
diagnosis as described in Chapter 3.  
 
Participants were re-assessed every 12 months in a prospective longitudinal design. Presence of 
the four core clinical DLB features (RBD, cognitive fluctuations, complex visual hallucinations, 
and parkinsonism), and severity of neurocognitive impairment (MCI or dementia) were re-
appraised at annual follow-ups by the clinical panel, with FP-CIT imaging results incorporated 
blind to clinical information. Participants were not followed-up after transition to dementia. 
4.2.2 Materials 
Cognitive measures 
Outcome measures were the ACE-R, from which MMSE score was derived, as were domain-
specific sub-scores for Attention and Orientation (0-18), Verbal Fluency (0-14), Memory (0-26), 
Visuospatial Function (0-16), and Language (0-26).  
 
TMT-A and TMT-B, and FAS verbal fluency were also administered annually, with the latter 
two used to assess executive functions.  
 
Computer-run tests included simple (SRT) and binary choice (CRT) reaction, and digit vigilance 
(DVT) tests of attention, and a line angle discrimination task (LAT) to assess visual perception 
(Wood et al., 2013a). 
 
Baseline-only tasks were the Rey Auditory Verbal Learning Test (RAVLT), Graded Naming 
Test (GNT), and computerised motion-detection task (Wood et al., 2013a). These were not re-





In the semi-structured clinical interview, the UPDRS-III, ESS and GDS were administered to 
patients. The IADL scale, NEVHI, NPI, MSQ, CAF and DCFS were administered to informants. 




As in the baseline study (Donaghy et al., 2018), cross-sectional differences between groups were 
compared at baseline using one-way ANOVA and chi-square tests.  
Longitudinal decline 
LMM assessed cognitive change in the overall MCI cohort, and any effect of diagnosis. Analyses 
were undertaken in R software using the packages lme4 (Bates et al., 2015) and lmerTest 
(Kuznetsova et al., 2017). 
 
Time, as a continuous fixed effect, predicted cognitive outcome, while controlling for 
conceptually-relevant covariates (education, age, gender). Models included random intercept and 
slope at the subject level, allowing for correlation between these when indicated by improved 
model fit. Both Akaike- (AIC) and Bayesian Information Criterion (BIC) were considered as 
complementary measures of model fit, with decrease in either representing an improvement in 
model fit when including a parameter, but the latter being the more conservative benchmark. 
Diagnostic group was then incorporated as a fixed effect, interacting with time where 
appropriate, in all models; if this did not improve model fit, an alternate best-fit (by BIC) model 
is also reported. 
 
Development models were fit by full maximum likelihood, and final reported models by 





Significance level was defined as p < .05 and no adjustment was made for multiple testing given 
the exploratory nature of this analysis, with domain-specific primary hypotheses requiring 
independent tests. 
4.3 Results 
4.3.1 Diagnostic groups 
At the time of data locking, participants had been followed-up for a mean of 1.9 years (SD = 1.1, 
Min = 0, Max = 5, Median = 2). 
 
 
Table 4.1. Clinical features of LewyPro baseline diagnostic groups. 
 MCI-AD 
(n = 23) 
Poss. MCI-LB 
(n = 12) 
Prob. MCI-LB 
(n = 41) 
Parkinsonism 0 (0%) 0 (0%) 19 (46%) 
Cognitive Fluctuations 0 (0%) 4 (33%) 23 (56%) 
REM Sleep Behaviour Disorder 0 (0%) 5 (42%) 20 (49%) 
Complex Visual Hallucinations 0 (0%) 0 (0%) 12 (29%) 
Abnormal FP-CIT SPECT 0 (0%) 3 (25%) 26 (67%)a 
aTwo participants did not consent to FP-CIT SPECT, but had sufficient clinical symptomatology 
to receive a probable MCI-LB diagnosis without confirmatory biomarkers  
 
 
Thirty-two participants (42%) had transitioned to dementia; seven MCI-AD (30%), five possible 
MCI-LB (42%), and 20 (49%) probable MCI-LB. Fourteen transitioned within the first year, 12 
in the second, five in the third, and one in their fourth. All seven cases of AD dementia had been 
previously diagnosed with MCI-AD. Of five possible DLB, three had been diagnosed as MCI-
AD but subsequently developed LB symptoms, and two had baseline diagnoses of possible MCI-
LB. All 20 cases of probable DLB had been diagnosed as probable MCI-LB. In comparison with 
MCI-AD, a Fisher’s exact test did not find diagnosis of possible MCI-LB to be significantly 
associated with an eventual diagnosis of possible DLB rather than AD (exact p = .152). Probable 
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MCI-LB diagnosis was significantly associated with eventual diagnosis of probable DLB versus 
AD (exact p < .001).  
 
Clinical diagnoses, demographics and baseline scores have been reported in detail previously 
(Donaghy et al., 2018) and are summarised in Table 4.1, Table 4.2, and Table 4.3. Diagnostic 
groups did not differ in age, education, or baseline global cognitive function. Probable MCI-LB 
presented with greater functional impairment than MCI-AD (lower IADL score), though all 
subjects had minimal impairments, as reflected by their MCI diagnosis; IADL scores were 
correlated (Spearman’s ρ) with UPDRS-III (ρ = -0.28, p = .023) but not ACE-R total scores (ρ = 
0.12, p = .344) suggesting that these related to motor, not cognitive, impairments. MCI-AD were 
mostly female, and probable MCI-LB mostly male. Higher daytime sleepiness (ESS), motor 
impairment (UPDRS-III), and neuropsychiatric symptomatology (NPI, GDS-15, NEVHI, CAF, 
and DCFS) were found in probable MCI-LB; this was expected as these relate to the symptoms 









(n = 23) 
Poss. MCI-LB 
(n = 12) 
Prob. MCI-
LB 
(n = 41) 
p 
Female 15 (65%) 5 (42%) 14 (34%) .055 
Male 8 (35%) 7 (58%) 27 (66%) - 
Age 78.2 (7.5) 75.3 (7.3) 75.5 (7.6) .335 
Years in Education 11.9 (3.0) 10.8 (2.1) 11.4 (2.8) .531 
CDR Total (Median) 0.5 (0) 0.5 (0) 0.5 (0) .206 
IADL Total (0-8) 7.2 (0.9) 6.6 (1.6) 6.1 (1.7) .038 
CIRS-G Total 9.2 (4.0) 12.1 (5.2) 9.1 (4.1) .097 
MSQ Q1 ‘Yes’ 3 (13%) 2 (17%) 20 (49%) .095 
ESS 4.2 (3.7) 6.8 (4.9) 10.4 (5.0) <.001 
GDS 2.4 (2.2) 2.9 (2.7) 4.4 (3.6) .039 
UPDRS-III 15.0 (7.1) 14.0 (7.8) 26.2 (16.2) .001 
NPI Total 5.8 (7.0) 12.9 (13.2) 13.7 (9.8) .021 
NEVHI 1.0 (2.8) 1.3 (3.4) 3.4 (4.4) .031 
CAF 0.3 (1.0) 2.0 (2.5) 2.4 (2.9) .019 
DCFS 5.6 (1.6) 7.4 (2.3) 8.9 (3.2) <.001 




Table 4.3. Baseline cognitive measures in LewyPro cohort. 




MMSE 26.5 (2.3) 26.2 (2.9) 26.5 (2.0) .901 
ACE-R Total 79.5 (11.70) 79.3 (14.1) 79.3 (8.3) .996 
ACE-R Att./Orient. 17.0 (1.4) 16.6 (2.1) 16.8 (1.4) .745 
ACE-R Memory 15.7 (5.8) 15.8 (5.9) 17.4 (4.4) .356 
ACE-R Fluency 9.7 (2.7) 8.2 (3.3) 7.9 (2.8) .041 
ACE-R Language 22.9 (3.3) 24.1 (2.9) 23.6 (2.1) .385 
ACE-R Visuospatial 14.2 (1.9) 14.7 (1.9) 13.5 (2.1) .125 
FAS Fluency 36.2 (13.1) 26.5 (16.3) 29.0 (14.5) .093 
Rey Delayed Recall 3.1 (4.3) 2.5 (2.6) 3.9 (3.1) .438 
Rey Recognition 12.0 (2.3) 10.3 (3.6) 11.7 (2.3) .184 
Rey % Trial 5 Recalled 35.2 (39.0) 37.5 (40.0) 53.9 (50.6) .253 
GNT 16.5 (6.8) 20.3 (5.9) 17.6 (5.7) .223 
SRT Mean (ms) 406 (149) 410 (177) 403 (155) .993 
CRT Mean (ms) 678 (131) 747 (355) 730 (250) .642 
DVT Mean (ms) 555 (75) 534 (72) 584 (72) .074 
Motion Task Score 0.70 (0.28) 0.67 (0.28) 0.65 (0.28) .784 
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4.3.2 Longitudinal change: global cognitive function 
To test the hypothesis that LB symptomatology would have a faster decline than AD, a model 
was developed incorporating diagnosis as a fixed effect (Figure 4.1) predicting ACE-R total 
score; this did not improve fit under either criteria. This full model, and alternate best-fitting 
model, are reported (Table 4.4). Diagnostic groups did not significantly differ in their initial 





Figure 4.1. Longitudinal observed individual (solid lines) and predicted diagnostic-specific (dashed lines) 
trajectories of global cognitive decline in LewyPro. 
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4.3.3 Domain-specific function 
This method was repeated for domain-specific measures. Estimates for ACE-R sub-scores are 
reported in Table 4.4, including diagnosis (full model), interacting with time where appropriate. 
Best-fit models are also reported in when diagnosis was not observed to have an effect, or as 
indicated by the more parsimonious Bayesian criterion. Age, gender, and education were 
included as covariates in all cases.  
 
Attentional functions (ACE-R Attention & Orientation) significantly declined over time, but 
there was no effect of diagnosis, with no improvement in model fit. 
 
Overall memory (ACE-R Memory) did not decline over time; incorporating diagnosis did not 
improve model fit, and diagnoses did not differ in their initial profiles or time-trajectories. 
Verbal fluency significantly declined in MCI. In the full model, probable MCI-LB was 
associated with poorer verbal fluency (ACE-R Fluency) than MCI-AD. However, including 
diagnosis did not improve fit sufficiently to include in the best-fit model with BIC. 
 
Speech and language (ACE-R Language) declined significantly over time. Including diagnosis 
did not improve fit; there were no differences between groups in initial language impairment or 
declines thereafter. 
 
For visuospatial functions (ACE-R Visuospatial), including diagnosis as a fixed effect interacting 
with time provided best fit under AIC (Table 4.4). Although probable MCI-LB had a lower 
baseline visuospatial sub-score, the error term around this was quite large. MCI-AD patients did 
not significantly decline in visuospatial performance over time, however probable MCI-LB had a 
significantly more rapid decline in comparison to MCI-AD (Figure 4.2). Possible MCI-LB did 
not significantly differ in baseline visuospatial performance or rate of decline compared to MCI-








Table 4.4. Fixed effects coefficients for linear mixed-effects models for ACE-R total and domain scores in LewyPro. 
aEstimate (SE), p value 
bBest fit models fit for parsimony with diagnosis parameter/interaction excluded when indicated by model fitting criterion 
 
 Intercepta Change from intercept Time Interaction with time 













    Best fitb 83.4 (10.60),  
< .001 






-3.2 (0.55),  
< .001 
No difference from MCI-
AD 












-3.2 (0.55),  
< .001 
No difference from MCI-
AD 
ACE-R Attention & Orientation 
    Best fit 16.1 (1.91),  
< .001 






-1.2 (0.19),  
< .001 
No difference from MCI-
AD 













 < .001 
No difference from MCI-
AD 
ACE-R Memory 
    Best fit 22.6 (6.60), 
 .001 








No difference from MCI-
AD 












-0.1 (0.22),  
.785 
No difference from MCI-
AD 
ACE-R Verbal Fluency 
    Best fit 7.2 (3.52), 
 .044 








No difference from MCI-
AD 














No difference from MCI-
AD 
ACE-R Language 
    Best fit 26.3 (3.05),  
< .001 







 < .001 
No difference from MCI-
AD 













 < .001 
No difference from MCI-
AD 
ACE-R Visuospatial 
    Best fit  12.3 (2.66), 
 < .001 






-0.5 (0.14),  
< .001 
No difference from MCI-
AD 




















As overall ACE-R memory score is a composite of various tasks; we also examined specific 
scores to explore memory patterns in-depth. Diagnostic groups did not differ in their registration 
or un-cued recall of information; performance in these sub-domains was not predicted by age, 
education, or gender, and did not significantly decline over time. In recognition of learned 
information, there was a significant difference at baseline between probable MCI-LB, and MCI-
AD, with the former performing better in the full model (Table 4.5). Incorporating diagnosis 
improved fit under AIC, but not BIC, so an alternate best-fit model is also reported. Recognition 
memory did not display any clear time trend overall, nor any group differences in decline. 
 
To explore visuospatial decline more clearly, ACE-R visuospatial totals were decomposed into 
visuo-constructional (pentagon and cube copying, and clock drawing), and perceptual scores 
(letter identification and dot-counting), each marked out of eight. There was no significant time 
trend in visuo-perceptual performance, no effect of age, education, or gender, and no influence of 
diagnostic status; none of these improved model fit. Visuo-constructional performance was 
significantly influenced by diagnosis (Table 4.5); probable MCI-LB performed poorer at 
baseline, and deteriorated at a faster rate than MCI-AD. AIC favoured this full model and BIC 
favoured a more parsimonious model without interaction term; this best-fit model is also 
reported in Table 4.5. After controlling for baseline function post hoc, without interaction with 
time (as indicated by AIC and BIC), the pattern of faster decline in probable MCI-LB remained 
(B = -0.7, SE = 0.30, p = .026), suggesting that the declining trend was not just an artefact of the 
lower starting function in probable MCI-LB. 
 
To adequately assess visuo-perception, a secondary model examined line-angle task 
performance, which showed utility in a previously reported cross-sectional study using the 
baseline data from this same study (Donaghy et al., 2018), and was administered repeatedly at 
subsequent follow-ups. Higher values reflect poorer angle discrimination (in degrees) and 
therefore worse performance. LAT performance was best predicted by the inclusion of diagnosis, 
without time-interaction, under both criteria (Table 4.5). Genders significantly differed in 
performance, with males better able to discriminate angle differences than females, but did not 
differ in their progressions. Probable MCI-LB was associated with significantly poorer angle 
judgement than MCI-AD at baseline. There was no significant time trend in LAT performance, 
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and no interaction of time with other effects. There were few repeated observations (n = 132), 
limiting the ability to estimate changes over time. 
 
Repeated measurements were also available for FAS verbal fluency; in the full model, probable 
MCI-LB had significantly poorer performance at baseline after controlling for covariates (Table 
4.5). There was no significant time effect, or interaction with diagnosis. Diagnostic status 
improved fit under AIC, but not BIC, so the alternate parsimonious model is also reported. As 
with the LAT, repeated measures were taken but observations were limited (n = 130). 
 
For TMT-A, completion time was best predicted by models incorporating age and education as 
non-interacting effects (Table 4.5); including diagnosis improved fit under AIC, but not BIC. 
Diagnostic effects were non-significant. For TMT-B there was no effect of diagnostic group. In 
both, higher education was associated with faster- and higher age with slower completion.  
 
Mean and SD of correct response times in both simple and choice reaction tests, and digit 
vigilance task, were not significantly predicted by age, education, or gender. Incorporating 
diagnosis did not improve model fits. Reaction times did not clearly improve or worsen over 





Figure 4.2. Observed individual (solid) and predicted diagnostic-group (dashed) trajectories of cognitive 






Table 4.5. Fixed effect coefficients for linear mixed-effects models for supplementary cognitive tests in LewyPro. 






























No difference from MCI-
AD 


















ACE-R Recognition Memory 
    Best fit 3.9 (1.12),  
< .001 






0.1 (0.07),  
.420 
No difference from MCI-
AD 














No difference from MCI-
AD 
LAT 














No difference from MCI-
AD 
TMT-A 
    Best fit -56.2 (41.24), 
.178 








No difference from MCI-
AD 















No difference from MCI-
AD 
TMT-B 
    Best fit -72.1 
(105.60), 
.498 









No difference from MCI-
AD 















No difference from MCI-
AD 
FAS Total 
    Best fit 14.4 (16.91), 
.399 








No difference from MCI-
AD 












0.3 (0.67),  
.688 
No difference from MCI-
AD 
aEstimate (SE), p value 




There was no clear difference in rates of global cognitive decline between diagnostic subgroups, 
contrary to our hypothesis, but as hypothesised, probable MCI-LB was associated with a faster 
deterioration in aspects of visuospatial function as assessed by the ACE-R. We did not observe 
different rates of decline in attentional or executive functions between groups. 
 
Overall memory performance did not differ between groups, either in initial impairment or 
decline thereafter. In exploratory analyses MCI-AD displayed poorer recognition memory than 
probable MCI-LB, but these did not differ in their progressions. 
 
The more severe pattern of visuo-spatial impairment in probable MCI-LB aligns with previous 
findings in dementia (Ferman et al., 2006; Metzler-Baddeley, 2007; Wood et al., 2013a), 
Parkinson’s disease (Weil et al., 2016) and MCI (Ferman et al., 2013; Yoon et al., 2015), and 
may reflect disruption to cortical (Minoshima et al., 2001; Fujishiro et al., 2013) and sub-cortical 
(Delli Pizzi et al., 2014) visual systems in DLB. Furthermore, the faster decline of visuo-
constructional skills in MCI-LB is consistent with recent observations of faster declining 
visuospatial functions in DLB and PDD in comparison to AD (Smirnov et al., 2020).While the 
ACE-R appears insensitive to visuo-perceptual decline in MCI, group differences are evident at 
baseline with the line angle discrimination task, suggesting that relatively pure perceptual tests 
might be valuable in assessing earlier visuospatial impairments in MCI. 
 
Probable MCI-LB did not deteriorate more quickly in global cognitive function than MCI-AD, 
consistent with some (Walker et al., 2012), but not all (Rongve et al., 2016) findings from the 
respective dementia stages, which did not support our hypothesis; this could suggest that an 
accelerated decline occurs in DLB later than at the MCI stage. Alternatively, total score in the 
ACE-R may not account for global cognitive decline in MCI-LB and MCI-AD equally given 
their different patterns of domain-specific cognitive impairment; ACE-R sub-scores are not 
equally weighted towards total score, or equally sensitive to dysfunction, and so may 
underestimate the relative contributions of some domains to global cognitive impairment. Further 
exploration may establish whether MCI-LB also has a comparable rate of dementia onset as 
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MCI-AD, or if the faster expected decline manifests in faster loss of independent function after 
onset of cognitive impairment. Furthermore, our subject numbers are modest, and longer follow-
up may be required to identify differences in decline. 
 
These results help resolve some of the previously reported inconsistencies between two different 
tests of verbal fluency (Donaghy et al., 2018); after controlling for relevant covariates and 
undertaking repeated measurement, ACE-R verbal fluency sub-score and FAS letter-fluency were 
consistent in finding greater impairments of verbal fluency in probable MCI-LB than in MCI-
AD. 
 
It was expected that MCI-LB would be associated with less memory impairment than MCI-AD. 
This hypothesis was only partially supported; while overall memory scores did not show this 
pattern, recognition-specific memory was worse in AD than probable MCI-LB. These results 
partially reflect previously observed patterns of memory impairments in AD and DLB, as 
assessed with dedicated verbal learning tests (Salmon et al., 1996; Ferman et al., 2006), with 
DLB displaying difficulties with encoding and recall but relatively preserved recognition, in 
comparison with the rapid ‘forgetting’ associated with AD. 
 
The unexpected lack of progressive decline in memory may be partially explained by floor 
effects, or repeated practice and familiarity with common screening tests, such as the ACE-R. 
Comparison with a healthy control cohort may clarify whether practice effects are contributing, 
and if observed declines in language and attention are related to neurodegenerative processes, or 
normal aging. This would also afford the opportunity to characterise cognitive profile 
categorically, for example as amnestic or non-amnestic (Ferman et al., 2013), in comparison to 
healthy normative data. 
 
Intended for dementia screening, ACE-R sub-scores may be insensitive to domain-specific 
decline in MCI. More sensitive and less familiar tests may be suitable for this purpose, such as 
computerised testing batteries. While the RAVLT was administered to a subset of those who 
entered a follow-up study, there were insufficient repeated observations to develop a longitudinal 
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model; repeated assessment with a suitable memory test may better demonstrate how memory 
progresses over the course of MCI. 
 
Using multiple domain-specific tests, these results are limited by the use of independent tests 
without adjustment for multiple comparisons, and limited improvement of model fit under the 
more conservative criterion; there is a need for replication of these findings, and future research 
with larger samples may benefit from the use of multivariate methods to succinctly describe 
multi-domain change. 
 
The characteristics of possible MCI-LB remain unclear as they did not differ from MCI-AD in 
cognitive performance. Given the limited sample size, there may be a lack of statistical power to 
identify any real differences from MCI-AD or probable MCI-LB. Further exploration may 
establish how LB symptomatology develops over time in this cohort, how this affects 
progression, and where possible MCI-LB diagnoses fit into this picture, as ‘possible’ diagnoses 
may include early-stage low-symptomatic MCI-LB cases, or atypical presentations of MCI-AD 
such as those with false-positive FP-CIT imaging. 
 
While some MCI cases demonstrate a clear cognitive decline towards dementia over the course 
of this study, others remain stable for many years; this could be explained by the existence of 
sub-groups with differing progressions. Specific clinical features, demographics, medical history, 
health anxiety or biomarkers may be associated with steeper or flatter trajectories of cognitive 
decline. Although differences were found between diagnostic groups in some cognitive domains, 
in only a handful of analyses was diagnostic status found to be a valuable predictor of function 
under the more parsimonious model-fitting criteria. 
 
While the differences between AD and DLB in verbal fluency, visuospatial functions, and 
recognition memory may already be observed in their respective MCI stages, with visuospatial 
functions also declining faster in the latter, expected differences in other executive functions, 
memory encoding and recall, attention, and global decline are not yet apparent at this stage and 
require further exploration. Repeated testing with appropriately sensitive visuospatial, recognition 
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memory, and fluency tests may therefore be appropriate in the assessment of cognitive decline in 
MCI-LB.  
4.5. Chapter summary 
On average, rates of global cognitive decline do not differ between MCI-LB and MCI-AD. 
Patterns of cognitive impairment do differ however, with probable MCI-LB featuring worse 
visuospatial function and verbal fluency, and MCI-AD worse recognition memory. Probable 
MCI-LB also may feature a faster decline in complex visuospatial functions. Any broad 
differences between groups are mild however, and diagnostic group does not consistently predict 
a difference in cognitive performance. 
 
The use of methods which average across the whole population within heterogeneous diagnostic 
groups may limit the ability to adequately describe the cognitive progressions experienced by 
people with MCI and may also limit statistical power. Latent class methods were considered as a 
suitable next step to explore cognitive decline in MCI.  
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Chapter 5. LewyPro: Latent Classes of Cognitive Decline 
These results are adapted from a published manuscript (Hamilton et al., 2020b). 
Within a broad MCI population there is heterogeneity in the pattern of cognitive impairments and 
in the rate and pattern of decline, with some emerging over time as a non-declining stable MCI 
(Geslani et al., 2005). There is a need to identify whether an individual with MCI is likely to 
decline towards dementia or remain stable over a longer period. A stable MCI may be a 
consequence of non-degenerative causes (Stone et al., 2015), but some of this heterogeneity may 
still reflect the complex biological processes underlying cognitive impairment in 
neurodegenerative diseases such as DLB and AD.  
Predicting rate of decline may be complicated by heterogeneity within clinical syndromes as well 
as between them: within population studies and prospective cohorts, patterns of underlying 
neuropathology (Zaccai et al., 2015) and emergent symptomatology (Donaghy et al., 2017) vary 
greatly. While individual trajectories of decline may differ due to as-yet unaccounted-for 
biological differences, such as an undiagnosed mixed aetiology (Malek-Ahmadi et al., 2019), 
these may also be associated with different patterns of clinical symptomatology, biomarkers, or 
imaging findings that are already evident in MCI. 
Previous findings from the dementia stages may provide a starting point for identifying 
hypothesised predictors of decline; findings are mixed as to whether any particular clinical 
symptom or imaging abnormality is associated with faster decline in DLB, or dementia in 
general. For example, presence of abnormal dopaminergic imaging has shown an association 
with faster cognitive decline (Kramberger et al., 2017). Neuropsychiatric symptoms such as 
delusions and hallucinations have also been implicated as predictors of faster cognitive decline in 
AD (Scarmeas et al., 2005b; D'Antonio et al., 2019), and faster conversion from MCI to 
dementia (Mauri et al., 2012), which may reflect a greater underlying cholinergic deficit 
responsible for these symptoms and decline (O'Brien et al., 2005). However, some symptoms of 
neurodegeneration are known to precede cognitive decline by many years in various syndromes, 
such as RBD and PD (Williams-Gray et al., 2007; Claassen et al., 2010; Aarsland, 2016), and do 




5.1. Aims and hypotheses 
We aimed to explore the heterogeneity in cognitive trajectories in greater depth by using LCMM 
to identify latent classes in an MCI cohort with distinct profiles of cognitive progression such as a 
faster or slower decline, stable progression without deterioration, or improvement, and to identify 
early-stage predictors of eventual trajectories.  
Based on the above we hypothesised that within an MCI cohort there would be a group of 
stable/very slow decliners, a group of rapid decliners (largely with LB disease) and an in-between 
group with slow but clear progression. We hypothesised that faster decline would be more likely 
in MCI-LB in MCI featuring visual hallucinations, and in those with abnormal dopaminergic 
imaging findings.  
5.2. Methods 
5.2.1. Participants and diagnoses 
Seventy-six participants were included from the LewyPro cohort, as in the previous analysis 
(Chapter 4), with clinical feature consensus, FP-CIT imaging, and consequent differential 
diagnoses operationalised in the same way. 
 
Additionally for this analysis, participant deprivation level was derived from publicly-available 
(Department for Communities and Local Government, 2011) English Index of Multiple 
Deprivation (IMD) score of their home neighbourhood at the time of study entry, sorted into 
nationally ranked deciles, as in previous studies (Stephens et al., 2014), with higher decile rank 
indicating greater local deprivation. 
5.2.2. Analysis 
Total score in the ACE-R at each observation was modelled as the cognitive outcome of interest. 
LCMM was used to identify subgroups with distinct cognitive trajectories using the lcmm 
package (Proust-Lima et al., 2017) for R statistical software. This method allows for data-driven 
identification of classes and their respective characteristics (intercept, slope, and curvilinearity). 
As an extension of LMM methods, the suitability of any models with latent classes may be 
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compared to a typical single-class mixed model by familiar model fitting criteria, allowing for the 
possibility that identifying latent classes may not improve the model. 
 
Selection of mixed model components and number of latent classes was based on BIC; a lower 
BIC value reflects better model fit, with a penalty for extra parameters, therefore favouring 
parsimony. Models were fit by maximum likelihood (ML) methods. 
 
All models controlled for age, education, gender, and deprivation as fixed effect covariates. 
Quadratic trajectories of decline were assessed for suitability but did not improve model fit over a 
linear-only time term in these data, and so were not retained in the final models. 
 
Predictive value of diagnostic group, clinical features, and FP-CIT imaging for each distinct 
trajectory class, were assessed by two multinomial logistic regression models; latent class was the 
three-level categorical outcome in both cases, with the intermediate trajectory as the reference. In 
the first model, diagnostic group was included as a three-level predictive factor, with probable 
MCI-LB as the reference due to being the largest group. In the second model, all five DLB 
diagnostic characteristics were included as baseline predictors initially; however, this number of 
predictors would not be supported by the assumptions of logistic regression given the sample 
size, and so backwards elimination of predictors was used to result in a best-fit model also 
reported, using BIC to assess changing model fit. Additional assumptions of logistic regression 
were checked after selection of the best-fitting model to confirm suitability. 
 
Alpha level was defined as p < .05; no corrections were made for multiple comparisons due to the 
exploratory nature of this analysis, with the use of BIC for conservative model fitting to favour 
parsimony and retain only the best-supported predictive factor(s).  
5.3. Results 
At the time of analysis, participants had been followed-up for a mean of 2.4 years (SD = 1.21) 
after consent at baseline, with a maximum of 5 years. Baseline characteristics of the overall MCI 
group, and diagnostic subgroups, were as reported previously in Chapter 4. These are briefly 
summarised again in Table 5.1, including deciles of multiple deprivation. 
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Table 5.1. Baseline characteristics of MCI diagnostic groups. 
 
MCI-AD 
(n = 23) 
Poss. MCI-LB 
(n = 12) 
Prob. MCI-LB 
(n = 41) 
Pa 
Female – n (%) 15 (65%) 5 (42%) 14 (34%) .055 
Male – n (%) 8 (35%) 7 (58%) 27 (66%) - 
Age – mean (SD) 78.2 (7.5) 75.3 (7.3) 75.5 (7.6) .335 
Years in Education – Mean (SD) 11.9 (3.0) 10.8 (2.1) 11.4 (2.8) .531 
IADL Total – Mean (SD) 10.3 (2.3) 10.5 (3.2) 14.3 (4.7) .002 
Deprivation Decile – Median (IQR) 5 (6.00) 7 (3.25) 6 (5.00) .709 
MMSE – Mean (SD) 26.5 (2.3) 26.2 (2.9) 26.5 (2.0) .901 
ACE-R Total – Mean (SD) 79.5 (11.70) 79.3 (14.1) 79.3 (8.3) .996 
aχ2 tests for gender, ANOVA/Kruskal-Wallis for all others 
IADL, Instrumental Activities of Daily Living; MMSE, Mini-Mental State Examination; ACE-R, Addenbrooke’s 
Cognitive Examination – Revised; Prob. MCI-LB, probable mild cognitive impairment with Lewy bodies; MCI-AD, 
mild cognitive impairment due to Alzheimer’s disease; Poss. MCI-LB, possible mild cognitive impairment with 
Lewy bodies.  
 
5.3.1. Identification of latent classes 
Five models were developed to explore; the initial longitudinal mixed model, without accounting 
for latent classes, provided a BIC value of 1612.07. A two-class model proved better-fitting (BIC 
= 1593.69), with the first latent class identified being too small to be meaningfully identified (n = 
10). A three-class model also maintained an improved fit (BIC = 1604.61), but identified larger, 
well-defined classes (n = 31 & 35) in addition to the small class. Within each competing model, 
subjects were assigned a posteriori to the class to which they had the highest membership 
probability (posterior probability > 0.5). Any additional groups identified in four- and five-class 
models were small (n < 10) and indistinct from existing classes. 
The three-class model was taken forward due to its identification of three clear clinically- and 
research-relevant groups with distinct trajectories, while maintaining an improved fit over the 





Table 5.2. Fixed effects on total ACE-R score in longitudinal model. 
Class Effects Intercepta Time Slope Intercept vs. Class 3 
Class 1 (fast decline) 
n = 10 
42.9 (8.79), < .001 -12.0 (1.38), < .001 -1.3 (0.37), < .001 
Class 2 (intermediate) 
n = 31 
61.3 (8.48), < .001 -3.6 (0.37), < .001 -0.2 (0.31), .603 
Class 3 (slow/stable) 
n = 35 
69.9 (8.21), < .001 -0.6 (0.37), .088 - 
Covariates    
Age at baseline -0.07 (0.09), .416 - - 
Years in education 1.29 (0.20), < .001 - - 
Male gender 2.7 (1.32), .038 - - 
Deprivation 0.99 (0.23), < .001 - - 
aEstimate (SE), p value 
 
5.3.2. Class characteristics 
The first identified class (n = 10, 13%) represented a rapid declining MCI; they were 
characterised by a lower baseline cognitive function (B = 42.9, SE = 8.79) and a steep decline (B 
= -12.0, SE = 1.38) in cognition. 
 
The second class (n = 31, 41%) began with an intermediate level of baseline functioning (B = 
61.3, SE = 8.48) and a significant, but less aggressive, trajectory of deterioration thereafter (B = -
3.6, SE = 0.58). This class was treated as the reference group going forward as they approximated 
the mean decline in the overall MCI group. 
 
The final and largest group (n = 35, 46%) began with the highest level of baseline functioning (B 
= 69.9, SE = 8.21), and did not significantly decline year-on-year over the observed time period 




Figure 5.1. Observed subject-specific (solid) and predicted class-specific (dashed) linear trajectories of global 
cognitive change, with latent trajectories predicted up to three years from baseline. 
 
Since baseline function was related to rate of decline in each group, we sought to examine the 
influence of impairment level at study entry. When controlling for baseline in the full sample, the 
mixed model without allowance for latent classes was the best-fitting (BIC = 1417) compared 
with two- (BIC = 1430), three- (BIC = 1417) and four-class (BIC = 1456) alternatives. We were 
therefore unable to identify any clear latent classes in the baseline-adjusted model. 
5.3.3. Clinical MCI diagnoses in latent classes 
In MCI-AD, 61% progressed with a slow/stable course, 22% had an intermediate trajectory, and 
17% a fast decline. In possible MCI-LB, 67% followed a slow/stable trajectory, 17% an 
intermediate decline, and 17% a fast decline. In probable MCI-LB, 32% demonstrated a 
slow/stable progression, 59% intermediate decline, and 10% fast decline. 
 
In comparison to probable MCI-LB, possible MCI-LB (OR = 7.38, 95% CI: 1.36 – 40.02), and 
MCI-AD (OR = 5.17, 95% CI: 1.52 – 17.58), were significantly more likely to demonstrate a 
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slowed decline relative to the intermediate trajectory (Table 5.3). Possible MCI-LB and MCI-AD 
were also overrepresented in the rapid declining group, but neither significantly predicted rapid 
decline, with wide confidence intervals likely reflecting the low overall prevalence of rapid 




Table 5.3. Latent trajectories observed in each diagnostic group, and multinomial logistic regression for 
diagnosis as predictor of prospective trajectory with probable MCI-LB and intermediate trajectory as the 
respective reference groups. 
  Diagnostic Group  
 Class Counts (%) Prob. MCI-LB MCI-AD Poss. MCI-LB 
Slow/Stable 13 (32%) 14 (61%) 8 (67%) 
Intermediate 24 (59%) 5 (22%) 2 (17%) 
Faster 4 (10%) 4 (17%) 2 (17%) 







[0.89, 25.96]  
.069 
6.00  





[0.28, 1.06]  
.075 
5.17  
[1.52, 17.58]  
.009 
7.38  
[1.36, 40.02]  
.020 
aOdds Ratio [95% Confidence Interval] p value 
Prob. MCI-LB, probable mild cognitive impairment with Lewy bodies; MCI-AD, mild cognitive impairment due to 
Alzheimer’s disease; Poss. MCI-LB, possible mild cognitive impairment with Lewy bodies. 
 
5.3.4. Time course differences – time to dementia 
We further explored the effects of time-to-dementia and baseline function to assess whether 
trajectory differences between classes could be explained by individuals being at different stages 
of decline upon study entry (i.e. rapid decliners being simply later-stage MCI than intermediate 
decliners), by running the LCMM analysis with time zeroed on their study end-stage (observed 
conversion to dementia, death, or withdrawal) rather than baseline assessment date, on the sub-
group where this was available (n = 39). In this manner, individual time trajectories were recoded 
to align at the intercept by their end-point rather than their start; a similar method of zeroing time 
to the point of dementia transition has previously shown utility in a model of decline in 




The best-fit model featured two classes, being an improvement over the null mixed model 
without latent classes (BIC: 687 < 696); these resembled the two declining trajectories observed 
from the full-sample model. The first and smallest (n = 7) group had a lower estimated function 
at the intercept (B = 23.0, SE = 12.36) and faster decline leading up to this (B = -12.7, SE = 1.64). 
The second group (n = 32) had higher estimated zero-point function (B = 54.1, SE = 12.34, p < 
.001) and a slower, but significant, decline to this (B = -3.8, SE = 0.80, p < .001). 
 
While a three-class model was also a better fit than the traditional mixed model (BIC: 691 < 696), 
the only further group identified was too small to draw meaningful conclusions from (n = 2). 
 
 
Figure 5.2. With time re-oriented to conversion to dementia or death, two declining groups with different 
rates of cognitive progression remain. 
 
The numbers in these observed two classes were considered too small to attempt to investigate 
further with a logistic regression. All seven of the rapid decliners had been classified as rapid 
decliners with time zeroed to the first observation (100% agreement). Twenty-four of 32 
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intermediate decliners had been classified as intermediate decliners in the earlier investigation 
(75%), and the remaining eight had been classified as slow/stable decliners (25%). There was no 
apparent stable group identified, likely due to the required observation of dementia or death in 
this second investigation.  
5.3.5. Clinical symptomatology and imaging 
In the second logistic model, the predictive value of specific symptoms and FP-CIT imaging was 
also explored in the three-class model. The presence at baseline of RBD, parkinsonism, or 
cognitive fluctuations as clinical symptoms in MCI was not associated with any particular 
cognitive trajectory (Table 5.4). Abnormal dopaminergic imaging was also not significantly 
associated with any particular trajectory of cognitive progression. 
 
In the full initial model, and after backwards removal of predictors to reach a best-fitting model 
under BIC (Table 5.4), the presence of complex visual hallucinations at baseline was associated 
with reduced likelihood of slow/stable, rather than intermediate, decline (OR = 0.06, 95% CI: 






Table 5.4. Full and reduced best-fit multinomial logistic regression models for included predictors of faster or 
slower cognitive trajectory in MCI, relative to the intermediate course of decline 
  Symptom/Biomarker Present 































































- - - - 
aOdds Ratio [95% Confidence Interval] p value 
Vis. Halls, complex visual hallucinations; RBD, REM sleep behaviour disorder; Cog. Flucs., cognitive fluctuations; 
Park., parkinsonism. 
5.4. Discussion 
Prospectively-identified MCI develops in a heterogeneous manner. Our analysis identified three 
patterns of decline; some people deteriorate at a much faster rate than their peers, others decline 
slowly or remain stable for several years, and some follow an intermediate trajectory which is 
comparable to the overall mean. People with probable MCI-LB were less likely to have a 
slow/stable course of progression compared with MCI-AD, and the majority declined at the 
intermediate rate. The majority of those meeting criteria for MCI-AD declined at a slower rate or 
remained stable. Possible MCI-LB did not clearly differ from MCI-AD in their likelihood of a 
faster or slower decline.  
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Overall, the presence of visual hallucinations at baseline was specifically associated with 
intermediate decline rather than a slow/stable cognitive trajectory. Contrary to our hypothesis and 
previous research findings, abnormal FP-CIT imaging was not associated with a declining 
trajectory, which did not support the findings of Kramberger et al. (2017) from DLB. These 
findings may suggest that individually-differing patterns of pathophysiology underlying MCI 
may contribute to differing risks of progression; the patterns of LB pathology in an MCI 
syndrome featuring complex visual hallucinations may contribute to a greater risk of decline than 
in MCI-LB cases without visual hallucinations (e.g. in individuals with parkinsonism and FP-CIT 
imaging abnormalities).  
Poorer baseline function makes some contribution to decline, as controlling for baseline cognitive 
function performance limits the ability to identify distinct time-courses. Since the time of consent 
into any research study is randomly variable, people will enter at different stages of their natural 
decline. However, different trajectories may not be due only to observations being at different 
stages of MCI, as distinct class trajectories are still evident after directly controlling for time to 
dementia conversion. The lower baseline functions estimated here benefit from the availability of 
subsequent repeated measures, and the ability to control for numerous covariates; while the group 
estimates show clear separation, the overall outcome measurement uncertainty at the intercept is 
much larger. More objective baseline predictors of progression (presence or absence of specific 
symptoms or biomarkers) may therefore have greater prognostic utility in clinical settings than 
baseline cognitive scores alone.  
Abnormal FP-CIT imaging was under-represented in the stable group with a low odds ratio, but 
with large confidence intervals this was not significant as a predictor of decline. Repeated and 
quantitative measurement of dopaminergic function may clarify the extent of any relationship, if 
one exists, and the value of FP-CIT imaging in predicting prospective decline. While 
dopaminergic imaging alone does not appear to be sufficiently predictive of decline, other 
imaging methods, diagnostic biomarkers, or a combination of these, may provide early signs of a 
prospective decline. Differing rates of decline may reflect different stages of disease course 
within the MCI stage, or individual burden of neurodegenerative processes, which a combined 
biomarker approach may be more sensitive to. Dopaminergic deficiencies are only one aspect of 
LB pathophysiology, and so other mediating effects (e.g. region-specific or wider cortical 
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degeneration) may account for differing risks observed for progressive higher-level cognitive 
decline. 
The delineation between a stable progression and slow decline was not entirely clear; within the 
slow/stable latent class identified some cases may be at an early stage of cognitive decline with 
undetectably slow progression, prior to any ‘turning-point’ previously observed (Rajan et al., 
2017), while others may continue with a long-term stable course – possibly suggesting a non-
neurodegenerative cause of apparent MCI. Despite the rigorous assessment involved in this 
cohort, with all participants having a diagnosis of MCI within the health service and having this 
confirmed according to NIA-AA criteria within this study, it remains plausible that some of these 
purported MCI cases may not have any neurodegenerative disease. Cognitive impairment 
secondary to depression, anxiety, or being functional or subjective in nature, may be causes of 
non-decline (Stone et al., 2015). Being able to identify non-degenerative MCI cases prospectively 
within clinical settings has many potential benefits for both clinicians and patients, and future 
research may look to more effectively separate these from slow-declining neurodegenerative 
cases. The inclusion of a healthy control group for comparison may allow for clearer separation 
of slow decline from non-decline, as the latter may be expected to display a cognitive trajectory 
indistinguishable from that of normal ageing.  
The early identification of slow/stable, progressive, and rapidly progressive MCI groups within 
MCI-AD and MCI-LB has important implications in clinical practice and research. Namely, 
limiting healthcare costs and individual burden due to diagnostic false-positives in the former, 
and appropriate stratification of samples in research and clinical trials. Lower baseline cognitive 
function and presence of visual hallucinations in MCI may warn of prospective decline. 
5.5. Chapter summary 
Individual cases of MCI vary in their progression of global cognitive scores. Latent class 
modelling methods identified three distinct sub-groups characterised, respectively, by stable/slow 
progression, intermediate decline, and rapid decline. The presence of diagnostic features for DLB 
in an MCI syndrome was predictive of a progressive decline, not stability, in comparison to MCI-
AD. Visual hallucinations in particular were predictive of decline. Rapid declining MCI cases 
could still be distinguished after controlling for time-to-dementia, suggesting that they were not 
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simply later-stage MCI. However, with a small sample size, a predictive model for rapid decline 
did not identify any consistent risk factors. 
 
This analysis demonstrates the statistical and conceptual value of characterising sub-groups 
within neurodegenerative conditions by data-driven methods; previously utilised in explorations 
of cognitive trajectories in AD and normal ageing, this is a novel application of latent class 
modelling to analysing the cognitive progression in the context of Lewy body disease. 
 
While these results suggest that patterns of domain-specific cognitive decline, and rates of 
cognitive stability or progressive decline may differ in MCI-LB from MCI-AD, it is unclear 
whether this translates into different rates of functional decline and prognosis of transition to 
dementia, which is not defined by cognitive decline alone.  
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Chapter 6. LewyPro: Clinical Conversion to Dementia 
6.1. Aims and hypotheses 
DLB is known to have a worse prognosis than AD, with increased risk of hospitalization 
(Mueller et al., 2018), shorter time to death (Mueller et al., 2019), and features a faster cognitive 
decline in some (Rongve et al., 2016) but not all (Walker et al., 2012) longitudinal studies; 
prognosis is especially poor in pathologically-confirmed mixed AD/DLB (Malek-Ahmadi et al., 
2019). Additionally, it has been found that as the DLB clinical profile increases in complexity 
(e.g. with more clinical features observed), healthcare costs also increase progressively (Espinosa 
et al., 2020). However, it remains unclear as to whether this also manifests as a faster transition to 
dementia in the respective MCI stages. We therefore first aimed to explore whether the presence 
of diagnostic characteristics of DLB (core clinical features and biomarkers) in MCI would confer 
greater risks of dementia onset in comparison with MCI-AD, and if these risks would increase in 
more clinically complex cases. 
AD (Scheltens et al., 2016) and DLB (Morenas-Rodríguez et al., 2018) are heterogeneous in their 
pathological and clinical presentation. Different subtypes of AD may vary in their prognosis 
(Ferreira et al., 2017), but it is unclear whether particular subtypes of DLB, or its cognitive 
prodrome in MCI, also differ in this manner. We also aimed to ascertain whether particular 
clinical presentations would be associated with a different prognosis. REM sleep behaviour 
disorder and Parkinson’s disease may remain as stable diagnoses without cognitive decline for 
many years (Claassen et al., 2010; Aarsland, 2016) and so MCI cases with sleep or motor 
symptoms may not be associated with increased conversion to dementia. Psychiatric symptoms in 
an amnestic MCI syndrome are associated with a faster conversion to dementia (Mauri et al., 
2012), and poorer outcome with faster decline in AD (Scarmeas et al., 2005b; D'Antonio et al., 
2019). In DLB, the presence of cognitive fluctuations has been associated with higher healthcare 
resource utilisation and economic costs of any core clinical feature, followed by visual 
hallucinations (Espinosa et al., 2020). MCI cases with neuropsychiatric symptoms of DLB 
(visual hallucinations or cognitive fluctuations) may therefore be associated with faster 
conversion to dementia. 
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Socio-economic background was anticipated to be a confounding variable; local-community 
deprivation has been directly associated with cognitive dysfunction in older age, and indirectly 
via other deprivation-related factors associated with increased risk of conversion to dementia 
from MCI (Xue et al., 2017). 
We hypothesised that MCI-LB would have a worse prognosis than MCI-AD, featuring a greater 
risk of clinical conversion to dementia over time. We also hypothesised that specific diagnostic 
characteristics of DLB, reflecting different patterns of underlying neurodegeneration, would 
influence risk of conversion to dementia, specifically that cognitive fluctuations and visual 
hallucinations would be associated with conversion to dementia whereas RBD and parkinsonism 
would not. 
6.2. Methods 
6.2.1. Participants and diagnosis 
Seventy-six participants were suitable for inclusion from the LewyPro cohort; MCI or dementia 
diagnoses, clinical review of DLB core features, and rating of FP-CIT imaging, were 
operationalised as previously reported. 
 
6.2.2 Analysis 
A competing risks multi-state model was estimated with the msm package for R software 
(Jackson, 2011). Three states were defined: MCI, dementia, and death. Dementia and death were 
treated as competing absorbing states with no subsequent transitions allowed; as participants 
ceased involvement in the study after conversion to dementia, no further information was 
available after clinical conversion. Exact dates were recorded for all deaths, but whether the 
participant had, or had not, developed dementia in the intervening time since last assessment was 
not known. Cause of death was not differentiated. 
 
All MCI diagnoses were included under the same MCI state. Likewise, all dementia diagnoses 
were included within a single dementia state. At each observation, participants could either 
remain as MCI, with or without some change in any covariates, or progress to dementia or death. 
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The emergence of diagnostic features later in the MCI course, and their association with 
subsequent dementia transitions, could therefore be assessed in this model in a flexible manner. 
 
Covariates theorised to have an association with clinical conversion were included to assess the 
association of DLB features and other demographic variables with risk of death or dementia: age, 
deprivation, gender, education, and number of DLB diagnostic characteristics (core clinical 
features and biomarkers, combined). MCI cases with no DLB characteristics (MCI-AD) were 
treated as the reference for the latter variable. An additional analysis included the same, with each 
of five specific diagnostic characteristics included as individually present or absent: complex 
visual hallucinations, cognitive fluctuations, parkinsonism, RBD, and FP-CIT abnormality. 
 
Model fit was assessed by Akaike Information Criterion (AIC) with a lowered AIC value 
indicating better model fit, with a penalty for inclusion of additional parameters. Covariates were 
chosen by backwards selection leading to the best-fitting models reported here. 
6.3 Results 
6.3.1 Demographics and baseline 
Baseline demographic and clinical information were as in previous chapters, summarised for 
convenience in Table 6.1. Thirty-three participants had converted to dementia at the time of data 
locking; the mean follow-up time had been 2.4 years (SD = 1.47) from baseline, with a maximum 
of 6.1 years. Participants had a median of 3 observations each. None of the possible MCI-LB 
were in receipt of cholinesterase inhibitors. While many of the MCI-AD and probable MCI-LB 
group were in receipt of cholinesterase inhibitors at baseline, there was no significant difference 
between these two groups (χ2= 2.54, p = .111). Those receiving cholinesterase inhibitors did not 
significantly differ in global cognitive function from those who were not receiving this treatment 
(Welch’s t(46.1) = 1.83, p = .074). 
 
Observed state-to-state transitions are summarised in Table 6.2. As no information was available 




Table 6.1. Baseline descriptive statistics for overall MCI group, and diagnostic sub-groups. 





Age, mean (SD)  76.0 (7.5) 78.2 (7.5) 75.3 (7.3) 75.5 (7.6) 
Number (% of total MCI group) 76 (100%) 23 (30%) 12 (16%) 41 (54%) 
Female, count (%) 34 (45%) 15 (65%) 5 (42%) 14 (34%) 
Clinical Dementia Rating, median 
(IQR) 
0.5 (0) 0.5 (0) 0.5 (0) 0.5 (0) 
Mini-Mental State Examination, mean 
(SD) 
26.4 (2.2) 26.5 (2.3) 26.2 (2.9) 26.5 (2.0) 
ACE-R total, mean (SD) 79.4 (10.3) 79.5 (11.7) 79.3 (14.1) 79.3 (8.3) 
IADL, mean (SD) 13 (4.4) 10 (2.3) 11 (3.2) 14 (4.7) 
Years of education, mean (SD) 11 (2.8) 12 (3.0) 11 (2.1) 11 (2.8) 
Deprivation decile, median (IQR) 5.5 (5) 5 (6) 7 (3) 6 (5) 
Prescribed cholinesterase inhibitors, 
count (%) 
25 (33%) 6 (26%) 0 (0%) 19 (46%) 
ACE-R, Addenbrooke’s Cognitive Examination – Revised; IADL, Instrumental Activities of Daily Living; IQR, 
interquartile range; MCI, mild cognitive impairment; SD, standard deviation. 
 
Table 6.2. State transition table from LewyPro cohort. 
 to MCI to Dementia to Death 
from MCI 124 33 5 
 
6.3.2 Overall DLB feature and biomarker count 
The best-fitting model included age and DLB clinical feature/biomarker count as non-interacting 
covariates (Table 6.3). Higher age was associated with an increased risk of death, and a small 
non-significant increase in dementia per year. In comparison to MCI-AD, each DLB diagnostic 
characteristic observed conferred an increasing risk of transition to dementia or death (modelled 
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as a linear dose-dependent relationship). An increasingly Lewy body-like clinical profile in MCI 
was therefore associated with worse prognosis as evidenced by an increased annual risk of 
conversion to dementia and to death. 
 
Table 6.3. Associations between age and presence of Lewy body diagnostic characteristics in transitions from 
mild cognitive impairment (MCI) to death or dementia in the LewyPro cohort. Reduced models after 
backwards elimination of predictors. 
Baseline Transition Probabilities from MCIa   Covariatesb 





















































aTransition Probability for One Year [95% Confidence Interval] 
bHazard Ratio [95% Confidence Interval] 
cMean-centred, hazard per year 
6.3.3 Specific DLB features 
The best fitting model favoured inclusion of age, visual hallucinations, and cognitive fluctuations 
as covariates (Table 6.3), without interaction. Increased age was associated with an increased 
hazard of both dementia and death. The presence of visual hallucinations was associated with 
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increased hazard of both dementia and death, while cognitive fluctuations were associated with 
increased hazard of dementia, and an increased risk of death but with wide confidence intervals. 
The full model, prior to backwards removal of covariates, is reported in Table 6.4. Presence of 
parkinsonism, RBD, and abnormal FP-CIT imaging were not associated with an increased 
transition risk of dementia or death compared to MCI-AD. Male gender was associated with  
increased risk of transition to dementia in the full model, but not in reduced models including this 







Table 6.4. Full multi-state model for clinical transition in LewyPro, prior to backwards elimination. 
aTransition Probability for One Year [95% Confidence Interval] 
bHazard Ratio [95% Confidence Interval] 
cMean-centred, hazard per year 
  
Baseline Transition 
Probabilities from MCIa  
 Covariatesb 




























































We hypothesised that an MCI syndrome presenting with diagnostic characteristics of DLB would 
have a worse prognosis than those without, and therefore meeting criteria for MCI-AD, 
increasing with greater clinical complexity. We found that, in comparison to cases with MCI 
alone, the presence of any DLB diagnostic characteristic in MCI was associated with an increased 
hazard of transition to dementia; this risk further increased as more core features or biomarkers 
were observed and was especially high for those experiencing complex visual hallucinations or 
cognitive fluctuations. The data therefore supported the hypotheses that an MCI with diagnostic 
characteristics of DLB would be associated with a worse prognosis than MCI-AD, that this 
prognosis would be worse in the more clinically complex cases, and that specific DLB diagnostic 
characteristics are associated with different rates of clinical progression. 
These results mirror recent findings on the prognosis of DLB or AD: it appears that in both MCI 
and dementia (Price et al., 2017), the presence of DLB-specific characteristics is associated with 
a worse prognosis, and that more complex cases with more diagnostic characteristics may have a 
worse prognosis, as in dementia (Espinosa et al., 2020). DLB features increased hospitalisation 
(Mueller et al., 2018), shorter time to full-time care, and shorter survival time (Mueller et al., 
2019), and worse quality of life for patients and carers than AD (Wu et al., 2018a). While our 
results here indicate that MCI-LB also has a greater annual risk of developing dementia than 
MCI-AD, with this risk increasing as more features or biomarkers of DLB are observed; this 
could suggest that MCI-LB cases with a greater number of diagnostic characteristics have more 
extensive neurodegeneration and therefore a worse prognosis. Alternatively, risks of clinical 
transition may be more specifically associated with particular symptoms (as discussed below), 
and more clinically complex cases may simply be more likely to feature those particular 
symptoms (and associated pattern of pathophysiology which may mediate these associations). 
The specific association between cognitive fluctuations and visual hallucinations, and a poorer 
prognosis in MCI, may indicate that these are symptomatic of a more aggressive clinical 
phenotype. Both fluctuations (O'Dowd et al., 2019) and visual hallucinations (Erskine et al., 
2019) are hypothesised to reflect particular patterns of neurodegeneration within Lewy body 
disease which may share a link in the cholinergic deficit which often occurs in DLB (O'Brien et 
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al., 2005) alongside other pathophysiological changes (e.g. dopaminergic dysfunctions). This 
could underlie the associations of these features with a progressive clinical decline, with greater 
cholinergic dysfunction leading to faster onset of dementia from MCI in some cases; this 
naturally requires exploring with biomarkers specific to the cholinergic system, such as EEG 
markers of NBM integrity (Schumacher et al., 2020b). 
6.5 Chapter summary 
An increasingly DLB-like clinical profile in an MCI syndrome is associated with greater annual 
risk of conversion to dementia, according to clinical criteria. Presence of cognitive fluctuations or 
visual hallucinations is particularly associated with increased risk of conversion annually. 
Parkinsonism, RBD, and FP-CIT SPECT abnormality are not individually associated with 
increased risk of conversion to dementia in comparison to MCI-AD however; higher dementia 
transition risks in more clinically complex cases may reflect that an increasingly manifest DLB-
like clinical profile is simply more likely to feature at least one of the two highest-risk clinical 
features of cognitive fluctuations or visual hallucinations, and therefore to decline to dementia. 
These results are consistent with the increased risk of global cognitive decline found in MCI-LB, 
and in MCI with visual hallucinations specifically. These results align with, and extend, previous 
findings that DLB has a shorter survival time (Price et al., 2017; Mueller et al., 2019), increased 
risk of hospitalisation (Mueller et al., 2018), and shorter time to nursing home admission than 
AD (Mueller et al., 2017). 
6.6 LewyPro Section Summary 
In comparison to probable MCI-AD, probable MCI-LB features an early pattern of cognitive 
impairment similar to that found in DLB, with more prominent executive and visuospatial 
dysfunction. Complex visuospatial skills may progressively decline over the time-course of MCI-
LB, and impairments in recognition memory are less severe than those in MCI-AD. These 
findings are consistent with the expected profiles of these syndromes as the respective cognitive 
prodromes of AD and DLB. 
 
While the average course of global cognitive decline does not differ between MCI-AD and MCI-
LB, exploration of cognitively declining and stable subgroups has suggested that MCI-LB is less 
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likely to remain cognitively stable than MCI-AD. Cases of MCI featuring complex visual 
hallucinations, a finding highly specific to DLB (Lin et al., 2018), were particularly unlikely to 
remain stable.  
 
Finally, consistent with the increased risk of global cognitive decline in MCI-LB, the presence of 
DLB diagnostic characteristics in MCI were associated with an increased annual risk of 
conversion to dementia, further increasing with each additional feature observed. Visual 
hallucinations and cognitive fluctuations in particular were associated with an increased risk. 
 
Taken together, the past literature and these results argue that the apparent presence of Lewy 
bodies in a neurodegenerative syndrome may be associated with a poorer prognosis; there is a 
greater risk of cognitive decline and clinical progression to dementia in MCI, and an increased 
risk of hospitalisation, full-time care and death, in dementia. These findings lend support to the 
value in identifying cases of possible or probable LB disease in the context of an MCI syndrome, 
as early features of DLB may differentiate those at risk of decline from stable MCI.  
 
In these cases, the presence of DLB features in an MCI syndrome does not necessarily indicate 
the absence of any AD co-pathology; indeed, pathological studies have suggested that a mixed 
DLB with AD may be the norm, rather than the exception (Selvackadunco et al., 2019). An 
unknown number of these MCI cases may feature an undiagnosed mixed pathology at this stage. 
At the dementia stage, an apparently mixed AD-DLB syndrome (based on CSF biomarker profile 
or neuropathological assessment) is associated with worse prognosis than either single disease  
with greater cognitive decline in some studies (Abdelnour et al., 2016; Blanc et al., 2017) and 
further increased nursing home admittance and mortality risk than DLB alone (Lemstra et al., 
2017); such cases could therefore account for the poorer prognosis in our MCI-LB groups. 
 
The improved identification of mixed AD-DLB, and by extension, a potentially mixed aetiology 
MCI may benefit from the post-mortem neuropathological diagnosis of longitudinal cohorts such 
as these. This would aid in the characterisation of pure AD, LB, and mixed AD-LB cases in 




Identification of these risk factors at the MCI stage may be of benefit in clinical settings to help 
guide treatment and management. However, these findings were limited by the small sample size 
and lack of healthy control group to provide further context; there was therefore a need for 
validation of these results. 
 
These results were also limited in their ability to answer one aspect of the research question at 
hand, specifically in regards to characterising cognitive sub-types as in Ferman et al. (2013); 
without a comparable healthy control cohort, there were no meaningful normative data to 
appropriately characterise MCI as single- or multi-domain, amnestic or non-amnestic. 
 
In response to this, a follow-up study was undertaken to validate the findings from the LewyPro 
cohort, with the addition of another biomarker and healthy control cohort.  
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Chapter 7. SUPErB Study Background 
Following up on the LewyPro cohort, the SUPErB study cohort was recruited to assess the utility 
of MIBG scintigraphy in the prodromal stages of DLB, compared with both MCI-AD and healthy 
controls to provide further context and normative data.  
 
For this work, the intention was to assess whether the development models from the LewyPro 
study would be validated with a comparable independent cohort. 
7.1 Study recruitment and assessment 
Both MCI patients (inclusion/exclusion criteria as in LewyPro) and healthy controls were 
recruited for inclusion in the SUPErB study cohort (see below for details on each group). Ethical 
approval for this study was given by the National Research Ethics Service Committee North East 
– Newcastle and North Tyneside 2 (Research Ethics Committee No. 15/NE/0420). All 
prospective participants provided written, informed consent to participate prior to baseline 
assessment. 
 
As in the LewyPro study, participants underwent detailed baseline assessment over several visits, 
and subsequently were followed-up approximately annually unless they withdrew, converted to 
dementia or other serious illness, or died. Due to postponement of follow-up assessments from 
March of 2020 as a result of the COVID-19 pandemic, datasets were locked for analysis with all 
available follow-up observations in April 2020. Mean follow-up time was 1.1 years (SD = 0.87), 
with a median of 2 total observations per participant.  
 
As in the LewyPro cohort, local deprivation level was assessed for each participant based on their 
community’s ranking of score in the 2019 English Indices of Deprivation; in this instance, 
scoring was inverted in the statistical release in comparison to previous indices, with a low score 
rank, and consequently low decile rank (e.g. of 1), corresponding to high local deprivation, while 




7.1.1 MCI patient group 
Participant recruitment for the SUPErB study ran from March 2016 to September 2019. Patients 
were recruited from local healthcare trusts in North-East England, were aged 60 years or older, 
and had a health service diagnosis of MCI. As in the LewyPro cohort, participants were identified 
from health service records if they reported any symptoms or signs which may be associated with 
prodromal DLB (but could be present in AD) including any suggestive features of DLB, visual 
disturbance, hyposmia, mood change, or autonomic dysfunction. Any core features of DLB were 
also a reason for approach to consent. Exclusion criteria for this group were the presence of 
dementia or lack of cognitive impairment at baseline, possible frontotemporal or vascular 
aetiology, or an established history of PD for more than one-year preceding onset of cognitive 
impairment. 
 
Eighty-nine new potential patients were assessed for inclusion, in addition to all remaining 
participants of the LewyPro cohort (excluding those contraindicated for MIBG imaging, those 
who had withdrawn, developed dementia, or died). Of these 89, seven were excluded due to 
having dementia at baseline, three were excluded due to absence of objective cognitive 
impairment, and four withdrew before completing baseline assessment. 
 
Including 28 LewyPro patients, 103 participants were deemed suitable for inclusion in the 
SUPErB MCI group at baseline. To maintain independence of the discovery and validation 
cohorts, these 28 LewyPro participants were removed from the following analysis of SUPErB 
data (Chapter 8). There were therefore 75 participants included in the patient group who were 
independent of the LewyPro sample and eligible for inclusion after baseline assessment. 
7.1.2 Healthy control group 
Thirty-four prospective participants were recruited for a healthy control group from friends or 
family members of patient-participants, or the Join Dementia Research volunteer network. 
Healthy controls were aged 60 years or older. Exclusion criteria were evidence of cognitive 




Three controls failed to complete baseline assessment; two died during the course of the baseline 
assessment due to unrelated emergent illness, and one withdrew. Thirty-one healthy control 
participants therefore completed all assessments at baseline and 28 were consequently followed 
up with at least one annual re-assessment. 
 
Data availability at each observation year, and any known loss to follow-up or censoring, are 
detailed in Figure 7.1. 
 
 





7.2.1 Neurocognitive syndrome 
As in the LewyPro study, patients were annually rated on the presence of neurocognitive 
impairment, either MCI or dementia, independently by the same panel of experienced old age 
psychiatrists. MCI diagnoses were made in accordance with NIA-AA criteria (Albert et al., 
2011), while dementia was determined according to McKhann et al. (2011) ‘all-cause dementia’ 
criteria, with the latter being a cause for exclusion (baseline) or an end to follow-up (repeat).  
7.2.2 Clinical symptoms  
Clinical symptomatology, including DLB core and supportive symptoms, were annually assessed 
by clinical interview, and quantified with a range of scales. At each annual visit the participant 
was administered the UPDRS-III (Ballard et al., 1997), NEVHI (Mosimann et al., 2008), ESS 
(Johns, 1991), and GDS (Yesavage et al., 1983). Informants of patients were also administered 
the IADL scale (Lawton and Brody, 1969), a modified scoring of which (Cromwell et al., 2003) 
is also reported in this research, the NPI (Cummings et al., 1994), MSQ (Boeve et al., 2011a), 
CAF (Walker et al., 2000b), and DCFS (Lee et al., 2014). Based on review of clinical notes, the 
CIRS-G (Miller and Towers, 1991) and CDR (Morris, 1993) were also completed. 
7.2.3 Biomarkers 
Data on several indicative and supportive biomarkers were available for each participant. These 
were administered to both patients and controls. 
 
FP-CIT SPECT dopaminergic imaging was performed at baseline assessment as in LewyPro and 
as previously published (Thomas et al., 2019), and repeated at the first annual follow-up. Images 
were rated as normal or abnormal by an experienced panel trained in image analysis, blind to 
clinical information. In cases where there was change or inconsistency in repeat images (i.e. 





Participants also undertook MIBG scintigraphy at baseline assessment to examine any wider 
denervation of the sympathetic nervous system, providing an additional indicative biomarker in 
accordance with current criteria for DLB. Images were taken both shortly after intravenous 
injection of the MIBG ligand, and after a ~ 4-hour (± 30 min) delay. Early images were used for 
comparison with delayed images outside of this work, whereas delayed images are the current 
standard use in diagnosis (Kane et al., 2019; Roberts et al., 2019). Delayed images were 
processed by two medical physicists blind to clinical information, allowing for quantification of 
heart:mediastinum uptake ratio values. Values of greater than two standard deviations below 
mean uptake in controls were rated as ‘abnormal’, with values above this threshold rated as 
‘normal’. Results of both MIBG and FP-CIT imaging were incorporated into differential 
diagnoses as discussed below. 
 
Structural and resting state functional MRI, and resting state EEG recordings were also collected 
at baseline. Blood samples were taken during medical review at baseline. All participants were 
offered a lumbar puncture to provide cerebrospinal fluid samples, though uptake was low. Results 
of these assessments were used as research outcomes (not in this work) and were not included in 
differential diagnoses, though structural MRI scans were able to provide further context to other 
clinical or imaging findings; one participant was found to have a striatal infarct on MRI, and so 
their FP-CIT imaging results were not included in diagnosis. 
 
7.2.4 Differential diagnosis 
After diagnosis of MCI or dementia, differential diagnosis of aetiology was operationalised in a 
manner consistent with the LewyPro study at baseline and follow-ups, but with the addition of 
MIBG imaging results from baseline. The same three-person expert panel of old age psychiatrists 
reviewed clinical notes taken at each annual visit, using clinical judgement of notes to rate the 
presence or absence of four core DLB clinical features: RBD, parkinsonism, complex visual 
hallucinations, and fluctuating cognition, providing a consensus decision on their presence or 
absence. These decisions were taken independently of and blind to the imaging results. 
These four clinical features, alongside the two indicative biomarkers (MIBG and FP-CIT 
imaging) provided a maximum of six possible DLB diagnostic characteristics which were 
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incorporated into MCI or DLB diagnoses: patients with MCI and no DLB diagnostic 
characteristics (no core clinical DLB features, and both imaging methods rated normal) received 
a diagnosis of MCI-AD, those with MCI and one DLB diagnostic characteristic (one core feature, 
or imaging abnormality) received a diagnosis of possible MCI-LB, and those with two or more 
DLB diagnostic characteristics (two or more core features, or one core feature with imaging 
abnormality) received a diagnosis of probable MCI-LB, in line with contemporary criteria for 
diagnosis of MCI-LB in research settings (McKeith et al., 2020), and mirroring current DLB 
consensus clinical criteria (McKeith et al., 2017). Diagnosis of probable MCI-LB could not be 
made based on the presence of two biomarkers alone; at least one core clinical diagnostic feature 
was also required for this. 
 
As with MCI or dementia diagnosis, core feature presence or absence, and consequent differential 
diagnoses, were reassessed after each follow-up to reflect the emergence of new diagnostic 
features, or new information coming to light (e.g. from an informant who was not previously 
available). 
7.3 Neuropsychological assessment 
The neuropsychological tests used in LewyPro were also administered in SUPErB, with the 
addition of other supplementary assessments. As in LewyPro, neuropsychological outcomes were 
not incorporated into differential diagnoses. 
7.3.1 Global cognition 
Total score on the ACE-R (Mioshi et al., 2006) was used to measure global cognitive 
functioning, from which MMSE was also derived. 
7.3.2 Attention and executive functions 
ACE-R and FAS verbal fluency (Baldo et al., 2006), and TMT-B assessed executive functioning. 
Raw and cognitive processing speeds were again measured with simple (SRT) and binary-choice 
(CRT) reaction time tasks. Higher level processing speed was assessed with TMT-A, as well as 




Sustained and selective attention were also assessed with the computerised continuous 
performance task (CPT). 
 
Stroop Colour (Stroop C) and Colour-Word (Stroop CW) interference tasks were administered as 
repeated measures to assess selective attention and executive functions. 
7.3.3 Memory and learning 
ACE-R memory sub-scores were available at each annual visit, and the RAVLT was 
administered at baseline. Additionally, a 15-minute delayed un-cued recall of the Rey-Osterrieth 
(ROCF; baseline) or Modified Taylor Complex Figure (MTCF; alternate form for follow-up) was 
utilised to assess visuospatial episodic memory at each visit. Scores for the complex figure copies 
were ratified by a second marker who second-marked a randomly-selected subset of 20% of the 
figure copy and recall sheets, blind to the first marker’s scores; the same two markers were used 
for assessing all MTCF images. ROCF images were marked by a second pair of markers in the 
same manner. 
7.3.4 Visuospatial functions 
The LAT was administered as a repeated measure (Wood et al., 2013a), and ACE-R visuospatial 
sub-scores were also available from each year. At baseline, computerised Corsi block-tapping 
and visual patterns (VPT) tests were administered on a touchscreen-capable study laptop to assess 
visuospatial working memory. These were supplemented by the addition of the complex figure 
copy test (ROCF or MTCF) at baseline and follow-up, to provide further sensitivity to higher-
level visuo-constructional deficits. The Pareidolia Test (Mamiya et al., 2016) was administered as 
a repeated measure to assess susceptibility to visual illusions and misperception of faces in 
ambiguous visual stimuli, having shown previous utility in assessing these in DLB.  
7.3.5 Speech, language, and intelligence 
The GNT (Bird and Cipolotti, 2007) and NART (Nelson and Willison, 1991) were completed by 
all participants at baseline to assess language and pre-morbid intelligence. Annually repeated 
ACE-R language sub-scores assessed change in speech and language function over time. 
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Auditory forwards and backwards digit span tests were repeated at each annual visit to assess 
attention and working memory. 
7.4 Procedure 
A longitudinal repeated-measures design was again utilised. Measures were taken at baseline, and 
again at approximately annual follow-ups, to track differences in within-subject progression 
between diagnostic groups in a mixed design. 
7.4.1 Baseline testing 
Visits were arranged as follows: 
 
1) Screening, consent, and neuropsychological testing 
2) Medical review 
3) FP-CIT SPECT 
4) MIBG scintigraphy 
5) EEG, MRI, and computerised testing 
6) (Optional) lumbar puncture 
 
FP-CIT and MIBG imaging were spaced out by a minimum of one week to prevent interference; 
visits were otherwise scheduled as close together as could be. Median delay between first and 
fifth visit was two months. 
7.4.2 Follow-up testing 
Neurocognitive assessment and clinical review were undertaken within a single session at each 
annual follow-up. After developing dementia, patients were not assessed further. Where 
participants were lost to follow-up due to a clinically relevant reason, such as conversion to 
dementia or death, this was recorded as appropriate. At each follow-up visit, healthy controls 
were assessed for any change in status. One control participant had developed a non-





Patient recruitment closed in October 2019, and all participants had completed their baseline 
assessments in December 2019. Follow-up data collection was arrested in March 2020. 
7.5 Analysis 
The same methods as used in LewyPro were repeated with this cohort to validate findings from 
the discovery cohort: domain-specific longitudinal patterns of cognitive function were assessed 
with simple LMM, while LCMM explored heterogeneity in trajectories of cognitive decline 
Finally, MSM methods were again applied to analysis of transitions from MCI to dementia, or 
death. These are described in depth in Chapter 8 with the respective results. 
7.6 Chapter summary 
The SUPErB study built on the conceptualisation of MCI-LB that resulted from the LewyPro 
cohort and offered the opportunity to assess the validity of the longitudinal findings from 
LewyPro in an independent cohort. This cohort was bolstered by the addition of a healthy control 





Chapter 8. SUPErB Study Validation Analyses 
8.1. Baseline information 
Recruitment for the SUPErB study closed in the Autumn of 2019, with the final baseline visit 
occurring in December 2019. Twenty-eight participants with MCI who had previously 
contributed to the LewyPro study were consented into the SUPErB study. These participants 
were excluded from validation analyses in this chapter to ensure independence of the cohorts. 
After clinical review, 75 new patients and 34 controls were included in the SUPErB cohort, with 
baseline characteristics presented in this section. Pairwise comparisons are reported in-text for 
baseline-only assessments; omnibus tests are reported for longitudinal measures, which are 
reported in depth in the longitudinal analysis which follows. Unless otherwise stated, for 
continuous measures where the mean is reported, group differences were assessed with one-way 
ANOVA with pairwise t-tests; where the median is reported, Kruskal-Wallis with pairwise 
Dunn’s tests were applied. Pairwise comparisons included Holm correction of p values in both 
parametric and non-parametric methods. For categorical outcomes, χ2 or Fisher’s exact tests were 
utilised, as appropriate. Significance level was set as p < .05 for all comparisons. 
8.1.1 Demographics 
Demographic data are presented in Table 8.1. As in the LewyPro cohort, there was a gender 
disparity with MCI-AD being more likely to be female, and probable MCI-LB being more likely 
to be male. The groups did not significantly differ in their mean ages, but controls had spent 
significantly more years in education than had patients (p = .017). Pairwise comparisons did not 
find any significant educational differences between the patient groups, however. The possible 
MCI-LB group had a lower median decile of deprivation than controls (p = .026), but MCI-AD (p 
= .806) and probable MCI-LB (p = .872) did not. Correspondingly the possible MCI-LB group 
had lower estimated premorbid function as accessed with the NART (p = .002) than controls, but 

















Gender      
Female 10 (29.4%) 18 (60.0%) 9 (52.9%) 1 (3.6%) < .001 
Male 24 (70.6%) 12 (40.0%) 8 (47.1%) 27 (96.4%)  
Baseline Age 74.2 (7.45) 75.2 (7.12) 73.5 (8.41) 74.6 (5.72) .888 
Years in Education 14.4 (3.82) 12.7 (3.43) 12.6 (4.66) 11.6 (2.39) .016 











NART Estimated Full-Scale IQ 114 (8.64) 108 (12.5) 103 (12.2) 108 (9.02) .003 
Missing 1 (2.9%) 2 (6.7%) 0 (0%) 1 (3.6%)  
Count (%), Mean (SD), or Median [Min, Max]. 
aOmnibus tests; corresponding post-hoc tests with adjustment in-text 
8.1.2 Clinical symptomatology 
In the probable MCI-LB group, the most common differential diagnostic characteristics were 
RBD and abnormal FP-CIT imaging results, each being present in 75% of cases (see Table 8.2). 
For the possible MCI-LB group, FP-CIT abnormality and visual hallucinations were the 
commonest DLB diagnostic characteristics. One MCI-AD patient reported experiencing visual 
hallucinations associated with advanced eye disease; these were interpreted by the diagnostic 
panel as symptomatic of Charles Bonnet syndrome and therefore did not contribute to a diagnosis 
of MCI-LB. For this same case, and in any others with significant non-cortical visual impairment, 





Table 8.2. Diagnostic characteristics for dementia with Lewy bodies present at baseline in diagnostic groups, 
diagnosis based on most recent follow-up. 











Parkinsonism 0 (0%) 0 (0%) 0 (0%) 10 (35.7%) 
Cognitive Fluctuations 0 (0%) 0 (0%) 1 (5.9%) 13 (46.4%) 
REM Sleep Behaviour Disorder 0 (0%) 0 (0%) 1 (5.9%) 21 (75.0%) 
Visual Hallucinations 0 (0%) 1 (3.3%)a 4 (23.5%) 7 (25.0%) 
Abnormal FP-CIT 2 (5.9%) 0 (0%) 5 (29.4%) 21 (75.0%) 
Missing 2 (5.9%) 4 (13.3%) 3 (17.6%) 0 (0%) 
Abnormal Delayed MIBG  2 (5.9%) 0 (0%) 3 (17.6%) 17 (60.7%) 
Missing 2 (5.9%) 0 (0%) 2 (11.8%) 1 (3.6%) 
aOne case of MCI-AD with Charles Bonnet syndrome due to eye disease-related visual 
impairment, visual hallucinations were interpreted by the clinical panel as not symptomatic of 
Lewy body disease. 
8.1.3 Clinical scores 
Due to their direct relationship with the differential diagnostic features which formed these 
groups, the diagnostic groups were anticipated, and indeed observed, to differ in their scores on a 
number of clinical rating scales, which are presented in Table 8.3. With issues of circularity in 
mind these were not considered as primary results of this work but are presented to provide 
context for the severity of clinical symptoms in each group.  
 
As not all patients had informants available, there were missing data in a number of clinical 
assessments requiring the presence of an informant to complete (IADL, NPI, CAF and DCFS) 
and greater missingness in the MSQ, which required an informant to also live with the patient. 
However these variables were not included in subsequent analyses, being used only to 
















CDR 0 [0, 0] 0.5 [0.5, 0.5] 0.5 [0.5, 0.5] 0.5 [0, 0.5] < .001 
IADL - 8 [2, 8] 7 [3, 8] 7 [4, 8] .027 
Missing - 8 (26.7%) 2 (11.8%) 1 (3.6%)  
CIRS 5.29 (3.29) 5.92 (3.29) 7.53 (2.72) 8.38 (4.58) .008 
MSQ Question 1 ‘Yes’ - 0 (0%) 0 (0%) 22 (78.6%) < .001 
Missing - 16 (53.3%) 10 (58.8%) 3 (10.7%)  
ESS 5 [0, 12] 4 [0, 13] 6 [1, 14] 8 [0, 16] .005 
GDS 1 [0, 9] 3 [0, 11] 3 [1, 12] 3 [0, 13] < .001 
UPDRS 5.55 (4.3) 15.4 (14.8) 16.4 (11.2) 23.3 (14.2) < .001 
NPI - 6 [0, 34.0] 3 [0, 44] 15 [0, 52] .045 
Missing - 8 (26.7%) 2 (11.8%) 1 (3.6%)  
NEVHI 0 [0, 3] 0 [0, 7] 0.5 [0, 15] 0 [0, 16] < .001 
CAF - 0 [0, 9] 0 [0, 6] 3 [0, 16] .003 
Missing - 8 (26.7%) 3 (17.6%) 1 (3.6%)  
DCFS - 7 [4, 11] 8 [4, 15] 8 [4, 17] .360 
Missing - 8 (26.7%) 2 (11.8%) 1 (3.6%)  
Lost Sense of Smell 5 (14.7%) 8 (26.7%) 8 (47.1%) 15 (53.6%) .007 
Missing 1 (2.9%) 0 (0%) 0 (0%) 0 (0%)  
MMSE 28.5 (1.13) 26.8 (2.10) 25.6 (3.02) 26.3 (2.37) < .001 
ACE-R Total 92.7 (4.27) 82.3 (8.06) 76.4 (11.5) 82.4 (9.65) < .001 
Count (%), Mean (SD), or Median [Min, Max]. 
 
All controls had a CDR of 0, and all patients a CDR of 0 or 0.5. While all patients had minimal 
impairment of independent function, reflective of their MCI diagnostic status, probable MCI-LB 
had slightly lower scores on the IADL scale (p = .043) than MCI-AD. 
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Only the probable MCI-LB group had more concurrent illness than controls (higher CIRS-G; p = 
.009); MCI-AD (p = .894) and possible MCI-LB (p = .166). 
 
Reflecting the presence of RBD in their diagnoses, informants for probable MCI-LB cases were 
more likely to answer ‘yes’ in response to question 1 of the MSQ: ‘Have you ever seen the 
patient appear to “act out his/her dreams” while sleeping? (punched or flailed arms in the air, 
shouted or screamed)’. Accordingly, probable MCI-LB patients also reported higher daytime 
sleepiness on the ESS than controls (p = .004) while MCI-AD (p = .440) and possible MCI-LB  
(p = .473) did not. 
 
All patient groups reported higher levels of depression at the time of assessment than controls, 
according to self-completion of the GDS (MCI-AD & probable MCI-LB p < .001, possible MCI-
LB p = .009). 
 
All MCI groups were found to feature greater motor impairment than controls (MCI-AD vs 
controls, p = .006) on the UPDRS-III. Consistent with the presence of parkinsonism, probable 
MCI-LB also featured significantly higher motor impairment than MCI-AD (p = .038), though 
possible MCI-LB did not (p = .785). 
 
While probable MCI-LB appeared to feature higher neuropsychiatric symptom severity (NPI total 
score), any pairwise differences between MCI groups were non-significant (probable MCI-LB vs 
MCI-AD, p = .066; possible MCI-LB vs MCI-AD, p = .832), Similarly, MCI groups reported 
significantly higher visual hallucination symptomatology (NEVHI total score) than controls 
(MCI-AD, p = .023), but possible (p = .767) and probable MCI-LB (p = .862) did not 
significantly differ from MCI-AD. 
 
Due to the diagnostic presence of cognitive fluctuations, probable MCI-LB featured greater levels 
of carer-reported fluctuating confusion or consciousness than MCI-AD (CAF total score; p = 
.003) while possible MCI-LB did not (p = .487). The DCFS was not sensitive to any differences 
between MCI-AD and possible (p = .896) or probable (p = .461) MCI-LB. 
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MCI-AD (exact p = .352) were no more likely than controls to report a lost sense of smell, 
though possible (exact p = .019) and probable (exact p = .002) MCI-LB were.  
8.2. Baseline cognitive scores 
8.2.1 Global cognitive function 
As expected, MCI-AD featured poorer MMSE (p = .010) and ACE-R (p < .001) scores at 
baseline than controls, and possible (p = .202) and probable (p = .603) MCI-LB did not differ 
from MCI-AD in their baseline MMSE, nor in their ACE-R total scores (p = .057 and p = .965, 
respectively). These are reported alongside clinical data in Table 8.3. 
8.2.2 Attention and executive functions 
Reported in Table 8.4, the patient group broadly differed from controls with poorer attention and 
executive functions, including worse scores on the ACE-R attention and orientation, and fluency 
sub-scores, fewer words produce in the FAS verbal fluency test, slower reaction times in simple, 
choice and continuous-performance response tasks, and produced fewer words at baseline in both 
Stroop test conditions. Administered at baseline alone, MCI was associated with slower 
completion of TMT-A (p < .001) but did not significantly differ from one-another (possible MCI-
LB vs MCI-AD, p = 1; probable MCI-LB vs MCI-AD, p = 1). Similarly in the TMT-B, MCI-AD 
was associated with slower completion than in healthy controls (p = .008), but the groups did not 
significantly differ (possible MCI-LB vs MCI-AD, p = .979; probable MCI-LB vs MCI-AD, p = 
.272). Only probable MCI-LB demonstrated a significantly different ratio of performance 
between tasks to healthy controls (p = .012), both MCI-AD (p = .979) and possible MCI-LB (p = 


















ACE-R Attention 17.8 (0.59) 17.1 (1.17) 16.8 (1.29) 16.9 (1.45) .005 
ACE-R Fluency 11.9 (1.50) 8.90 (2.66) 7.65 (2.98) 8.57 (2.60) < .001 
FAS Total 43.4 (9.70) 33.3 (10.8) 26.5 (11.4) 31.5 (12.0) < .001 
Simple Reaction Time 340 (67.6) 441 (164) 550 (331) 423 (130) .002 
Missing 3 (8.8%) 1 (3.3%) 2 (11.8%) 2 (7.1%)  
Choice Reaction Time 507 (131) 691 (272) 861 (495) 649 (180) .001 
Missing 7 (20.6%) 3 (10.0%) 3 (17.6%) 2 (7.1%)  
CPT Reaction Time 376 (55.6) 422 (79.3) 417 (76.2) 441 (97.6) .018 
Missing 3 (8.8%) 4 (13.3%) 7 (41.2%) 4 (14.3%)  










Missing 0 (0%) 1 (3.3%) 2 (11.8%) 0 (0%)  










Missing 0 (0%) 10 (33.3%) 9 (52.9%) 5 (17.9%)  










Missing 0 (0%) 10 (33.3%) 9 (52.9%) 5 (17.9%)  
Stroop C Items 86.5 [54, 112] 74[23, 104] 48 [21, 93] 62 [33, 95] < .001 
Missing 2 (5.9%) 3 (10.0%) 3 (17.6%) 5 (17.9%)  
Stroop CW Items 32 [19, 52] 20 [0, 29] 12 [6, 33] 19.5 [2, 45] < .001 
Missing 2 (5.9%) 3 (10.0%) 5 (29.4%) 4 (14.3%)  
Stroop Interference 55.7 (17.7) 55.7 (17.7) 39.3 (20.1) 41.6 (11.2) .001 
Missing 2 (5.9%) 3 (10.0%) 5 (29.4%) 5 (17.9%)  




Reported in Table 8.5, three DSST processing speed subtests were administered at baseline. 
Post-hoc tests indicated that all MCI groups had slower symbol copying than controls (all p < 
.001) and neither possible (p = 1) nor probable (p = 1) MCI-LB differed from MCI-AD.  
 
In the DSST ‘original’ task, after controlling for baseline symbol copying speed, MCI-AD (p = 
.021) and probable (p = .012) MCI-LB also experienced more interference from the task than 
controls, though possible MCI-LB did not (p = .284). The same pattern was found in the ‘error 
check’ task, with MCI-AD (p = .005) and probable MCI-LB (p = .013) experiencing more 
interference than controls, after controlling for copy speed, but not possible MCI-LB (p = .536). 
 
The omnibus test indicated that the number of errors made on the ‘original’ task was uneven 
between groups, but there were no significant differences between controls and possible MCI-LB 
(p = .076), probable MCI-LB (p = 1) or MCI-AD (p = .055). This may reflect the low number of 
















DSST Symbol Copy 95.5 (18.0) 67.1 (23.1) 68.7 (26.8) 62.3 (22.4) < .001 
Errors 0 [0, 10] 0 [0, 1] 0 [0, 3] 0 [0, 4] .720 
Missing 0 (0%) 2 (6.7%) 3 (17.6%) 3 (10.7%)  
DSST Original 45.7 (10.6) 29.3 (11.4) 26.8 (10.9) 26.0 (8.67) < .001 
Errors 0 [0, 2] 0 [0, 3] 0 [0, 3] 0 [0, 1] .015 
Missing 0 (0%) 2 (6.7%) 2 (11.8%) 3 (10.7%)  
DSST Error Check 48.1 (9.54) 37.1 (11.9) 31.8 (13.2) 29.6 (10.2) < .001 
Errors 0 [0, 3] 0 [0, 1] 0 [0, 4] 0 [0, 3] .467 
Missing 0 (0%) 3 (10.0%) 5 (29.4%) 8 (28.6%)  
DSST Original 
Interference 
-49.8 (13.5) -37.8 (17.3) -40.5 (19.8) -36.3 (15.6) .006 
Missing 0 (0%) 2 (6.7%) 3 (17.6%) 3 (10.7%)  
DSST Error Check 
Interference 
-47.3 (15.4) -31.9 (16.2) -38.6 (23.0) -32.4 (17.1) .002 
Missing 0 (0%) 3 (10.0%) 5 (29.4%) 8 (28.6%)  
















ACE-R Memory 22.6 (2.93) 18.4 (4.98) 16.1 (5.04) 19.1 (4.68) < .001 
Rey Delayed Recall 8 [2, 15] 1 [0, 12] 2 [0, 13] 5 [0, 10] < .001 
Missing 0 (0%) 1 (3.3%) 0 (0%) 1 (3.6%)  
Rey Cued Recognition 14 [9, 15] 12 [6, 15] 11 [5, 14] 12 [6, 15] .006 
Missing 0 (0%) 3 (10.0%) 2 (11.8%) 1 (3.6%)  










Missing 0 (0%) 1 (3.3%) 0 (0%) 1 (3.6%)  
Complex Figure % Recall 48.5 (16.7) 27.1 (16.2) 22.4 (15.1) 35.5 (15.2) < .001 
Missing 1 (3%) 4 (13%) 1 (6%) 2 (7%)  
Count (%), Mean (SD), or Median [Min, Max]. 
 
As reported in Table 8.6, MCI was associated with poorer retention of words from the RAVLT, 
in both free recall and cued recognition trials. After adjustment for the maximum number of 
words learned over the trials, recall was poorer than controls for MCI-AD (p < .001); possible 
MCI-LB (p = .804) and probable MCI-LB (p = .358) did not significantly differ from MCI-AD. 
Both MCI-AD (p = .021) and possible MCI-LB (p = .018) had poorer cued recognition than 





At baseline (Table 8.7), MCI groups had poorer performance in ACE-R visuospatial and 
construction tasks, poorer visuospatial working memory in the Corsi task, and worse copy and 
incidental recall of a complex figure. They did not show broad group impairments in visuo-
perception as assessed with the LAT, however. 
 
In the baseline-only tests, post-hoc comparisons of the Corsi task with Dunn’s tests indicated that 
probable MCI-LB (p = .012) and MCI-AD (p = .047) had impaired visuospatial working memory 
relative to the controls, but possible MCI-LB (p = .301) did not. MCI was associated with poorer 
performance overall on the VPT than in controls (p < .001), but probable (p = 1.00) and possible 

















ACE-R Visuospatial 16 [13, 16] 15 [8, 16] 14 [5, 16] 14 [11, 16] .004 
ACE-R 
VisuoConstruction 
8 [5, 8] 7 [2, 8] 6 [1, 8] 6.5 [3, 8] .010 
LAT Discrimination 8 [5.12, 16.2] 
10.5  
[5.12, 88.4] 




Missing 10 (29.4%) 7 (23.3%) 7 (41.2%) 7 (25.0%)  
Corsi Block Span 5 [3, 8] 5 [3, 6] 5 [2, 5] 4 [2, 6] .009 
Missing 3 (8.8%) 6 (20.0%) 7 (41.2%) 1 (3.6%)  
Complex Figure Copy 35 [30, 36] 32 [8, 36] 30.75 [6.5, 36] 32 [13, 36] < .001 
Missing 1 (3%) 2 (7%) 1 (6%) 2 (7%)  
Complex Figure Recall 16.7 (5.73) 8.5 (5.53) 6.6 (4.83) 10.8 (5.33) < .001 
Missing 1 (3%) 4 (13%) 1 (6%) 2 (7%)  
VPT Score 29.4 (5.40) 20.4 (8.50) 21.6 (4.80) 21.0 (7.58) < .001 
Missing 7 (20.6%) 13 (43.3%) 8 (47.1%) 5 (17.9%)  
Pareidolia Task 
Correct 
40 [35, 40] 39 [24, 40] 36 [20, 40] 38 [26, 40] .002 
Missing 0 (0%) 1 (3.3%) 3 (17.6%) 1 (3.6%)  
Pareidolia False 
Positive 
0 [0, 5] 1 [0, 16] 3.5 [0, 20] 1 [0, 14] .005 
Pareidolia False 
Negative 
0 [0, 1] 0 [0, 2] 0 [0, 3] 0 [0, 2] .373 




8.2.5 Speech and language 
As reported in Table 8.8, MCI was associated with poorer performance than controls in ACE-R 
language sub-scores, and poorer auditory working memory span on both forward and backward 
tasks. In the GNT, administered at baseline only, MCI-AD (p < .001), probable (p = .030) and 
possible (p = .002) MCI-LB all featured poorer semantic memory compared to controls, but did 
not significantly differ from each other. 
Possible MCI-LB had significantly shorter forward digit span than controls (p = .009) but MCI-
AD (p = .143) and probable MCI-LB (p = .826) did not. All MCI groups had impaired backwards 
digit span relative to controls (MCI-AD, p = .008; possible MCI-LB, p = .014; probable MCI-LB, 
p = .019) but did not significantly differ from each other. 
Probable MCI-LB had a significantly higher backwards task cost than controls (p = .038), while 
MCI-AD (p = .647) and possible MCI-LB (p = .931) did not. 
 
 












ACE-R Language 25 [21, 26] 24 [18, 26] 23 [15, 26] 24.5 [20, 26] < .001 
GNT 24 [12, 30] 20 [7, 25] 20 [0, 25] 21 [7, 28] < .001 
Missing 0 (0%) 1 (3.3%) 0 (0%) 1 (3.6%)  
Digit Span Forward 9 [4, 14] 7 [4, 13] 6 [3, 10] 9 [5, 11] .004 
Missing 0 (0%) 1 (3.3%) 0 (0%) 1 (3.6%)  
Digit Span Back 6.50 [2, 13] 5 [2, 10] 5 [2, 7] 5 [3, 11] .002 
Missing 0 (0%) 1 (3.3%) 0 (0%) 1 (3.6%)  
Count (%), Mean (SD), or Median [Min, Max].  
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8.3 Validation analyses of longitudinal models from LewyPro 
At the point of data locking for this work in April 2020, the mean follow-up time in the SUPErB 
cohort was 1.1 years (SD = 0.87), up to a maximum of 3.7 years from baseline, though 32 
participants had not undertaken at least one follow-up visit at this time with three of these having 
died after baseline assessment. Validation analyses were undertaken as planned with the data 
available, with all previous LewyPro participants excluded to maintain independence of the two 
cohorts. 
8.4.1 Domain-specific cognitive progressions 
Validation analyses of the domain-specific LMM models developed from the primary outcomes 
of LewyPro were run with the data available from the independent SUPErB cohort to date, 
including healthy controls as an additional diagnostic group. These were again undertaken with 
the lme4 and lmerTest packages for R software. Each cognitive measure was included as a 
separate outcome predicted by time, diagnosis, and where previously indicated, time x diagnosis 
interaction in an LMM with random slope and intercept. Continuous covariates were mean-
centred to aid interpretation. Parameters indicated by the development cohort were included for 
this validation cohort. These models are presented in Table 8.9. Corresponding models, including 
time x diagnosis interactions in all cases, are displayed in Figure 8.1. 
 
Visuospatial functions 
The LewyPro cohort (4.3 Results) identified that probable MCI-LB featured worse visuospatial 
functions than MCI-AD and possible MCI-LB including poorer perception in the LAT, and that 
complex visuoconstruction task performance also progressively declined over time in the former 
group, while in the latter two these functions did not.  
 
In the SUPErB study (Table 8.9), broad visuospatial functions as assessed with the ACE-R did 
not significantly decline over time in MCI-AD. Neither possible nor probable MCI-LB had 
significantly poorer estimated visuospatial functions at baseline than MCI-AD but appeared to 
differ in their decline in these. The interaction between time and diagnosis was significant for 
possible, but not probable, MCI-LB indicating a significant decline over time in the former 
group. In the latter group the size of the negative effect was comparable to that identified in the 
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same diagnostic group in the LewyPro cohort, with an additional loss of ~ 0.6 points per year in 
overall visuospatial functions, though possibly underpowered in this instance. Providing further 
context, healthy controls did not differ from MCI-AD in either initial visuospatial functions, or in 
their time trajectories. This suggests that MCI-AD did not only feature relatively less visuospatial 
impairment than MCI-LB, but that they typically featured no clear visuospatial impairment 
relative to controls at this stage. 
 
In performance in more complex visual construction tasks specifically assessed by the cube, 
pentagons, and clock drawing tests only of the ACE-R, similar patterns of initial function and 
non-decline were observed for both MCI-AD and healthy controls. Possible, but not probable, 
MCI-LB featured significantly poorer initial performance. Both MCI-LB groups then 
demonstrated comparable loss of function over time in these tasks; the point estimate (B = – 0.66 
and B = – 0.64, respectively) in both being comparable to the findings from LewyPro (B = – 0.6, 
SE = 0.24); however this difference was only significant in probable MCI-LB, which may reflect 
the small number of possible MCI-LB, or high heterogeneity in this measure. 
 
In lower-level simple visual perception assessed with the LAT, no significant differences were 
identified between MCI-AD and controls, nor MCI-LB and MCI-AD, with no significant time 
trend. This was inconsistent with the findings from LewyPro. However, given the modest effects 
in each direction, it appears that probable MCI-LB may have poorer discrimination of line angles 
than controls, with MCI-AD and possible MCI-LB occupying the middle ground between these 
groups, though with large variation. Furthermore, this variable had a greater level of missingness 




In the LewyPro study (4.3 Results), probable MCI-LB had worse verbal fluency than MCI-AD in 
both the ACE-R subscale and FAS fluency task. All MCI groups progressively declined, but with 




In the validation models (Table 8.9), controls performed better than MCI-AD in both tests of 
verbal fluency, while possible MCI-LB produced fewer words on average than other MCI-AD; 
this difference only being significant in the FAS expanded phonemic task. Contrary to the 
findings from LewyPro, a probable MCI-LB diagnosis was not associated with poorer fluency on 




In the LewyPro study (4.3 Results), MCI-AD had poorer recognition memory than probable 
MCI-LB. Contrary to these findings, in the validation model (Table 8.9) recognition memory in 
the ACE-R was found to be significantly poorer in possible MCI-LB than MCI-AD. Neither 
controls nor probable MCI-LB performed better than MCI-AD. There was a significant, slight 




Of the differences in cognitive profile and progressions observed in LewyPro, only the 
progressive decline in visuoconstruction performance was replicated in the SUPErB cohort based 
on data available so far. While limited by the number of observations due to disruption to follow-
up schedule, taken at face value this represents a partial validation of the development model in 
an independent sample, suggesting that differences in this particular aspect of visuospatial 

















































































































































































































































Figure 8.1. Predicted trajectories for each diagnostic group. Shaded area is 95% confidence interval for 
diagnostic effects only. 
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8.4.2 Latent classes of decline 
The LewyPro development cohort identified three latent classes with distinct cognitive 
trajectories (5.3. Results): slow or stable progression, intermediate decline, and rapid decline. A 
probable MCI-LB diagnosis was found to predict a greater chance of decline, rather than stable 
progression, as was the presence of complex visual hallucinations as a clinical feature in MCI. A 
validation model was therefore conducted, with the same specifications of the underlying LMM, 
though latent classes were freely identified. 
 
In the validation model with time zeroed on study entry as in LewyPro, no latent classes were 
identifiable in the SUPErB data available to date, failing to validate this model; this may be a 
consequence of the limited number of follow-up observations to date causing any trajectory 
differences to be indistinguishable from noise. In an alternative model with time centred for each 
individual to maximise differences at the intercept, including only those with two or more 
observations (n = 77), a two-class model was identified, though this did not improve model fit 
over the standard mixed model (BIC 580 > 563), which was reasonably well-defined by its 
posterior classification probabilities (means ≥ .9 for both classes). These two classes; one 
declining, one stable, are described in Table 8.10. 
 
Table 8.10. Latent classes identified in two-class model for SUPErB cohort; intercept centred in time 
(midpoint in observations for each individual). 
Class Intercepta Time 
Declining 
(n = 28, 36%) 
68 (2.87), < .001 -10 (2.75), < .001 
Stable/slow decline 
(n = 49, 64%) 
90 (2.11), < .001 -0.5 (2.60), .847 
Covariates   
Age -0.28 (0.09), .001  
Education 0.89 (0.20), < .001  
Gender (Male) 0.23 (1.62), .888  
Deprivation 0.33 (0.26), .197  
                           aEstimate (SE), p value 
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Diagnostic predictors of cognitive decline 
The presence of each diagnostic group within these latent classes is presented in Table 8.11. All 
but two controls were classified as stable progressors, and so this trajectory was considered as a 
control-like cognitive progression. As in LewyPro, MCI-AD was treated as the reference group 
for a logistic regression, also presented in Table 8.11. While controls were naturally more likely 
to remain cognitively stable, no significant differences were apparent yet in cognitive prognosis 
between MCI groups. 
 
 
Table 8.11. Distribution of diagnostic groups across latent cognitive classes and logistic regression model with 
MCI-AD as reference group. 




(n = 30) 
MCI-AD 
(n = 14) 
Poss. MCI-LB 
(n = 9) 
Prob. MCI-LB 
(n = 24) 
Slow/Stable 28 (93%) 7 (50%) 3 (33%) 11 (46%) 
Declining 2 (7%) 7 (50%) 6 (67%) 13 (54%) 




[0.01 – 0.42], 
.004 
1.00 
[0.35 – 2.85], 
.999 
2.00 
[0.35 – 11.36], 
.434 
1.18  
[0.32 – 4.42], 
.804 
aOdds Ratio [95% Confidence Interval], p value 
 
Visual hallucinations as a predictor of cognitive decline 
The logistic model including visual hallucinations as a predictor of cognitive decline was 
repeated as in LewyPro, though this did not improve fit over the intercept-only model; controls 
were excluded from this analysis due to the necessary absence of hallucinations in this group (see 
Table 8.12). The presence of visual hallucinations was not a significant predictor of cognitive 
decline, in reality being under-represented (non-significantly) in the declining group. However, 
out of twelve participants with visual hallucinations at baseline, only six had been assessed with 





Table 8.12. Distribution of visual hallucinations between declining and non-declining latent classes, and 
logistic model predicting decline. 




(n = 41) 
Present 
(n = 6) 
Slow/Stable 17 (41%) 4 (67%) 
Declining 24 (59%) 2 (33%) 




[0.76 – 2.63], 
.277 
0.35 
[0.06 – 2.16], 
.260 
                                              aOdds Ratio [95% Confidence Interval], p value 
 
Section summary 
The findings from the LewyPro LCMM analysis could not be validated with the data available 
from the SUPErB study so far; the development model did not identify any latent classes in the 
validation cohort, likely given the limited number of repeated observations in the MCI group at 
this time. A version of this model modified post-hoc to centre time trajectories for each 
individual was capable of differentiating those with a healthy control-like cognitive trajectory 
from those with a declining trajectory, suggesting that this method may be an effective means of 
objectively characterising non-degenerative cases with a fuller dataset, but no predictors of 
decline or non-decline were observed in the logistic models indicated by the development cohort. 
 
8.4.3 Clinical prognosis in SUPErB study cohort 
Two multi-state transition models were derived from the LewyPro cohort (6.3 Results), finding a 
dose-effect of the increasing presence of core clinical features and biomarkers of DLB being 
associated with an increased risk of onset of dementia in MCI. When considering these features 
and biomarkers separately, cognitive fluctuations and visual hallucinations specifically were 




These models were therefore specified in the same manner for the SUPErB data to date, using the 
msm package for R software. Only MCI cases were included; while the rate of conversion of 
healthy ageing to mild cognitive impairment could be a useful addition to these models, and 
healthy controls were assessed for any emergent cognitive impairment, no apparent cases of 
neurodegenerative disease had emerged within the control group to date, though some degree of 
normal age-related cognitive decline may have been observed (as evidenced by two controls 
being categorised within the poorer performing latent class in previous analysis). 
 
As previously, all cases of mild cognitive impairment were included under the same state, with 
diagnostic and demographic features included as covariates moderating the hazard of 
transitioning to the absorbing state of dementia. State transitions are summarised in Table 
8.13.With only one patient death in the first year of assessment, and this occurring soon after 
baseline assessment, including death as an outcome resulted in non-estimable models. This case 
was therefore censored, and only dementia transitions were modelled to facilitate convergence. 
 
Table 8.13. State-to-state transition table in the SUPErB study cohort. 
 to MCI to Dementia to Death 
from MCI 43 8 1 
 
 
Both validation models are reported in Table 8.14. As in the LewyPro cohort, there was an 
apparent increased hazard of transition to dementia from MCI with increasing age, and the 
increasing presence of DLB diagnostic characteristics, with confidence intervals overlapping with 
those from the development model in both cases, validating these effects.  
 
In the second model exploring specific diagnostic characteristics, the presence of cognitive 
fluctuations was again associated with an increased risk of developing dementia; though with 
wide confidence intervals lending uncertainty as to the magnitude of this effect, there was overlap 




However, contrary to the findings of the development model (6.3 Results), visual hallucinations 
were not a meaningful predictor of dementia in this model, with effects not estimable. Of eleven 
participants with complex visual hallucinations at baseline (one case of Charles Bonnet syndrome 
excluded), five had not undertaken any follow-up visit at the time of data locking, limiting the 
utility of this parameter at this time. 
 
 
Table 8.14. Validation of multi-state models for SUPErB cohort, incorporating overall Lewy body diagnostic 
characteristic count, or specific features as covariates. 
Baseline Transition Probabilities from 
MCIa 
 Covariatesb 


































aTransition Probability for One Year [95% Confidence Interval] 
bHazard Ratio [95% Confidence Interval] 






The aims of this chapter were to present the baseline characteristics of the SUPErB study cohort, 
and to utilise this group, including the addition of a healthy control cohort, to assess whether the 
models developed from the LewyPro study (Chapters 4-6) would be validated in an independent 
cohort.  
 
The MCI stage of DLB was again found to feature a progressive decline in complex 
visuoconstructional skills relative to MCI-AD, who followed a control-like trajectory without 
clear decline. This represents a deterioration in complex visually-guided copying tasks, including 
several tasks common in clinical screening tests, and previously indicated as sensitive to 
dysfunction in DLB, including clock, cube and overlapping-pentagon drawing tasks. This result 
is consistent with the same finding from the LewyPro cohort (Chapter 4), and also with recent 
research conducted in parallel suggesting that visuospatial dysfunctions continue to progress at a 
faster rate over the course of dementia in DLB and PDD in comparison to AD (Smirnov et al., 
2020). MCI-LB also featured poorer visuo-perception than controls, as assessed with the LAT, 
though there was overlap with the MCI-AD group occupying the middle-ground; this was 
inconsistent with the findings from the LewyPro study, where the separation between MCI-AD 
and MCI-LB was much clearer with a larger effect in the same direction. 
 
Verbal fluency appeared to be more impaired in the possible, but not probable, MCI-LB group, 
contrary to earlier findings. Unexpectedly, recognition memory was also more impaired in the 
possible MCI-LB group than in MCI-AD, suggesting that more appropriate selection of memory 
testing methods may be required. 
 
When attempting to identify latent classes of global cognitive decline, the development model as 
previously specified in Chapter 5 (Hamilton et al., 2020b) was unable to identify any distinct 
classes, which may reflect the lack of clear separation in trajectories to date. Adapting this model 
to maximise differences at the intercept by centring each individual’s growth curve allowed for 
the identification of two distinct trajectories; a non-declining class characteristic of all but two of 
the controls as well as a number of patients, and a cognitively impaired, declining class. None of 
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the predictors of decline identified in the LewyPro cohort were clearly supported in this altered 
model, and indeed the development model itself was unable to identify any distinct latent classes, 
suggesting that more longitudinal data may be required to observe clearer separation in global 
functioning. As it stands with the current data availability, this represents a failure to validate the 
findings of the development model, which previously identified an association between probable 
MCI-LB diagnosis, visual hallucinations, and progressive cognitive decline. However, this does 
demonstrate the prospective utility of this method in objectively classifying cases of MCI with a 
non-declining cognitive profile comparable to healthy controls. 
 
Finally, there was an indication that the presence of LB diagnostic characteristics in MCI were 
again associated with an increasing risk of transition to dementia, as was increased age. 
Specifically, cognitive fluctuations were again associated with particularly increased risk of 
transition to dementia, though visual hallucinations were not; the former being consistent with the 
development cohort, but the latter was not, with few hallucinators having been available for 
follow-up to date. This again represents a partial validation of the respective findings from the 
LewyPro cohort (Chapter 6), suggesting that MCI-LB may have an increased annual risk of 
developing dementia compared to MCI-AD, and that this risk increases in individuals with a 
more clear DLB-like clinical profile. However, with low death rates in the SUPErB study so far, 




Chapter 9. Supplementary Analysis of the SUPErB and LewyPro Cohorts 
Additional data were available from the SUPErB study which were not available in the LewyPro 
study, including repeated measures data using the Stroop, digit span, and pareidolia tasks. These 
measures were not administered in LewyPro, and so no development models were available to 
validate. The following models were therefore developed from the ground-up, retaining all 
participants from the SUPErB study, including those who originated in LewyPro in contrast with 
the previous validation analyses. An additional final analysis was undertaken with both cohorts 
combined to describe the available repeat cognitive data as fully as possible. 
9.1 SUPErB-only repeat cognitive tests 
9.1.1 Analysis 
Continuous outcome measures were converted to z-scores based on the mean and SD of 
performance in the healthy control group at baseline; error rates in the pareidolia task were not 
standardised in this manner, as this was considered likely to reduce, rather than improve, their 
interpretability with a median error rate of 0 in controls. LMM were utilised as in the LewyPro 
development and validation models, with the addition of NART-estimated IQ as a covariate to 
approximate premorbid functioning. A generalised LMM with log link function was considered 
in the analysis of error counts following a Poisson distribution. Linear and non-linear terms were 
assessed for continuous predictors, with diagnostic group included as a predictive factor in all 
cases, and suitability of time x diagnosis interactions assessed in each model. Models were fit and 
compared by AIC. As in previous analyses, effects were considered as statistically significant 
when p < .05, after controlling for relevant covariates. 
9.1.2 Results 
In all cases, no non-linear relationships were supported between any continuous predictors 
(including time) and any outcomes. There was no improvement to any model by the inclusion of 





Stroop C (colour) and CW (colour-word) task performances are presented in Table 9.1. In both 
tasks there was a declining trend for performance, with fewer words correctly recited over time. 
Additionally, MCI groups showed poorer performance in both Stroop tasks than controls, with 
estimated performance over 1 SD poorer in simple reading speed, and approximately 2 SDs 
below healthy performance in the CW interference task. Compared to MCI-AD, possible and 
probable MCI-LB had slower word-reading speed, though this difference was only significant for 
possible MCI-LB. MCI-LB did not differ in performance from MCI-AD in the Stroop CW task; 
after controlling for baseline reading speed (C – CW) to provide a measure of the interference 
caused by the CW task, both MCI-LB groups appeared to experience less interference than MCI-
AD.  
 
Digit span task 
MCI groups did not show impairment in forward digit span relative to controls (Table 9.1) but 
did show mildly poorer performance in the backwards span task, which may reflect the greater 
complexity in the latter measure. There was no difference in performance between MCI 
diagnostic groups, and no significant time trend. 
 
Pareidolia test 
In analysis of false positive ‘pareidolias’ and false negative ‘missed’ error rates in the pareidolia 
task, a log-link function offered a substantial improvement in model fit over the general LMM, 
with models presented in Table 9.2. MCI-LB groups generally produced more false positive 
‘pareidolia’ responses compared to MCI-AD and controls, with incident rate ratios of 3.93 in 
possible MCI-LB, and 3.05 in probable MCI-LB, though this increased error rate subsided over 
time in the former group. Higher premorbid functioning was associated with lower incidence of 
pareidolia responses.  
Only increasing age was associated with incidence of false negatives (missed true faces in 
stimuli) across all groups. 
MCI-AD did not significantly differ from controls in either production of false positives, or false 
negatives in the pareidolia task. 
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To test whether pareidolia production was related to the presence of visual hallucinations, an 
additional generalised LMM was constructed including this clinical feature as a predictor; this 
was not found to be a significant predictor of false positive pareidolia perceptions (Incidence rate 
ratio = 0.73, 95% CI = 0.31 – 1.73). Finally, a repeated measures correlation analysis did not 
identify any clear association between the production of false positives and false negatives 









































































































































































































































































































































aEstimate [95% Confidence Interval] p value 





There was no apparent loss of simple auditory working memory capacity measured by digit span 
in any MCI group, though there was mild impairment of backwards digit span relative to healthy 
older adults; the greater difficulty of the latter task may make it more sensitive to identify 
dysfunction, or  this may reflect interference from impairment other domains, such as executive 
dysfunctions. 
 
MCI-LB featured less apparent interference in the Stroop task, this may reflect their slower 
reading speeds in the non-interference CW condition; their task completion may be so slow as to 
prevent any automatic interference effects from colour-word incongruency. While the Stroop task 
may therefore be an effective measure of processing speed impairment in MCI-LB, it may be 
insensitive to dysfunction of executive functions such as error detection, response inhibition, and 
attention direction. These findings are not consistent from past research from the dementia stages, 
where DLB were seen to perform worse than AD, and AD worse than controls, in a Stroop task 
(Calderon et al., 2001); such differences, if true, may only become apparent further into the 
dementia stages. However, these results were based on findings from a particularly small cohort 
(DLB n = 10, AD n = 9), which may not be representative of the wider population of DLB or 
AD. 
 
The pareidolia task has shown utility in previous research, with ‘pareidolia’ false positive 
responses (false perception of faces within ambiguous visual noise) being interpreted as 
phenomena analogous to visual hallucinations in DLB (Uchiyama et al., 2012; Mamiya et al., 
2016), and being associated with cognitive impairments and conversion to DLB or PD in 
idiopathic RBD (Honeycutt et al., 2020). Those with an MCI-LB diagnosis were more likely to 
falsely report the presence of faces in visual stimuli, though this should not be taken to imply a 
clear separation between groups as pareidolia rates were low even in this group. Visual 
hallucinators were not shown to be more likely to produce pareidolic responses, and so it is 
unclear that these false positives reflect true hallucination-like experiences in LB disease; other 
processes could account for apparent misperceptions in DLB and MCI-LB, including a lower 
threshold for the perception of faces, a misunderstanding of task instructions, or application of a 
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biased task strategy (e.g. falsely reporting seeing faces when unsure, to avoid a perceived ‘low 
score’), though each of these would implicate different processes and could differ between 
individuals. While these are speculative examples for other potential causes of false positive 
answers, there is evidence that experimentally induced negative mood can increase the rate of 
false positive misidentifications in this task in DLB (Watanabe et al., 2018), suggesting that face 
misidentifications in this group may be a consequence of emotionally-moderated perceptual 
biases, rather than an expression of primary visuospatial cognitive deficits. Meanwhile in this 
study (Table 9.2), higher premorbid functioning was associated with a lower rate of false 
positives, which could be interpreted as lending support to cognitive-mediated explanations of the 
mechanisms underlying pareidolias, though more exploration is clearly warranted. 
 
Only age appeared to be associated with false negative rate in the pareidolia tasks (missed true 
faces), though of marginal significance, which may reflect age-related perceptual decline (e.g. 
visual acuity loss) rather than any cognitive or psychiatric process. False negative errors were 
also not significantly associated with production of false positive pareidolia responses, supporting 
the distinction drawn between these two error types. These results suggest that the false positive 
‘pareidolia’ error rate may be the more pertinent score to assess for the intended purpose than the 
false negative ‘miss’ rate or overall correct identification score, and that this test may be sensitive 
to differences at the MCI stages as in dementia, though the mechanisms underlying this and their 
relationships to other aspects of MCI-LB are not entirely clear. 
9.2 Combined cohort analysis – domains of cognitive impairment 
To provide the best characterisation of MCI-LB with the data available, data from both cohorts 
were combined, including key outcome and predictor measures that were uniform across both 
studies. Deprivation deciles were updated for LewyPro participants to be consistent in direction 
with the SUPErB study; lower deciles (e.g. one) correspond to more community deprivation 
(Noble et al., 2019). Observation times were centred on the first observation point (i.e. LewyPro 
baseline assessment) for cross-study participants. Diagnoses were based on the most up-to-date 
clinical information for each individual at the time of writing; there were therefore changes to 
diagnoses in some cases (e.g. where new information had come to light, or new clinical features 




Continuous outcomes were centred and scaled into z-scores in reference to baseline performance 
in the healthy control group. LAT discrimination was log-transformed prior to scaling to reduce 
skewness; after scaling, z-scores in this measure were linear transformed by -1(x) to reverse value 
signs so that negative values indicated poorer performance, consistent with other outcomes. As 
previously, MCI-AD was treated as the reference group. Linear mixed models were fit 
controlling for key covariates as in Chapters 4 and 8, while assessing the suitability of non-
linear terms for continuous predictors (non-improvement in all cases). Model fit was assessed by 
improvements in AIC. Significance was considered as p < .05. 
9.2.2 Results 
Results of the mixed models with the full cohort are reported in Table 9.3.  As expected, the 
three MCI groups had global cognitive impairment relative to controls (95% CI: 1.3 to 3.1 SDs 
below control performance). Probable MCI-LB did not significantly differ from MCI-AD, though 
the possible MCI-LB group were slightly worse at baseline. While the MCI groups had 
significant global decline over time, controls did not. No difference was indicated in rate of 
decline between MCI groups. 
 
In the overall ACE-R memory subscale, controls performed better than MCI, with no significant 
diagnostic group differences within MCI. While MCI sub-groups did not clearly decline over 
time, this may reflect the counteracting effects of learning effects as healthy controls showed 
slight, but significant improvement in performance relative to MCI-AD. In the pooled analysis 
there were sufficient observations for analysis of the Rey AVLT, reflecting the delayed recall as a 
percentage of each participant’s best number of words recited on trial 5, as by Ferman et al. 
(2013). MCI-AD had significantly poorer retention of learned words than controls, being 
approximately two standard deviations below healthy performance in this sample. While possible 
MCI-LB did not clearly differ from MCI-AD, probable MCI-LB showed significantly less 




Verbal fluency was impaired relative to controls, with both ACE-R subtest and FAS fluency 
measures, in all MCI groups, and significantly more-so in possible MCI-LB than MCI-AD. 
Probable MCI-LB had poorer performance in both tests than MCI-AD, but this was non-
significant in both cases. While the ACE-R verbal fluency measure was sensitive to decline over 
time, the FAS task was not. To explore these inconsistencies more comprehensively, a post-hoc 
model was constructed including both verbal fluency measures as a composite outcome measure; 
in this case, probable MCI-LB was associated with non-significantly poorer verbal fluency (B = -
0.42, SE = 0.22, p = .058) while possible MCI-LB had significantly poorer  fluency (B = -0.89, 
SE = 0.27, p = .001). This model also indicated that there was a significant decline in verbal 
fluency over time (B = -0.08, SE = 0.03, p = .015), but no group differences in time trend. 
 
In both overall ACE-R visuospatial score, and the visuoconstructional sub-score previously 
identified, probable MCI-LB had poorer baseline performance than MCI-AD and controls. Both 
possible and probable MCI-LB featured progressive decline in this domain, while MCI-AD and 
controls remained stable. In the LAT, all MCI groups were impaired relative to controls, and 
probable MCI-LB had significantly more visual-perceptual dysfunction than MCI-AD. There was 
no clear time effect on any group. 
 
MCI groups had poorer language skills than controls, though the diagnostic groups did not differ 
from each other. There was a slight deterioration in speech and language over time across groups, 
with no interaction between time and diagnosis supported. 
9.2.3 Discussion 
Understandably, the findings from the combined cohorts largely mirror the profiles of cognitive 
decline observed in the separate development (Chapter 4) and validation (Chapter 8) cohorts 
which comprise this dataset. However, these provide the strongest evidence yet that the profiles 
of cognitive decline in MCI-LB and MCI-AD may match those of their eventual dementia 
syndromes, with MCI-AD featuring worse retention of learned information, and MCI-LB 
featuring worse executive and visuospatial dysfunction, with the latter progressively worsening 
as the MCI progresses, in contrast to typical MCI-AD and healthy controls and consistent with 
observations from DLB (Smirnov et al., 2020). With sufficient repeated measurements available 
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in the combined cohort, the Rey AVLT assessment also showed sensitivity to different patterns of 
memory dysfunction in MCI-AD and MCI-LB, to which the ACE-R memory scale was not 
sensitive. While probable MCI-LB had worse retention of learned words than the healthy 
comparison group, both possible MCI-LB and MCI-AD had notably worse performance than 
probable MCI-LB. 
 
The addition of controls provides further context as to the magnitude of cognitive impairments in 
all groups showing that, despite the differences observed between groups, all three MCI groups 
were typically impaired relative to controls in most domains (Figure 9.1). These group 
differences are therefore not clear-cut, even at the mild stage.  The cognitive domain with the 
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Figure 9.1. Two-year predicted neuropsychological test performance in combined LewyPro-SUPErB cohort.  
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9.3 Pooled LCMM 
Analysis of the full dataset was undertaken as in Chapter 5, exploring the presence of latent 
classes with distinct trajectories of cognitive decline. 
9.3.1 Analysis 
Total scores on the ACE-R were centred and scaled to z-scores in reference to baseline 
performance in the healthy control group. As previously, a random intercept and slope model was 
fit with the lcmm package for R software, assessing the suitability of any non-linear terms (non-
significant in all cases). The number of latent classes was decided by an improvement in model 
fit according to BIC over the single-class alternative, while maintaining well-defined and 
clinically relevant sub-groups based on their sizes and posterior classification probabilities. 
Models with between one and five classes were specified for initial consideration. More complex 
models (i.e. six or more classes) were to be considered if progressive improvements in fit were 
sustained up to the five-class model. 
 
As previously, predictors of cognitive trajectory class were examined with logistic regression, 
with diagnostic status, core clinical features of DLB, and imaging results considered as predictors 
in these. 
9.3.2 Results 
A three-class model was the best characterised, maintaining an improved fit over the one, two, 
four, and five-class alternatives, and with clearly defined subgroups. These classes included slow 
declining, intermediate declining, and small rapid declining groups (Table 9.4, Figure 9.2). 
Nearly all healthy subjects were characterised by high starting point with slow progression ( 
Table 9.5), though one appeared with a relatively lower level of cognitive function so as to be 
classified within the intermediate declining group.  
 
In the logistic model including diagnostic group as a predictor of cognitive trajectory, with 
probable MCI-LB and the slow trajectory as reference categories for the predictor and outcome, 
respectively, controls were significantly more likely to follow a slow progressing cognitive 
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trajectory, as expected. The only difference in prognosis within MCI groups was a non- 
significant increased risk of rapid decline within the possible MCI-LB group; in all other cases, 
MCI-LB and MCI-AD did not significantly differ in their cognitive prognosis. In the second 
model including specific diagnostic characteristics as predictors (MIBG and FP-CIT imaging 
abnormalities, complex visual hallucinations, RBD, parkinsonism, and cognitive fluctuations), 
only cognitive fluctuations improved model fit ( 
Table 9.5). As expected, controls had a considerably lower rate of intermediate cognitive decline 
than MCI. While the point estimates suggested an increased risk of intermediate or rapid 
cognitive decline in MCI cases with cognitive fluctuations, these were not statistically significant 
with wide confidence intervals, particularly in the latter. 
 
Table 9.4. Estimated intercept and time effects for ACE-R Total z-score for each class, and covariates. 
Class Intercepta Time 
Slow Decline 
(n = 109, 60%) 
-1.53 (0.24),  
< .001 
-0.13 (0.06),  
.021 
Intermediate Decline  
(n = 59, 32%) 
-4.24 (0.31),  
< .001 
-0.66 (0.12),  
.002 
Rapid Decline 
(n = 14, 8%) 
-7.77 (0.46),  
< .001 
-2.02 (0.31),  
< .001 
Covariates   
Age -0.07 (0.02), < .001  
Education 0.19 (0.03), < .001  
Gender (Male) 0.25 (0.27), .183  
Deprivation 0.03 (0.04), .529  




Figure 9.2. Latent classes with distinct trajectories (dashed) identified within the combined LewyPro-SUPErB 
cohorts, with shaded 95% confidence intervals reflecting uncertainty in the fixed effects for class estimates 






Table 9.5. Diagnostic group versus latent class, and multinomial logistic models, probable MCI-LB and 
intermediate declining trajectory as reference categories in model 1, MCI without cognitive fluctuations as 
reference in model 2. 
 Diagnostic Group 









Slow Decline 35 (49.3%) 33 (97.1%) 27 (55.1%) 14 (50%) 
Intermediate Decline
a
 32 (45.1%) 1 (2.9%) 18 (36.7%) 8 (28.6%) 
Rapid Decline 4 (5.6%) 0 (0%) 4 (8.2%) 6 (21.4%) 
Logistic Model 1b (Intercept)    













Rapid vs. Slow 
0.11  














Controls MCI with Fluctuations 
Intermediate vs. Slow 
0.62  
[0.42, 0.93],  
.022 
0.05  
[0.01, 0.37],  
.004 
2.14  
[0.98, 4.68],  
.057 
Rapid vs. Slow 
0.16  




[0.45, 5.91],  
.459 
aReference group 
bOdds Ratio [95% Confidence Interval], p value 
9.3.3 Discussion 
These results extend previous findings (Chapter 5), similarly identifying three distinct cognitive 
trajectories in MCI, and suggesting that MCI patients with a slow cognitive decline follow a 
trajectory comparable to that of cognitively healthy older adults. However, while the majority of 
healthy controls were classified as cognitively slow progressing, one was included within the 
intermediate declining class; the distinctions are therefore not clear-cut. With the limited follow-
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up available to date in the SUPErB cohort, class allocations may be largely indicative of 
differences at the intercept (i.e. cognitive function at baseline) in the model as specified, rather 
than any subsequent decline which may require longer follow-up. With more data available, those 
with a declining trend may separate more clearly from those with only a low initial function, but 
overall stability. 
 
However, the finding of the logistic models predicting cognitive trajectories were not consistent 
with the results of the LewyPro-only cohort. In this analysis, cognitive fluctuations were the only 
DLB symptom predictive of a declining trajectory, though this was non-significant. MCI-AD and 
probable MCI-LB did not significantly differ in their odds of developing in a stable, slow 
declining, or rapid manner. This was in contrast to the LewyPro study, which identified that a 
probable MCI-LB diagnosis, and the presence of visual hallucinations, were predictive of 
progressive decline. Possible MCI-LB may feature a poorer prognosis, with a disproportionate 
number following a rapidly-declining trajectory, though non-significant as a predictor; with small 
relative numbers in both groups, this could merely be an artefact of the small sample, or as 
discussed previously (Chapter 5), could suggest that greater cognitive impairment may obscure 
the presence of DLB features, and that these may be cases with a greater mixed pathological 
burden. 
 
9.4 Transitions from MCI to dementia or death in combined LewyPro-SUPErB cohorts 
The MSM analysis of transitions from MCI to dementia was repeated as in Chapters 6 & 8 
including the full combined LewyPro-SUPErB cohort and covariates common to both cohorts. 
This provided 111 patients with at least two observations, over which time there were 6 deaths 
and 38 diagnoses of dementia. Mean (SD) follow-up time was 2.26 (1.38) years, with a maximum 
of 6.67 years after baseline. This section has been adapted from a manuscript under peer review. 
9.4.1 Analysis 
Using the msm package for R software, a three-state model was specified, including MCI, and the 
two absorbing states of dementia or death, with death times being exact and freely estimated. 
Healthy controls were excluded from analysis. As previously, two models were fit: one including 
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DLB core clinical feature and indicative biomarker count, and one including specific DLB core 
clinical features and indicative biomarker presence or absence separately. Additional covariates 
common across cohorts were also assessed in both models, with continuous variables mean- or 
median-centred as appropriate: age, education, gender, and deprivation decile. Parameters were 
selected by backwards elimination based on improved model fit assessed by AIC. 
9.4.2 Results 
Results from both models are reported in Table 9.6. 
Lewy body characteristic count 
Increasing age was associated with increasing hazard of transition to dementia, or of death. 
Additionally, the presence and increasing number of diagnostic characteristics of DLB in MCI 
was associated with a progressively increasing hazard of transition to dementia. There was a non-
significant effect whereby DLB diagnostic characteristics were also associated with increased 
hazard of the competing risk of death. 
 
Specific Lewy body characteristics 
In addition to age as previously noted, the best-fit model favoured inclusion of visual 
hallucinations and cognitive fluctuations as covariates. Cognitive fluctuations were a significant 
risk factor for progression to dementia, with a large effect of non-significance for death. The 
presence of visual hallucinations meanwhile was significantly associated with increased hazard of 
death, though with wide confidence intervals reflecting the lower numbers, and a large but non-







Table 9.6. Multi-state models for transitions from MCI to dementia or death in combined LewyPro-SUPErB 
cohort. 
Baseline Transition Probabilitiesa  Covariatesb 
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to Dementia 
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aTransition Probability for One Year [95% Confidence Interval] 
bHazard Ratio [95% Confidence Interval] 





While conceptually comparable to the results from the respective separate cohorts (Chapters 6 & 
8), these findings provide more precise estimates of the clinical and statistical significance of the 
associations between diagnostic characteristics of DLB in an MCI syndrome, and risks of 
converting to dementia while accounting for death as a competing risk. Even in the combined 
dataset however, death rates were low overall (n = 6); caution will be required when interpreting 
the large size of some effects given the low confidence in estimates of hazards for death.  
 
These results arguably provide the strongest evidence within this work that an MCI with core 
clinical diagnostic features or indicative biomarkers of DLB (i.e. MCI-LB) has a poorer 
prognosis than MCI-AD, that the presence of more features or biomarkers is associated with 
worse prognosis, and that specific features differ in their associated risk. Specifically, features 
reflecting altered consciousness and perception (cognitive fluctuations, and complex visual 
hallucinations) are associated with a worse prognosis. These results are consistent with recent 
research which has suggested that more clinically complex cases of DLB, in particular those 
featuring fluctuating cognition, are associated with greater healthcare reliance and therefore 
economic burden (Espinosa et al., 2020). While all findings naturally require further independent 
replication, the association between visual hallucinations and prognosis may require further 
exploration; while the effect of the association is fairly large in both dementia and death 
transitions, the confidence intervals are wide in both, and statistically non-significant in the 
former.  
9.5 Chapter summary 
In addition to its use in validating models developed from the LewyPro cohort, the SUPErB study 
included a number of additional supplementary cognitive assessments. Consistent with findings 
from DLB, MCI-LB was associated with an increased incidence of false-positive errors on the 
pareidolia task relative to MCI-AD and controls. Additional analysis was also undertaken with 
both cohorts combined, to provide comprehensive estimates of effects from the primary 
development and validation models with the full sample. Overall, MCI-LB featured a distinct 
declining visuospatial profile relative to MCI-AD and controls, while MCI-AD featured worse 
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amnestic memory impairment. MCI-LB also transitioned to dementia faster than MCI-AD, with a 
notably worse prognosis in those with more clinically apparent LB disease, and specifically in 
those experiencing cognitive fluctuations, or visual hallucinations. However, latent classes of 
cognitive progression were not as clearly distinguished in this combined cohort as in the 
LewyPro study alone, which may be due to the limited follow-up undertaken in the SUPErB 
cohort to date.   
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Chapter 10. Discussion 
10.1 Summary of research question 
The motivation of this research was to test the hypothesis that the cognitive prodromes of the two 
most common neurodegenerative dementias, DLB and AD, would feature different cognitive 
patterns, progressions, and prognosis. This research question was informed by the current 
understanding of the clinical and cognitive manifestations of dementia in the typical syndromes 
of DLB and AD, and comparable work from cross-sectional and retrospective MCI cohorts with 
differential neurodegenerative diagnoses. 
10.2 Broad group differences in cognitive pattern and progression 
It was hypothesised that the profile of cognitive decline in MCI-LB would manifest as an early 
reflection of the cognitive profile found in DLB, which in comparison to AD is typified by less 
memory impairment, and greater visuospatial, attention, and executive dysfunction. These were 
assessed by analysis of baseline group differences and longitudinal changes with linear mixed 
effects models (Chapters 4, 8, and 9). 
10.2.1 Attention and executive functions 
Background 
Attention and executive dysfunctions are typically greater in DLB than AD (Metzler-Baddeley, 
2007), being qualitatively characterised by more distractibility, intrusions and confabulation 
(Doubleday et al., 2002), featuring poorer performance on Stroop, verbal fluency, and selective 
attention tasks (Calderon et al., 2001), and slower reaction times in simple and two-choice 
response tasks (Ballard et al., 2001b). It was therefore hypothesised that MCI-LB would feature a 
comparable, but milder, pattern of performance to DLB, with greater attention and executive 
dysfunction than in MCI-AD. 
 
Summary of findings 
While two tests of verbal fluency (ACE-R subscale and FAS fluency task) indicated poorer 
performance in MCI-LB than MCI-AD (Chapter 4), this was not consistently significant across 
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cohorts, or between MCI-LB groups (Chapters 8 and 9). With groups otherwise comparable in 
language abilities, differences in verbal fluency performance may be taken to reflect greater 
executive dysfunction, lending some tentative support to the hypothesis that these dysfunctions 
would be greater in MCI-LB than MCI-AD. While somewhat poorer in MCI-LB, impairments in 
this domain were not specific to this group as the MCI-AD group also featured poorer fluency 
than controls. Verbal fluency declined over time in MCI, but group trajectories did not clearly 
diverge nor converge, suggesting that these differences were not emerging over the course of 
MCI, but rather had already emerged earlier in the prodromal or preclinical stages; though, an 
alternate explanation is that any continuing separation was simply so small or inconsistent as to 
be undetectable over this time-course. 
 
However, MCI-LB and MCI-AD did not appear to differ in their performance on a range of other 
tests of attention and executive functions, including simple and choice reaction times, or TMT-A 
and –B completion speeds; both of which have previously been sensitive to differences between 
DLB and AD (Ballard et al., 2001b; Ferman et al., 2006). Attention and executive functions 
being broad and multi-faceted domains, this inconsistency may reflect a different staging of 
deterioration in particular tests of attention and executive functions; some functions may 
deteriorate earlier and others later, or particular neuropsychological tests may have varying 
sensitivity to decline at different stages. This would not necessarily be inconsistent with the past 
literature; for instance, Breitve et al. (2018) identified that TMT-A completion speed declines 
faster in DLB than AD, suggesting that performance differences in this particular test may still be 
emerging later into the dementia stage than over the course of MCI. Both TMT measures (but 
particularly TMT-B) are complicated by completion failure being common, while the cause of 
these may not be comparable between individuals.  
 
Due to the complexity and diversity inherent to these particular cognitive functions including 
inhibitory control, mental flexibility, abstract reasoning, a wider range of neuropsychological 
tests may be required to assess any impairments, which may differ between individuals, or a 
battery of tests similar to the Frontal Assessment Battery, which encompasses a number of 
relevant functions (Dubois et al., 2000), though this specific battery may not be appropriate in 
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The attentional and executive system appears to be widely distributed both anatomically and 
functionally (Petersen and Posner, 2012), and there are a number of neurochemical systems 
which may contribute to normal attention and executive function, or dysfunction (Thiele and 
Bellgrove, 2018). One possible explanation for the greater observed impairments in DLB is the 
particular association of LB disease with dysfunction of the cholinergic basal forebrain (Perry et 
al., 1995), which innervates, amongst others, areas of the frontal lobes and thalamus (Perry et al., 
1999), which may contribute to normal executive and attentional functions (van der Werf et al., 
2003). There is considerable evidence supporting the role of the cholinergic system in normal 
attentional functions (Thiele and Bellgrove, 2018). Attentional dysfunctions could therefore share 
a neural substrate with the fluctuating cognition characteristic of DLB; attention is the cognitive 
domain most typified by fluctuations in performance (Ballard et al., 2001b), and cognitive 
fluctuations have been previously related to cholinergic dysfunction observed at autopsy (Ballard 
et al., 2002), consistent with the role of the cholinergic system in modulation of wakeful brain 
states (Harris and Thiele, 2011). 
 
However, the cholinergic system does not contribute to attention and executive functions in 
isolation; dopaminergic function plays an important role in normal attention and executive 
functions independently and in interaction with cholinergic functions (Robbins and Arnsten, 
2009). In PD it has been hypothesised that at least some aspects of attentional and executive 
dysfunctions may be reflective of dopaminergic fronto-striatal dysfunctions (Dirnberger and 
Jahanshahi, 2013), though there may also be overlap with cholinergic dysfunctions (Kehagia et 
al., 2013). Given that dopaminergic dysfunctions are typical to both DLB and PD, as evidenced 
by the commonly abnormal striatal dopamine uptake in DLB (O'Brien et al., 2004) and MCI-LB 
(Thomas et al., 2019), dopaminergic dysfunctions may also be a possible contributing factor to 
attention and executive dysfunctions in MCI-LB. There may naturally be further heterogeneity in 
this domain even within a given clinical syndrome; some individuals may have a more prominent 
cholinergic deficiency, while others may have a greater dopaminergic deficiency, with both 
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resulting in either qualitatively similar, or possibly differing presentations of attention and 
executive dysfunctions (e.g. impairments on different cognitive tests), requiring exploration. 
 
Summary of attention and executive functions 
While verbal fluency may be more impaired in MCI-LB than MCI-AD, as in the respective 
dementia syndromes, this difference is inconsistent between cohorts, and does not clearly extend 
to other assessments of attention or executive dysfunctions included. More suitable and in-depth 
tests may be required, given the variety inherent to executive and attentional functions, or any 
differences may be obscured by heterogeneity within MCI groups; this may be explored by 
considering the neuropsychological profiles present within each disease-characterised diagnostic 
group, as by Ferman et al. (2013). This could provide a clearer description of whether attention or 
executive dysfunctions are more common in MCI-LB than MCI-AD, and whether these differ in 
pattern (i.e. as a single-domain impairment, or within a multi-domain profile of cognitive 
impairment). 
10.2.2 Episodic memory  
Background 
The typical pattern of cognitive impairment in AD is characterised by amnestic episodic memory 
impairment; while this may also occur in DLB, it is typically less severe. The presence of 
episodic memory dysfunction may reflect the effects of AD-related hippocampal atrophy within a 
mixed AD-DLB phenotype. Based on cognitive profile, an amnestic MCI syndrome is more 
likely to transition to an AD-type dementia while a non-amnestic syndrome more typically 
transitions to DLB (Ferman et al., 2013), while retrospective analyses with clinical differential 
diagnosis have identified that memory dysfunction and decline may typically also be poorer in 
MCI-AD than MCI-LB (van de Beek et al., 2020). It was therefore hypothesised that episodic 
memory functions would typically be less impaired cross-sectionally and longitudinally in 
prospectively identified MCI-LB than in MCI-AD. 
 
Summary of findings 
While broad memory functions as assessed with the ACE-R did not differ between MCI-LB and 
MCI-AD, in recognition memory specifically MCI-AD presented with more impairment in the 
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LewyPro cohort (Chapter 4), though this was not validated subsequently (Chapter 8). The 
RAVLT, anticipated to be more sensitive to memory dysfunction in the MCI stages than 
dementia screening scales, did not identify any baseline differences between groups in a simple 
analysis for LewyPro, and lacked sufficient repeated observations to develop a longitudinal 
model (Chapter 4), but after incorporating results from both cohorts (Chapter 9) a more 
complete model could be formed, demonstrating that MCI-AD does feature a poorer retention of 
words after delay in the RAVLT, as a percentage of best performance from the learning trials 
(demonstrating that this is not a failure of attention, but rather a failure of retention; a 
phenomenon comparable to amnestic forgetfulness). These results are consistent with the 
amnestic memory impairments typically found in AD, and with these being less severe (Ferman 
et al., 2006) though still often present (Barber et al., 1999), in DLB. 
 
The lack of clear memory decline in MCI may be due to the influence of practice effects in 
mildly impaired patients, which will naturally have a greater effect in memory domains, or 
insensitivity of tests utilised to performance differences within individuals, and between groups; 
such practice effects in memory tests have been identified previously in amnestic MCI patients, 
even to the point of improvement in scores (Campos-Magdaleno et al., 2017). Controls were seen 
to have significant improvement over time in the ACE-R memory domain, supporting the 
possibility of practice effects. A greater variety of tests, specifically those not in use in clinical 
settings and therefore more resistant to practice effects, or composite scores of these (e.g. van de 
Beek et al., 2020) may be required to adequately describe intra-individual change in memory 
performance should these differ between disease groups; however recent longitudinal study in a 
neuropathologically-assessed cohort did not identify any clear differences in rate of memory 
decline between DLB and AD (Smirnov et al., 2020), so it remains possible that any trajectory 
differences may likewise not be present in MCI. 
 
Discussion 
Amnestic memory impairment is a common cognitive feature of AD, being present in many, but 
not all AD-related clinical syndromes, but also occurring in other neurodegenerative conditions. 
Memory impairments often occur in DLB (Hamilton et al., 2004; Metzler-Baddeley, 2007), and 
may reflect concurrent AD-related MTL atrophy. These findings support previous observations 
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that the prodromal stage of AD features episodic memory impairment relative to controls (Wilson 
et al., 2011), and extends these to demonstrate that these impairments are generally worse than in 
the prodromal stage of DLB. 
 
Memory impairments in both groups may reflect early MTL atrophy, which has been theorised to 
emerge prior to any clinical symptoms in AD (Jack et al., 2010), and with this typically being 
greater in AD than DLB (Burton et al., 2008). MTL integrity is an important contributor in 
normal learning and memorisation, and so likely mediates the associations between 
neurodegeneration and amnestic memory dysfunctions. This naturally warrants direct exploration 
with MRI in a differentially diagnosed MCI cohort to establish whether specific patterns of 
atrophy on MRI in MCI-LB are associated with amnestic memory dysfunctions (and possibly 
therefore AD co-pathology) with a sufficiently sensitive and specific cognitive assessment.  
 
Assessing memory impairment in a quantitative manner may be complicated by the nature of this 
particular cognitive process: accurate recall of information in a memory test requires allocation of 
attention to the information, sufficient working memory capacity to incorporate the number of 
items to be memorised, appropriate encoding of information to long-term memory, and 
subsequent retrieval with or without cues. This provides numerous potential points of failure in a 
cognitive impairment syndrome, any of which may result in failed recall of information, but with 
only failures in the latter two representing episodic memory failures as typically described (e.g. 
amnestic complaints in AD), reflecting the key role of the MTL structure and activity in memory 
encoding (Kopelman et al., 1998), recall (Tanaka et al., 2014) and recognition (Bird, 2017). 
Complicating assessment, failure in the earlier steps will present as apparent memory 
dysfunction, which could account for inconsistencies between tests. Verbal learning tests such as 
the RAVLT may therefore more specifically assess episodic memory impairments, with the 
repeated learning trials limiting the influence of working memory capacity and attention on 
performance, explaining why this test may identify group differences that the more brief ACE-R 
sub-test does not reliably find (Chapter 9). In longitudinal research cohorts, the utility of the 
RAVLT may be limited by its length and difficulty being a barrier to some patients; shorter 
verbal learning tests such as the Hopkins verbal learning test (Benedict et al., 1998) may be more 




In addition to verbal-oriented episodic memory assessments, tests may assess long-term 
memorisation of visuospatial information, such as in delayed recall of complex figures. Such tests 
have found comparable levels of performance in AD and DLB previously (Collerton et al., 2003), 
suggesting that the primary visuospatial impairments may carry over into poorer visually-oriented 
memory performance. Selection of suitable episodic memory assessments should therefore 
consider the intended use: while visual episodic memory tests may be more sensitive in screening 
for cognitive impairments in DLB, they may not assess pure episodic memory impairments as 
specifically as a verbal learning test, since verbal skills are less typically impaired in DLB and 
AD. 
 
Summary of episodic memory functions 
While there is inconsistency between assessments, possibly due to the complexity of the 
underlying cognitive process, MCI-AD may feature worse episodic memory impairment than 
MCI-LB in keeping with their respective dementia syndromes, though the latter are not wholly 
unimpaired. Memory dysfunction in both syndromes may be presumed to reflect early MTL 
atrophy, though this remains unexplored at this stage. 
10.2.3 Visuospatial 
Background 
DLB typically features greater impairment of simple visual perception and complex construction 
skills than AD; this manifests in less automatic ‘pop-out’ of visual features prior to the direction 
of visual attention (Cormack et al., 2004), worse discrimination of visual features such as size, 
orientation, angles, form and motion (Mosimann et al., 2004; Wood et al., 2013a), and worse 
complex task performance such as copying of pictorial stimuli including clocks, cubes, and 
overlapping figures (Collerton et al., 2003; Noe et al., 2004). These findings suggest that patterns 
of LB pathology contribute to greater dysfunction in both simple visuo-perceptual tasks, and 
complex visuoconstruction tasks, than is typically found in AD; though while direct comparisons 
are rare, an AD phenotype manifesting in a PCA syndrome may be the natural exception to this 




People with DLB have also been shown to be more prone to making pareidolic misidentifications 
in response to ambiguous visual stimuli, for instance mistakenly perceiving human faces within 
visual noise; this has been interpreted as an example of a hallucination-like phenomenon 
(Mamiya et al., 2016), though the precise aetiology remains unclear, and could be attributed to 
more general cognitive processes such as attention and executive dysfunctions. 
 
Summary of findings 
In this work, it was found that simple visuo-perception, assessed by a line angle discrimination 
task, was more impaired in probable MCI-LB than MCI-AD in the LewyPro cohort (Chapter 4 
and 9); the effects were mild, with an effect size comparable to the gender differences observed 
in the same task. There was no apparent decline over time in any MCI group in visual perception; 
this could suggest an insensitivity of this test to change over the course of MCI, or a lack of 
sufficient repeated observations to estimate a meaningful time effect. The same model run with 
the SUPErB cohort alone failed to support these findings however (Chapter 8); while MCI-LB 
groups had poorer estimated discrimination sensitivity than MCI-AD, as in LewyPro, the size of 
the effect was less than that of the LewyPro group. The MCI-AD group appeared to have poorer 
performance on this task in SUPErB than the comparable group in LewyPro, and occupied the 
middle ground between controls and MCI-LB. In the combined analysis (Chapter 9), results 
were consistent with the LewyPro cohort in identifying worse visuo-perception in probable MCI-
LB than MCI-AD, and also suggested that MCI-AD performed slightly worse than controls.  
 
Two baseline-only assessments of visuospatial working memory were administered to the 
SUPErB cohort (Chapter 8); a touchscreen variant of the Corsi block-tapping task, and a 
computerised visual patterns test (VPT). While identifying poorer performance in MCI groups 
than healthy controls, these tasks did not capture any clear quantitative performance differences 
between MCI groups.  
 
MCI-AD did not appear to feature a clear impairment or progressive deterioration in more 
complex visuoconstructional skills (i.e. figure copying) relative to healthy controls, but these 
were observed to decline over time in probable MCI-LB, with this being consistent across the 




Finally, MCI-LB was associated with an increased rate of false positive ‘pareidolia’ responses in 
the Pareidolia task (i.e. reporting the presence of human faces in visual noise stimuli when none 
were present) than MCI-AD, who did not differ from controls (Chapter 9), suggesting that 
respective findings from the dementia stages are already apparent at the milder stages.  
 
Discussion 
The visual domain showed a clearer separation between diagnostic groups than other cognitive 
domains. MCI-AD did not feature any clear dysfunction relative to controls in 
visuoconstructional tasks, nor progressive decline in these, while MCI-LB had poorer 
performance, and progressively declined in performance in these tasks. MCI-AD had similarly 
low rates of pareidolic misidentifications to healthy controls, while these had a higher incidence 
in MCI-LB. While MCI-AD had some impairment in visuo-perceptual discrimination, this was 
much more impaired in MCI-LB. These results are consistent with findings from DLB, and 
suggest that visuospatial impairments, and progressive decline in these, may be more typical in 
MCI-LB than in MCI-AD.  
 
These results contextualise how the visuospatial deficits evident from the early stages of DLB 
(Hamilton et al., 2012) might manifest over the course of MCI-LB, and are consistent with recent 
findings that DLB and PDD both feature a greater initial impairment and faster decline in 
visuospatial functions than in dementia due to AD (Smirnov et al., 2020). Early deficits in lower-
order perceptual cognitive functions (with LAT performance as only one possible example of 
these) may be evident at the early stages of MCI-LB (Donaghy et al., 2018), but this does not 
appear to progressively decline further over the course of MCI (Chapter 4) or dementia (Wood 
et al., 2013b), despite a pattern of decline being observed in more complex construction tasks in 
MCI-LB (Chapter 4) and DLB (Smirnov et al., 2020). A possible explanation for this disparity 
is that performance in constructional tasks is multifaceted, requiring the integration of multiple 
forms of visual and spatial perceptual information (Possin et al., 2011); dysfunction of, for 
example, line angle judgement alone may not be sufficient to cause clear dysfunction in complex 
tasks at the early stages. Deterioration in these constructional tasks may therefore reflect 
progressive loss of a greater range of the individual functions which comprise of visuospatial 
 
176 
functioning (e.g. orientation, shape, size, distance) which may not be reflected in longitudinal 
assessment of a single sub-domain such as the LAT (Wood et al., 2013a). Additionally, complex 
functions may benefit more from remaining cognitive reserve in early MCI, e.g. using heuristics 
and semantic knowledge to help approximate the copying of a cube even in the absence of a 
consistent visual representation for the stimulus, thereby compensating for simple loss of visual 
perception. Such compensations could break down as MCI develops, manifesting in deterioration 
in more complex tasks over the course of MCI.  
 
There was inconsistency between some tasks; MCI groups in general had impaired visual 
working memory, with no clear group differences (assessed at baseline only). Visual working 
memory capacity may therefore not be affected to a greater extent than MCI-AD in the early 
stages of MCI-LB; application of respective assessments as repeated measures could establish 
whether visual working memory performance diverges over time. An alternative explanation is 
that the tasks themselves and method of assessment incurred an additional barrier in these 
measures. While drawing from intact lower-level domain-specific resources (visual imagery or 
speech rehearsal), working memory functions are complex and closely entwined with domain-
general executive functions and supportive coding from other modalities even in the prominent 
multi-component model (Chai et al., 2018). This introduces additional potential points of failure 
(e.g. in those with executive dysfunctions) as well as potential mechanisms for compensation in 
those who can make effective use of multimodal strategies (Brown and Wesley, 2013), 
potentially obscuring domain-specific cognitive differences when task failures may represent 
different processes in different individuals. 
 
Additionally, in contrast to other computerised tasks which required only a left or right response 
with handheld buttons (e.g. the LAT), these tasks required use of a mouse or touchscreen. While 
previous research suggested that there was minimal additional task demand in touchscreen block-
tapping tasks compared with the traditional manual variant (Robinson and Brewer, 2016), this 
was based in a much younger sample (all aged < 50 years), which may be more familiar with 
touchscreen technology and therefore not comparable to either the cognitively impaired or 
healthy older adult groups in this work (all aged ≥ 60 years). These tasks could therefore be 
limited by the additional difficulty incurred by unfamiliar technology in cognitively impaired 
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groups, which could introduce additional measurement error and obscure any differences, should 
they exist. 
 
While they did not clearly worsen over time, pareidolic misidentifications were more common in 
MCI-LB than MCI-AD and controls. However, these arguably represent a unique form of visual 
perceptual anomaly, which may arise through an interaction between uncertainty in visual input 
(experimentally induced with visual noise, but could reflect cognitive visual dysfunction in real-
world settings) and an increased weighting towards prior expectations rather than bottom-up 
sensory perception; this reliance on prior knowledge is typically greater in cases of DLB with 
visual hallucinations (Zarkali et al., 2019) and may be experimentally or emotionally induced 
(Watanabe et al., 2018). Given the absence of either visual ambiguity or this shift to prior 
knowledge, pareidolias may not occur as consistently. Therefore, while pareidolia tasks may be a 
useful method of assessing and understanding visual hallucinations in DLB and PD, they may not 
be as sensitive in assessing visuospatial dysfunctions due to the moderating role of prior 
expectations in pareidolia production. 
 
Adequate detection of early visuospatial deficits in MCI may be particularly important given their 
role as a risk factor in dementia. In addition to increasing risk of falls in AD and DLB (Kudo et 
al., 2009) and nursing home admission in PD (Aarsland et al., 2000), visuospatial dysfunctions in 
DLB are also associated with faster cognitive decline (Hamilton et al., 2008); visuospatial 
cognitive impairments may therefore reflect a more aggressive underlying aetiology, in addition 
to being a particular risk factor in themselves. DLB has been previously associated with a greater 
degree of dysfunction in the occipital lobes, including hypometabolism (Imamura et al., 1999) 
and hypoperfusion (Ishii et al., 1999; Lobotesis et al., 2001); while the occipital lobes are 
generally spared from the formation of cortical Lewy bodies (Gomez-Tortosa et al., 1999; 
Harding et al., 2002; Khundakar et al., 2016), DLB features more severe occipital white matter 
spongiform changes and gliosis than AD, comparable to those found in CJD (Higuchi et al., 
2000), which has been theorised to be a pathological substrate of occipital dysfunction in DLB. 
Cognitive visual decline in DLB could therefore arise from physiological dysfunction of the 




However, complex cognitive functions (rather than perception alone) may rarely be isolated to 
specific cortical regions or lobes, and typically rely on widely distributed cortical networks for 
normal functioning. Other aspects of the pathology of DLB which could account for the typically 
greater presence of visuospatial dysfunction include the distinct cholinergic deficit typical of 
DLB which may underlie the presence of complex visual hallucinations (Perry et al., 1999), 
while changes to the sub-cortical visual system in DLB could also contribute to visual 
dysfunctions, due to impaired regulatory functions of the pulvinar and superior colliculus 
(Erskine et al., 2019). 
 
While the pathology underlying this association remains uncertain, and could be heterogeneous, 
there remains a clear association between cognitive dysfunction in the visual domain, the clinical 
syndrome of DLB including its cognitive prodrome, and a more aggressive pathology.  
 
Summary of visuospatial functions 
The visuospatial domain shows the clearest separation between diagnostic groups, with those 
with MCI-AD often performing comparably to healthy controls across the course of MCI, while 
those with MCI-LB have poorer simple visual perception at the early stages, with progressive 
decline in more complex visual tasks over time, and higher rates of pareidolic misperceptions. 
10.2.4 Speech and language 
Background 
AD and DLB are not characteristically associated with significant speech and language 
dysfunction; nor do they typically differ in their level of speech and language impairments, or 
semantic knowledge (Collerton et al., 2003). The exception to this being particular atypical 
syndromes such as primary progressive aphasias which are clinically characterised by prominent 
speech and language dysfunction (Gorno-Tempini et al., 2011). These may occur in AD, but may 
also rarely arise in apparent Lewy body disease (Caselli et al., 2002; Teichmann et al., 2013; 
Watanabe et al., 2020); in both diseases though, aphasic syndromes are uncommon.  
 
One aspect of speech and language production which may be variably affected in DLB and AD is 
auditory working memory, which may contribute to language comprehension and speech 
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preparation through the ‘phonological loop’ working memory component (Baddeley et al., 1991). 
Retention and reproduction of verbal items may be impaired in both DLB and AD, though there 
is little evidence that this impairment is greater in DLB (Collerton et al., 2003). 
 
Summary of findings 
Consistent with the past literature from their dementia stages, no differences were found in 
baseline function or longitudinal decline in vocabulary or semantic knowledge between MCI-AD 
or MCI-LB in this work, based on comparison of the GNT, ACE-R language domain score, and 
NART. This supports the utility of vocabulary tests such as the NART (Nelson and O'Connell, 
1978; O'Carroll et al., 1987) as estimates of premorbid functioning in prodromal DLB as in AD. 
General language skills were observed to decline over the course of MCI in the language domain 
score of the ACE-R (Chapters 4 and 9).  
 
MCI groups had poorer semantic memory than controls, though not differing from each other, 
with poorer naming performance in the GNT (Chapter 8). However, auditory working memory 
was not meaningfully impaired in any MCI group relative to controls (Chapter 9), though 
backwards digit span performance was slightly poorer, reflecting only slight impairment. Neither 
showed clear deterioration over time to date.  
 
Discussion 
These results are conceptually consistent with the expected lack of difference in speech and 
language functions between prodromal AD and DLB syndromes, though there may be some early 
divergence from healthy controls. Given the observed slight deterioration in language skills, tests 
of premorbid function may provide better estimates at earlier stages of the neurodegenerative 
process than later, though these declines could be attributed to global cognitive deterioration.  
 
Prominent speech dysfunctions are more generally associated with particular frontotemporal 
patterns of neurodegeneration affecting the widely-distributed language networks, resulting in an 
atypical aphasic-type syndrome, which may have widely varying presentations (Vinceti et al., 
2019); regions affected by structural or functional neurodegeneration may include the left-
posterior perisylvian cortex and parietal lobe in logopenic variant PPA, the left-posterior fronto-
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insular cortex in nonfluent or agrammatic PPA, or the anterior temporal lobe in semantic variant 
PPA (Gorno-Tempini et al., 2011). While these patterns may arise in AD or DLB, they are 
clearly far from typical and may not be represented in a sample of this size.  
 
Summary of speech and language functions 
Some speech and language functions were mildly poorer in MCI than healthy controls, with 
slight deterioration over time of broadly-assessed language skills. The MCI diagnostic groups did 
not differ in their typical level of language impairment, however. Mild speech and language 
impairments may be a primary dysfunction in themselves, or may be secondary to dysfunction in 
other domains, or in domain-general global cognition. 
10.2.5 Neuropsychological performance in MCI-AD and MCI-LB: a summary 
The domain-specific patterns of cognitive decline in MCI-AD and MCI-LB were consistent with 
these being mild presentations of the cognitive patterns of their typical respective dementia 
syndromes. Relative to healthy ageing, memory, executive, and mild language dysfunctions were 
typical in both MCI types, but varied in their magnitude with greater episodic memory 
impairments in MCI-AD, and possibly greater executive dysfunction in MCI-LB. Visuospatial 
dysfunctions presented a clearer separation with MCI-AD being typically comparable to healthy 
controls in cross-sectional and longitudinal performance, while MCI-LB showed impairment in 
multiple aspects of visuospatial function, and further progressive decline.  
 
These differences may reflect the differing pathologies responsible for cognitive decline in the 
two groups; hippocampal atrophy may be more typical in MCI-AD, while a central cholinergic 
dysfunction, posterior hypometabolism, and fronto-striatal dopaminergic dysfunctions may be 
more characteristic of MCI-LB, with these contributing to their respective cognitive impairment 
patterns. The associations between these specific pathological patterns individually and in 
combination, or biomarkers for these, could provide further evidence in support of this and help 




10.3 Heterogeneity in mild cognitive impairment 
MCI is known to have a variable prognosis; while some cases progress cognitively and clinically 
to dementia, others remain stable or revert to apparent cognitive health. These associations were 
explored with approaches characterising latent trajectories of cognitive decline, and the clinical 
progressions of MCI to dementia, in Chapters 5, 6, 8 and 9. 
10.3.1 Prognosis of progressive cognitive and clinical decline in MCI 
Background 
The clinical prognosis of MCI-AD has been reasonably well examined through both retrospective 
and prospective study, albeit with considerable variation in findings due to differing recruitment 
settings, diagnostic criteria, and lengths of follow-up. Observed percentages of MCI cases which 
transition to dementia over a 5-10 year period range from lows of 24-30% (Mitchell and Shiri-
Feshki, 2009; Xue et al., 2017) to highs of over 60% (Prichep et al., 2006; Pagani et al., 2010; 
Mauri et al., 2012). Regardless of the ‘true’ figure, there is therefore a considerable amount of 
variability in the clinical prognosis of MCI, which remains largely unexplained and may be a 
source of uncertainty for people receiving a diagnosis of MCI with an indeterminate prognosis. 
 
In assessing the cognitive prognosis of AD, heterogeneous trajectories have been identified in the 
lead-up to (Verlinden et al., 2016), and after diagnosis of dementia (Leoutsakos et al., 2015). 
However, such studies may not adequately describe the phenomenon of apparently stable MCI 
which are not observed to ever reach dementia, inconsistent with the presumed neurodegenerative 
disease underlying this syndrome; as highlighted previously, in some settings the majority of 
MCI cases do not clearly decline, which may reflect fundamental differences in how MCI is 
conceptualised (as the prodromal stage of dementia with a presumed neurodegenerative cause, or 
as an objective description of individual functioning without necessary presumption of 
underlying disease).  
 
As an emerging concept at the time of this work, with only recently-published guidelines on its 
diagnosis in research settings (McKeith et al., 2020), there was little in the way of evidence for 
the expected typical, and atypical, prognosis (either clinical or cognitive) of a prospective 
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diagnosis of MCI-LB, which this work aimed to address. In dementia, DLB and AD have been 
found to feature different prognoses, with the former having a shorter time to death (Mueller et 
al., 2019), increased hospitalisation (Mueller et al., 2018) and healthcare costs (Espinosa et al., 
2020), and greater dependence with less ability to live well for patients and carers (Wu et al., 
2018a). Prior to this work, it was unclear as to whether this poorer prognosis would already be 
evident in the MCI stage of DLB. Based on current understanding of the respective dementia 
stages, it was hypothesised that MCI-LB would have a poorer prognosis than MCI-AD, with a 
greater risk over time of cognitive decline and clinical transition to dementia. 
 
An additional interest was in the varying prognosis within MCI-LB. The prodromal and manifest 
stages of LB disease are heterogeneous; some cases may present initially and for extended 
periods with isolated RBD or PD without apparent cognitive symptoms (Claassen et al., 2010), 
while others may present with early cognitive or psychiatric symptoms leading to DLB (McKeith 
et al., 2016; McKeith et al., 2020). It was theorised that cases of MCI featuring core 
neuropsychiatric symptoms of DLB alongside cognitive impairment (complex visual 
hallucinations and cognitive fluctuations) would represent a more unstable clinical phenotype 
with greater risk of decline; either in global cognition, or in clinical transition to dementia. While 
RBD and parkinsonian signs may warn of long-term decline in previously healthy individuals, 
being symptomatic of a synucleinopathy in general, these were not anticipated to be associated 
with greater risks of decline over the short term in people already suspected to have a 
neurodegenerative disease (i.e. conferring no greater risk of progression than in AD). 
 
Summary of findings 
Three MCI sub-groups with distinct cognitive prognoses were identified in the LewyPro cohort 
after a mean of 2.4 years of follow-up; MCI with slow or stable cognitive progression (46% of 
cohort), MCI with intermediate cognitive decline comparable to the overall group mean (41%) 
and a small group (13%) of rapid-declining MCI cases; 54% of MCI cases therefore developed 
with a measurable cognitive decline over this brief time period (Chapter 5). Correspondingly, 
42% of MCI cases transitioned to dementia over a similar period, with 58% remaining as MCI 
(Chapter 6). While these numbers are still emerging and derived from a shorter time period than 
past studies, with follow-up still ongoing, this does already identify a higher rate of cognitive 
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decline and clinical progression than found in some previous studies (Mitchell and Shiri-Feshki, 
2009; Xue et al., 2017), which may reflect the recruitment methods, detailed assessment, expert 
clinical panel review undertaken, and high proportion of LB disease in these cohorts.  
 
In the SUPErB cohort, the slow or stable sub-group was populated mostly by healthy controls, 
but also included a number of apparent MCI cases, with 45% of MCI cases with at least two 
observations maintaining a control-like profile of cognitive progression (Chapter 8); while 
longer follow-up is clearly needed for this cohort, some of these could represent non-
degenerative cases of MCI. 
 
Crucially, differentially diagnosed MCI subtypes demonstrated markedly different clinical and 
cognitive prognoses: a probable MCI-LB diagnosis was associated with an increased risk of 
following an intermediate cognitive decline trajectory in comparison with MCI-AD and possible 
MCI-LB, which were more likely to remain cognitively stable (Chapter 5). Accordingly, an 
increasingly DLB-like clinical profile in MCI was also associated with an increased annual risk 
of clinical transition to either dementia or death (Chapters 6, 8 & 9), though death rates were 
low overall. Taken together, these results support the hypothesis that as the cognitive prodrome 
of DLB, MCI-LB may feature a poorer prognosis than MCI-AD with a greater risk of progressive 
cognitive decline, and greater annual risk of onset of dementia. 
 
However, there was some inconsistency whereby probable MCI-LB diagnoses were 
underrepresented in the small rapidly-declining group (Chapter 6), despite over-representation in 
the intermediate declining class. Our data do not explain why some individuals decline faster; this 
could represent an artefact of the small size of this group, amounting to a sample of only ten, 
these could be cases of AD with particularly widespread neurodegeneration, or as discussed in 
the relevant section, this could reflect the non-emergence of diagnostic characteristics for DLB in 
cases who decline too quickly. 
 
Specific core clinical features of DLB were associated with different prognoses: cases of MCI 
featuring complex visual hallucinations had a greater risk of cognitive and clinical decline 
(Chapters 5 and 6) in the LewyPro cohort, though these findings were not validated in the data 
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from the SUPErB study to date (Chapter 8). Those with MCI featuring fluctuating cognition and 
attention characteristic of DLB also had an increased annual hazard of dementia (Chapter 6), a 
finding that was validated in the SUPErB study cohort (Chapter 8) and the combined cohort 
(Chapter 9), but did not feature a greater risk of measurable cognitive decline (Chapters 5 & 8) 
though there was a non-significant effect in this direction in the combined cohort (Chapter 9).  
 
These findings suggest that within MCI-LB, a phenotype including neuropsychiatric core clinical 
features may be an early sign of a clinically or cognitively progressive syndrome. This is a novel 
finding, but in keeping with previously observed associations between neuropsychiatric 
symptoms and a poorer prognosis in AD, with increased risk of dementia from amnestic MCI 
(Mauri et al., 2012) and greater cognitive decline after onset of dementia (D'Antonio et al., 
2019); hallucinations in AD are also associated with worse prognosis (Scarmeas et al., 2005a), a 
finding that holds after exclusion of pathologically-confirmed DLB cases. 
 
Discussion 
The associations between DLB features in MCI and a poorer prognosis is consistent with the 
worse prognosis observed in DLB in comparison to AD (Mueller et al., 2018; Mueller et al., 
2019), suggesting that this may already be apparent at the MCI stage. 
 
The inconsistency in associations between fluctuating cognition and risks of progressing to 
dementia, but not with progressive cognitive decline, could suggest that the intra-individual 
cognitive variability in fluctuating patients may obscure any progressive linear decline in tests of 
global cognition; for example, if a baseline cognitive assessment takes place on a particularly 
low-functioning day for a patient who experiences fluctuations, while subsequent follow-up 
measures occur when the patient is relatively more lucid, this may underestimate their typical 
initial daily function, and any subsequent decline may not be evident due to the biased baseline 
measure. This disparity demonstrates the value in including conversion to dementia as a distinct 
outcome in longitudinal studies; cognitive assessments are limited in their ability to describe the 
real everyday cognitive difficulties encountered by individuals, who may be capable of sustaining 
brief periods of better-than-usual cognitive performance when faced with intense testing. Clinical 
progression to dementia does not reflect cognitive decline alone, but rather loss of independent 
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function due to multiple factors leading to an increased dependency on family and caregivers for 
everyday functioning, which may better reflect their true daily function (though with a loss of 
objectivity). This outcome may have greater clinical relevance, though lacks the ability to 
characterise progressive decline within an MCI syndrome with the granularity afforded by 
cognitive measures, and requires considerable clinical expertise to judge appropriately which 
may not be feasible in larger-scale studies; both types of outcome arguably have a part to play in 
understanding the prognosis of MCI. 
 
The associations between LB disease and a poorer prognosis in MCI and dementia may reflect 
the particular combination of neuropathological processes found across the spectrum of LB 
disease; within this, the presence of visual hallucinations or cognitive fluctuations may also be 
symptomatic of a more aggressive clinical phenotype within DLB and MCI-LB. Though the 
pathological effects of LB disease are multifaceted, including dopaminergic denervation (Thomas 
et al., 2017) amongst other processes, the pronounced cholinergic deficit often found in DLB 
(Lemstra et al., 2003) has also been identified as a potential contribution to both visual 
hallucinations and cognitive fluctuations (O'Brien et al., 2005; Delli Pizzi et al., 2015). The 
worse prognosis identified may therefore be an outcome of a greater cholinergic dysfunction in 
these cases, of which visual hallucinations and cognitive fluctuations may also be symptomatic. 
Quantitative EEG has identified a loss of cholinergic drive in DLB relative to AD and controls 
(Schumacher et al., 2020b), and so may be a useful biomarker to assess this in MCI-LB 
(Schumacher et al., 2020a). These findings naturally warrant further exploration to establish 
whether markers for cholinergic denervation (e.g. reduced alpha reactivity on EEG, or quantified 
MRI analysis of NBM integrity) are similarly predictive of faster dementia onset or cognitive 
decline in MCI across diagnostic groups and within MCI-LB specifically, in contrast to FP-CIT 
imaging abnormalities, which were not (see Chapters 5, 6, 8 & 9). 
 
The presence of a rapid declining sub-group was consistent with previous research suggesting 
that 20% of AD cases may present with particularly rapid deterioration (Nance et al., 2019); in 
the LewyPro study (Chapter 5), 17% of MCI-AD and possible MCI-LB patients had a relatively 
more rapid declining cognitive trajectory. However, probable MCI-LB patients were 
unexpectedly under-represented in this latent trajectory, which may be an artefact of the small 
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group size. With a sufficiently sized sample or neuropathological study, it may be possible to 
better describe such rapid decliners in more depth, if indeed this group is consistently identified. 
 
After a longer period of follow-up, MCI patients who continue to follow a healthy-like stable 
cognitive trajectory may be considered as non-degenerative cases, which may include subjective 
or functional cognitive disorders. Non-degenerative MCI cases would likely not benefit from 
disease-modifying therapies intended to treat neurodegenerative diseases, and so better  
prospective identification of such cases may have implications for the management of these 
syndromes, and in efforts to treat neurodegenerative causes of cognitive impairment.  
 
Summary of clinical and cognitive prognosis 
A probable MCI-LB syndrome is more likely to develop with progressive cognitive decline than 
MCI-AD. People with MCI and core clinical features or indicative biomarkers for LB disease are 
at greater annual risk of developing dementia, and this risk increases when more features or 
biomarkers are present. Not all symptoms or biomarkers are associated with an equal level of risk 
however; RBD, parkinsonism, and abnormal FP-CIT or MIBG imaging are not associated with 
increased individual risks of either cognitive decline or clinical progression from MCI, while 
fluctuating cognition and visual hallucinations are. 
 
10.4 General discussion and future directions 
These two cohorts represent some of the earliest attempts to prospectively characterise MCI-LB, 
a syndrome only recently studied in research settings, and requiring further large-scale study in 
order to reach sufficient maturity to apply in clinical settings (McKeith et al., 2020). Wider work 
is ongoing to characterise the clinical and imaging findings in these cohorts, which do not lie 
within the scope of this thesis, but there is consequently considerable scope for further refinement 
of the diagnostic criteria and clinical characterisation of MCI-LB in future research.  
10.4.1 Strengths and implications of this work 
The cohorts characterised in this work underwent detailed, repeated assessment with clinical 
review by an experienced panel in accordance with the current gold standard criteria for 
 
187 
antemortem diagnosis (McKeith et al., 1998), ensuring accurate judgement of clinical 
symptomatology, signs, and cognitive impairment, with appropriate consideration for competing 
diagnoses including subjective impairments and frontotemporal aetiologies, which were cause for 
exclusion. These studies also offered a comprehensive battery of imaging to all eligible 
participants regardless of diagnosis, including FP-CIT in both, and MRI and MIBG in SUPErB. 
FP-CIT imaging was repeated, and assessed by an experienced, trained panel blind to clinical 
information, providing more certainty in the abnormalities reported. This rigorous assessment is a 
particular strength of these cohorts, lending a great deal of confidence in the clinical ratings, 
imaging findings, and consequent diagnoses. The prospective nature of follow-up is more readily 
applicable to real-world clinical settings, providing an accurate reflection of the clinical 
symptoms, features and biomarkers present during the MCI stage, rather than at the dementia 
stage as in comparable, but retrospective, studies (van de Beek et al., 2020). 
 
These findings may help guide future research into the diagnosis and management of prodromal 
DLB, which first and foremost will require a clear and consistent characterisation of the clinico-
cognitive syndrome of MCI-LB, and its prognosis. As in DLB (Taylor et al., 2020), MCI-LB 
may have specific management and treatment needs in comparison to MCI-AD. Caregivers have 
previously identified a need for clear information on what to expect following diagnosis of DLB, 
and how to manage these challenges (Killen et al., 2016), and earlier diagnosis has been 
associated with better outcomes for carers of people with dementia (Woods et al., 2019). Early 
identification of the likely presence of LB disease in MCI may help prepare patients and 
caregivers to proactively recognise and manage any emergent symptoms and signs, with the 
potential to reduce patient and caregiver distress, e.g. through the recognition of newly emergent 
hallucinations or sleep disturbances as expected outcomes of the same underlying disease 
process, and to bring these to the attention of clinicians for management. Appropriate recognition 
of the presence or emergence of DLB symptoms in MCI (particularly visual hallucinations or 
cognitive fluctuations, given their apparent risks) may also help prepare diagnosticians for the 





Early diagnosis of cognitive impairment may raise the risk of overdiagnosis (e.g. diagnosis of 
neurodegenerative MCI which has other, non-degenerative, causes) and so diagnosis must be not 
only early, but specific to avoid introducing unnecessary burden. In addition to their value in 
differential diagnosis (e.g. from MCI-AD), identifying the presence of biomarkers or clinical 
features of LB disease in MCI may also provide more certainty that a neurodegenerative disease 
is present, rather than any cognitive impairment due to major depression, subjective impairment, 
or a functional disorder. 
 
Additionally, the differences in cognitive profiles, and decline in these, may have implications for 
the screening for mild cognitive impairments in clinical settings; given the declining trajectory of 
visuoconstructional skills, executive dysfunction, and less severe amnestic memory impairments 
found in MCI-LB, common screening tests such as the MMSE may be insensitive to mild and 
progressive cognitive decline in the context of LB disease. 
 
The varied analytical approaches were able to characterise the progression of a cognitive 
impairment syndrome in a comprehensive manner, and are a strength of this work; individual 
trajectories of decline were described with LMM by incorporating all observations into a subject-
specific curve, which may include multiple and unequally-timed observations, therefore being a 
more efficient and flexible alternative to traditional approaches to repeated measures (e.g. change 
scores or repeated measures ANOVA). These methods are also reasonably robust in 
incorporating missing data. 
 
By applying latent class methods to this longitudinal data, the clinically-recognised heterogeneity 
within MCI could be appropriately described in a research setting; such considerations are often 
missing in contemporary MCI and dementia research, which often treat groups as homogeneous. 
While limited by the number of observations available in some analyses, this method 
demonstrated clear utility in describing the LewyPro cohort and is a particular strength of this 
work. 
 
Utilising MSM methods to describe clinical transitions from MCI provides a flexible framework 
from which this work may be developed in the future; while such transitions may be adequately 
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described with a simple survival analysis, MSM approaches may be readily extended to include 
time-varying covariates as well as competing risks (though these do not separately require this 
approach), but may also be developed in future studies to account for other observable transitions 
(e.g. from normal cognition to MCI, or even reversion to healthy cognition).  
10.4.2 Limitations and future directions 
These cohorts are representative of the population from which they were drawn, reflecting 
prodromal cases of DLB and AD assessed in memory service settings in North-East England, 
UK. Findings from this broad area may not be mirrored in other areas of the United Kingdom; 
recognition of DLB in clinical settings is higher in the North-East of England than in other areas 
of the country (Kane et al., 2018), which may reflect the influence of DLB research in the North-
East on local medical education and service practice. The clinical profile of cases within these 
cohorts may therefore not reflect the spectrum of ostensible MCI-LB cases as diagnosed in other 
areas of the country. The identifiability, and consequent utility, of specific clinical features or 
biomarkers may vary in different areas with more or less familiarity with DLB. There may, as a 
hypothetical example, be a greater focus in some regions or services on biomarkers or clinical 
features which are clearly sensitive to a synucleinopathy (i.e. RBD, parkinsonism, and 
dopaminergic imaging) though these may not be specific to a declining MCI. 
 
North-East England contains many of the most deprived areas of the United Kingdom 
(Department for Communities and Local Government, 2011; Noble et al., 2019), a limitation of 
the localised recruitment in regards to wider generalisability. Deprivation may impact on 
apparent cognitive function through a number of mechanisms; more deprived individuals may 
have lower estimated premorbid functioning and cognitive reserve through reduced opportunities 
in education, attainment, and cognitive health-influencing behaviours through early and mid-life 
(Norton et al., 2014; Clare et al., 2017; Olivera et al., 2018), while health inequalities may reduce 
access to memory services and anti-dementia treatment in later life (Cooper et al., 2016). 
Increased deprivation is also associated with poorer quality of life after dementia diagnosis (Wu 
et al., 2018b). In this research setting, both baseline cognitive scores and observed rates of 
decline are likely to reflect local effects of deprivation which may not generalise to other areas; 
note for instance that mean baseline ACE-R scores in MCI in these cohorts (Chapters 4 and 8) 
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fall below the 82-point cut-off found to be highly specific to dementia within a Cambridge, UK 
based sample (Mioshi et al., 2006). Distributions of deprivation deciles of the cohorts are 
presented in Figure 10.1, which are uniformly distributed on a national scale by definition; while 
there were peaks at deciles three (moderately high deprivation) and nine (lower relative 
deprivation), there was no clear skew in deprivation in this sample, which may reflect the 
counteracting effects of greater local deprivation in the North-East (Basta et al., 2007) and the 
previously-observed bias in research participation towards less-deprived communities (Gao et al., 
2015) resulting in an approximately evenly distributed sample. 
 
 
Figure 10.1. Distributions of English IMD deciles in LewyPro and SUPErB cohorts combined (n = 187), 
dashed line as reference for uniform distribution. 
 
In an apparently heterogeneous condition such as DLB, or its prodromal stages, the clinical 
profiles observed in a research setting will to an extent reflect the healthcare services from which 
participants were recruited; those recruited from movement disorders service may naturally 
feature a more PD-like profile, while those recruited from memory services may feature a more 
AD-like presentation, though these differences may be difficult to quantify. This is of course 
complicated by the differing overlaps of service specialities and care pathways in different 
countries; the Amsterdam Dementia Cohort, for instance, identified much higher rates of 
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parkinsonism and FP-CIT imaging abnormalities in their prodromal DLB sample than observed 
in the LewyPro and SUPErB cohorts (van de Beek et al., 2020), which may reflect intangible 
differences in culture between the services from which these cases are recruited leading to a more 
PD-like profile in MCI-LB in the former, with implications for direct comparisons between 
cohorts (e.g. resulting in a cohort with more typical dopaminergic dysfunction, and therefore 
different patterns of cognitive impairment). 
 
To address these limitations, there may be a benefit in future work exploring differences in the 
cognitive and clinical presentations and progressions of MCI-LB nationally, across different 
services, and internationally, to establish if there exist any fixed (e.g. regional deprivation) or 
random (e.g. clinical culture in a particular service) effects which influence the presentation or 
prognosis of this syndrome. 
 
While emerging evidence from these cohorts seems to support that MCI-LB transitions to 
clinically-diagnosed DLB in the short term (Chapter 4), it will eventually be necessary to 
demonstrate, when such data is available, that a prospective clinical diagnosis of MCI-LB is 
specifically associated with a neuropathological confirmation of the presence of LB disease, 
which may co-occur with AD pathology. Participants in these cohorts, including both controls 
and patients, have been provided information on volunteering as a donor to the Newcastle Brain 
Tissue Resource, but given the early stage of disease assessed in these studies, these data may 
take some time to reach fruition. By way of comparison, neuropathological follow-up of people 
with dementia has shown utility in identifying clinical symptoms associated with mixed 
neuropathologies (Thomas et al., 2018), in assessing the accuracy of clinical diagnosis 
(Selvackadunco et al., 2019), and in characterising the global cognitive trajectories of pure and 
mixed AD and DLB (Malek-Ahmadi et al., 2019). Such confirmation of both the presence, and 
extent (i.e. pathological staging) of AD, LB, and other pathologies (e.g. TDP-43) in the brain 
could help to characterise the relative contributions and interactions of these on the domain-
specific cognitive and clinical profiles, and progression of MCI. For example, the presence of 
greater AD-related pathology alongside prominent LB disease may cause greater amnestic 
memory impairment and less clearly manifest clinical features of MCI-LB, and this syndrome 
might also be expected to deteriorate at a faster rate relative to cases with less mixed pathology.  
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At various times throughout this work, it has been speculated that observed associations between 
DLB clinical features and cognitive or clinical progression may reflect shared patterns of 
neurodegeneration (e.g. central cholinergic deficiencies underlying both cognitive fluctuation 
symptoms and transition to dementia). Prior to the availability of pathological confirmation, it 
may be possible to build on this work using a combined biomarker approach to assess whether 
such patterns of neurodegeneration theorised to mediate the associations between underlying 
disease (AD or LB), the consequent clinical features (RBD, parkinsonism, visual hallucinations, 
and cognitive fluctuations) and cognitive profiles (e.g. amnestic, dysexecutive, visuospatial 
dysfunction) are evident. While both MIBG and FP-CIT are useful biomarkers for differential 
diagnosis of DLB from AD, neither appeared to predict cognitive decline or dementia onset in 
this work (Chapter 9), and so could reflect less aggressive phenotypes within LB disease (being 
respectively related to autonomic and dopaminergic dysfunctions). Various underlying 
mechanisms could mediate cognitive and clinical outcomes, with various corresponding 
biomarkers, for example: MTL atrophy (MRI), occipital activity reductions (perfusion or 
metabolism), dopaminergic dysfunctions (FP-CIT), and central cholinergic deficiencies (EEG) 
could vary in severity both within and across diagnostic groups, possibly with consequences for 
individual cognitive and clinical presentations as theorised throughout. Clarifying whether 
different patterns or combinations of biomarker findings are associated with different cognitive 
patterns and progressions, clinical feature presence, and rates of transition to dementia, could 
help explain some observed clinical and cognitive heterogeneity. If these speculated associations 
are observed, this could aid in prospective stratification of MCI cases.  
 
This work largely focussed on the associations of core clinical features and indicative biomarkers 
of DLB with cognitive and clinical decline; while these characteristics are well-supported in 
differentiating DLB from AD (McKeith et al., 2017), and MCI-LB from MCI-AD (McKeith et 
al., 2020), it is possible that other features of LB disease such neuropsychiatric supportive 
features (Donaghy et al., 2020), clinical features or biomarkers of neurodegenerative diseases in 
general, or other health factors, may be more predictive of a poorer prognosis within MCI.   
 
While the analytical methods were flexible and appropriate for the longitudinal form of data, 
there remain limitations. Missing data were not imputed due to the complexity of incorporating 
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multiply-imputed datasets into less-widely supported R packages such as lcmm and msm. Data 
missingness due to censoring (dementia or death) was accounted for in models of discrete state 
transitions (MSM) or through adjusting for time to onset of dementia or death (LCMM), but not 
otherwise included as an additional competing outcome when assessing change in continuous 
outcomes (i.e. cognitive decline); with sufficient data, this could be incorporated into a joint 
cognitive trajectory and survival model.  
 
While efforts were made to adjust for time-to-censoring, as well as to control for effects which 
may lead to delayed diagnoses, such as local deprivation, it remains likely that different 
individuals will have begun observation at different, arbitrary points following onset of cognitive 
symptoms. This could account for some observed differences in trajectories both between, and 
within, these groups. While the differential diagnostic groups were broadly similar in their global 
cognitive function on entry to these studies, as noted previously different underlying patterns of 
cognitive impairment may lead to incomparable raw scores on global cognitive assessments.  
 
As anticipated, with relatively few observations per individual in both cohorts there was a limited 
ability to describe non-linear time effects in cognitive decline, which were routinely assessed as 
might be expected based on larger-scale (Yoo et al., 2020) or longer-running studies (Muniz 
Terrera et al., 2008). While this limits the accuracy with which the true latent cognitive 
trajectories may be described, this is in keeping with more comparable clinical studies (Rongve et 
al., 2016; Breitve et al., 2018; van de Beek et al., 2020), though whether non-linear effects were 




In comparison to MCI-AD, an MCI syndrome which features core clinical symptoms or signs of 
LB disease (RBD, parkinsonism, complex visual hallucinations, or fluctuating attention and 
cognition) or supportive biomarkers of LB disease (striatal dopaminergic imaging abnormalities, 
or reduced cardiac uptake of MIBG) may also feature greater executive dysfunction, greater and 
progressive decline in visuospatial functions, and less severe episodic memory impairment. This 
profile of cognitive decline is consistent with this syndrome being the cognitive prodrome of 
DLB, as this reflects the typical domain-specific impairments found in comparison with AD.  
 
MCI-LB also has a greater risk of progressive global cognitive decline than MCI-AD, and a 
greater annual risk of progressing from MCI to dementia: this risk increases further as more 
clinical features or biomarkers of LB disease become apparent. However, not all clinical findings 
are equally hazardous; individuals experiencing complex visual hallucinations may be at more 
risk of progressive cognitive decline, while those experiencing fluctuations in attention and 
cognition appear to be at greater risk of developing dementia, while those with parkinsonism or 
RBD as slower-progressing core features do not appear to be at any greater risk of progression 
than MCI-AD (though likely retaining a greater risk of dementia than those without any 
neurodegenerative disease at all). Such findings could help inform future clinical trials in MCI-
LB, for instance when balancing groups by clinical features which may be anticipated to have 
different rates of cognitive decline or transition to dementia. 
 
As the clinical differential diagnosis of MCI is an emerging concept, further research is required 
to explore the mechanisms underlying these risk factors, cognitive impairments, and any worse 
prognosis, as these may have implications for potential future therapies. It must also be 
demonstrated that these differentially diagnosed clinical syndromes reliably progress to their 
respective dementia syndromes in other settings which may lack the diagnostic rigour afforded in 
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